Document_and_Entity_Informatio
Document and Entity Information | 3 Months Ended | |
Mar. 31, 2014 | 1-May-14 | |
Document And Entity Information [Abstract] | ' | ' |
Document Type | '10-Q | ' |
Amendment Flag | 'false | ' |
Document Period End Date | 31-Mar-14 | ' |
Document Fiscal Year Focus | '2014 | ' |
Document Fiscal Period Focus | 'Q1 | ' |
Entity Registrant Name | 'ALERE INC. | ' |
Entity Central Index Key | '0001145460 | ' |
Current Fiscal Year End Date | '--12-31 | ' |
Entity Filer Category | 'Large Accelerated Filer | ' |
Entity Common Stock, Shares Outstanding | ' | 82,592,966 |
Consolidated_Statements_of_Ope
Consolidated Statements of Operations (USD $) | 3 Months Ended | |
In Thousands, except Per Share data, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Income Statement [Abstract] | ' | ' |
Net product sales | $495,445 | $508,276 |
Services revenue | 215,965 | 226,909 |
Net product sales and services revenue | 711,410 | 735,185 |
License and royalty revenue | 5,212 | 4,064 |
Net revenue | 716,622 | 739,249 |
Cost of net product sales | 246,112 | 253,078 |
Cost of services revenue | 117,732 | 120,158 |
Cost of net product sales and services revenue | 363,844 | 373,236 |
Cost of license and royalty revenue | 1,539 | 1,756 |
Cost of net revenue | 365,383 | 374,992 |
Gross profit | 351,239 | 364,257 |
Operating expenses: | ' | ' |
Research and development | 38,699 | 41,454 |
Sales and marketing | 147,064 | 156,456 |
General and administrative | 139,536 | 135,858 |
Operating expenses | 325,299 | 333,768 |
Operating income | 25,940 | 30,489 |
Interest expense, including amortization of original issue discounts and deferred financing costs | -52,044 | -57,399 |
Other income (expense), net | 4,722 | -470 |
Loss before benefit for income taxes | -21,382 | -27,380 |
Benefit for income taxes | -9,917 | -36,871 |
Income (loss) before equity earnings of unconsolidated entities, net of tax | -11,465 | 9,491 |
Equity earnings of unconsolidated entities, net of tax | 5,352 | 2,934 |
Net income (loss) | -6,113 | 12,425 |
Less: Net income (loss) attributable to non-controlling interests | 108 | -25 |
Net income (loss) attributable to Alere Inc. and Subsidiaries | -6,221 | 12,450 |
Preferred stock dividends | -5,250 | -5,250 |
Net income (loss) available to common stockholders | ($11,471) | $7,200 |
Basic net income (loss) per common share attributable to Alere Inc. and Subsidiaries: | ($0.14) | $0.09 |
Diluted net income (loss) per common share attributable to Alere Inc. and Subsidiaries: | ($0.14) | $0.09 |
Weighted-average shares-basic | 82,387 | 81,199 |
Weighted-average shares-diluted | 82,387 | 81,300 |
Consolidated_Statements_of_Com
Consolidated Statements of Comprehensive Loss (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Statement Of Income And Comprehensive Income [Abstract] | ' | ' |
Net income (loss) | ($6,113) | $12,425 |
Other comprehensive loss, before tax: | ' | ' |
Changes in cumulative translation adjustment | -11,340 | -75,355 |
Unrealized losses on available for sale securities | -17 | 0 |
Unrealized gains on hedging instruments | 8 | 11 |
Minimum pension liability adjustment | 74 | 605 |
Other comprehensive loss, before tax | -11,275 | -74,739 |
Income tax benefit related to items of other comprehensive loss | 0 | 0 |
Other comprehensive loss, net of tax | -11,275 | -74,739 |
Comprehensive loss | -17,388 | -62,314 |
Less: Comprehensive income (loss) attributable to non-controlling interests | 108 | -25 |
Comprehensive loss attributable to Alere Inc. and Subsidiaries | ($17,496) | ($62,289) |
Consolidated_Balance_Sheets
Consolidated Balance Sheets (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Current assets: | ' | ' |
Cash and cash equivalents | $433,026 | $361,908 |
Restricted cash | 4,222 | 6,373 |
Marketable securities | 781 | 858 |
Accounts receivable, net of allowances of $78,054 and $76,643 at March 31, 2014 and December 31, 2013, respectively | 528,793 | 548,729 |
Inventories, net | 371,136 | 364,185 |
Deferred tax assets | 62,616 | 60,689 |
Prepaid expenses and other current assets | 120,529 | 129,672 |
Total current assets | 1,521,103 | 1,472,414 |
Property, plant and equipment, net | 545,051 | 545,164 |
Goodwill | 3,090,056 | 3,093,691 |
Other intangible assets with indefinite lives | 55,916 | 56,702 |
Finite-lived intangible assets, net | 1,617,254 | 1,684,611 |
Restricted cash | 28,856 | 29,370 |
Deferred financing costs, net, and other non-current assets | 80,056 | 84,073 |
Investments in unconsolidated entities | 90,445 | 86,830 |
Deferred tax assets | 7,449 | 7,959 |
Total assets | 7,036,186 | 7,060,814 |
Current liabilities: | ' | ' |
Current portion of long-term debt | 65,252 | 49,112 |
Current portion of capital lease obligations | 6,220 | 6,855 |
Accounts payable | 190,448 | 187,371 |
Accrued expenses and other current liabilities | 430,261 | 429,848 |
Total current liabilities | 692,181 | 673,186 |
Long-term liabilities: | ' | ' |
Long-term debt, net of current portion | 3,745,796 | 3,772,788 |
Capital lease obligations, net of current portion | 15,090 | 14,407 |
Deferred tax liabilities | 307,574 | 329,249 |
Other long-term liabilities | 194,989 | 188,336 |
Total long-term liabilities | 4,263,449 | 4,304,780 |
Commitments and contingencies | ' | ' |
Stockholders' equity: | ' | ' |
Series B preferred stock, $0.001 par value (liquidation preference: $709,763 at March 31, 2014 and December 31, 2013); Authorized: 2,300 shares; Issued: 2,065 shares at March 31, 2014 and December 31, 2013; Outstanding: 1,774 shares at March 31, 2014 and December 31, 2013 | 606,468 | 606,468 |
Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 90,224 shares at March 31, 2014 and 89,666 shares at December 31, 2013; Outstanding: 82,545 shares at March 31, 2014 and 81,987 shares at December 31, 2013 | 90 | 90 |
Additional paid-in capital | 3,334,264 | 3,319,168 |
Accumulated deficit | -1,642,448 | -1,636,227 |
Treasury stock, at cost, 7,679 shares at March 31, 2014 and December 31, 2013 | -184,971 | -184,971 |
Accumulated other comprehensive loss | -37,837 | -26,562 |
Total stockholders' equity | 2,075,566 | 2,077,966 |
Non-controlling interests | 4,990 | 4,882 |
Total equity | 2,080,556 | 2,082,848 |
Total liabilities and equity | $7,036,186 | $7,060,814 |
Consolidated_Balance_Sheets_Pa
Consolidated Balance Sheets (Parenthetical) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, except Per Share data, unless otherwise specified | ||
Statement Of Financial Position [Abstract] | ' | ' |
Accounts receivable, allowances | $78,054 | $76,643 |
Series B preferred stock, par value | $0.00 | $0.00 |
Series B preferred stock, liquidation preference | $709,763 | $709,763 |
Series B preferred stock, shares authorized | 2,300 | 2,300 |
Series B preferred stock, shares issued | 2,065 | 2,065 |
Series B preferred stock, shares outstanding | 1,774 | 1,774 |
Common stock, par value | $0.00 | $0.00 |
Common stock, shares authorized | 200,000 | 200,000 |
Common stock, shares issued | 90,224 | 89,666 |
Common stock, shares outstanding | 82,545 | 81,987 |
Treasury stock, shares | 7,679 | 7,679 |
Consolidated_Statements_of_Cas
Consolidated Statements of Cash Flows (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Cash Flows from Operating Activities: | ' | ' |
Net income (loss) | ($6,113) | $12,425 |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ' | ' |
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs | 4,141 | 5,217 |
Depreciation and amortization | 98,086 | 104,970 |
Non-cash charges for sale of inventories revalued at the date of acquisition | 0 | 461 |
Non-cash stock-based compensation expense | 5,704 | 4,123 |
Impairment of inventory | 589 | 0 |
Impairment of long-lived assets | 161 | 0 |
Loss on disposition of fixed assets | 2,072 | 172 |
Equity earnings of unconsolidated entities, net of tax | -5,352 | -2,934 |
Deferred income taxes | -24,636 | -50,907 |
Other non-cash items | -3,659 | 1,941 |
Changes in assets and liabilities, net of acquisitions: | ' | ' |
Accounts receivable, net | 19,898 | -20,167 |
Inventories, net | -12,745 | -17,171 |
Prepaid expenses and other current assets | 4,330 | -5,833 |
Accounts payable | 5,231 | -1,988 |
Accrued expenses and other current liabilities | 8,363 | 42,096 |
Other non-current liabilities | 13,313 | 795 |
Cash paid for contingent consideration | -3,475 | -2,139 |
Net cash provided by operating activities | 105,908 | 71,061 |
Cash Flows from Investing Activities: | ' | ' |
(Increase) decrease in restricted cash | 2,151 | -8,573 |
Purchases of property, plant and equipment | -27,540 | -36,105 |
Proceeds from sale of property, plant and equipment | 129 | 1,143 |
Cash received from disposition | 4,373 | 0 |
Cash paid for business acquisitions, net of cash acquired | 0 | -158,421 |
Cash received from (paid for) investments | -507 | 10,771 |
Cash received from sales of marketable securities | 60 | 0 |
Increase in other assets | -2,925 | -5,569 |
Net cash used in investing activities | -24,259 | -196,754 |
Cash Flows from Financing Activities: | ' | ' |
Cash paid for financing costs | -7 | -1,427 |
Cash paid for contingent purchase price consideration | -4,195 | -19,098 |
Proceeds from issuance of common stock, net of issuance costs | 14,698 | 6,135 |
Proceeds from issuance of long-term debt | 939 | 10,053 |
Payments on long-term debt | -15,823 | -19,638 |
Net proceeds under revolving credit facilities | 233 | 162,483 |
Cash paid for dividends | -5,323 | -5,323 |
Excess tax benefits on exercised stock options | 292 | 104 |
Principal payments on capital lease obligations | -1,840 | -1,721 |
Net cash provided by (used in) financing activities | -11,026 | 131,568 |
Foreign exchange effect on cash and cash equivalents | 495 | -6,988 |
Net increase (decrease) in cash and cash equivalents | 71,118 | -1,113 |
Cash and cash equivalents, beginning of period | 361,908 | 328,346 |
Cash and cash equivalents, end of period | $433,026 | $327,233 |
Basis_of_Presentation_of_Finan
Basis of Presentation of Financial Information | 3 Months Ended |
Mar. 31, 2014 | |
Accounting Policies [Abstract] | ' |
Basis of Presentation of Financial Information | ' |
(1) Basis of Presentation of Financial Information | |
The accompanying Consolidated Financial Statements of Alere Inc. are unaudited. In the opinion of management, the unaudited Consolidated Financial Statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these Consolidated Financial Statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations, comprehensive income and cash flows. Our audited Consolidated Financial Statements for the year ended December 31, 2013 included information and footnotes necessary for such presentation and were included in our Annual Report on Form 10-K, as amended, filed with the Securities and Exchange Commission, or SEC, on March 3, 2014. These unaudited Consolidated Financial Statements should be read in conjunction with our audited Consolidated Financial Statements and notes thereto for the year ended December 31, 2013. | |
Certain reclassifications of prior period amounts have been made to conform to current period presentation. These reclassifications had no effect on net income or equity. | |
During the three months ended March 31, 2014, we recorded net after-tax expense charges of $1.3 million to correct prior period items, including a net after-tax charge of $2.8 million related to the fair value of the MedApps Holding Company, Inc., or MedApps, contingent consideration obligations. We consider the adjustments to be immaterial to both the prior period and the current period financial statements. | |
Certain amounts presented may not recalculate directly, due to rounding. |
Cash_and_Cash_Equivalents
Cash and Cash Equivalents | 3 Months Ended |
Mar. 31, 2014 | |
Cash And Cash Equivalents [Abstract] | ' |
Cash and Cash Equivalents | ' |
(2) Cash and Cash Equivalents | |
We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At March 31, 2014, our cash equivalents consisted of money market funds. |
Restricted_Cash
Restricted Cash | 3 Months Ended |
Mar. 31, 2014 | |
Text Block [Abstract] | ' |
Restricted Cash | ' |
(3) Restricted Cash | |
We had restricted cash of $33.1 million and $35.7 million as of March 31, 2014 and December 31, 2013, respectively. $28.9 million and $29.4 million of our restricted cash as of March 31, 2014 and December 31, 2013, respectively, was classified as non-current on our Consolidated Balance Sheet, as it secures a foreign bank loan arrangement that we entered into during the third quarter of 2013 and, under the terms of the loan agreement, is required to remain on deposit for two years. |
Inventories
Inventories | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Inventory Disclosure [Abstract] | ' | ||||||||
Inventories | ' | ||||||||
(4) Inventories | |||||||||
Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands): | |||||||||
March 31, 2014 | December 31, 2013 | ||||||||
Raw materials | $ | 124,020 | $ | 118,571 | |||||
Work-in-process | 73,848 | 79,559 | |||||||
Finished goods | 173,268 | 166,055 | |||||||
$ | 371,136 | $ | 364,185 | ||||||
StockBased_Compensation
Stock-Based Compensation | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ' | ||||||||
Stock-Based Compensation | ' | ||||||||
(5) Stock-based Compensation | |||||||||
We recorded stock-based compensation expense in our Consolidated Statements of Operations for the three months ended March 31, 2014 and 2013, respectively, as follows (in thousands): | |||||||||
Three Months Ended March 31, | |||||||||
2014 | 2013 | ||||||||
Cost of net revenue | $ | 287 | $ | 232 | |||||
Research and development | 1,191 | 747 | |||||||
Sales and marketing | 891 | 716 | |||||||
General and administrative | 3,335 | 2,428 | |||||||
5,704 | 4,123 | ||||||||
Benefit for income taxes | (1,778 | ) | (862 | ) | |||||
$ | 3,926 | $ | 3,261 | ||||||
Net_Income_Loss_Per_Common_Sha
Net Income (Loss) Per Common Share | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Earnings Per Share [Abstract] | ' | ||||||||
Net Income (Loss) Per Common Share | ' | ||||||||
(6) Net Income (Loss) per Common Share | |||||||||
The following table sets forth the computation of basic and diluted net income (loss) per common share for the three months ended March 31, 2014 and 2013 (in thousands, except per share amounts): | |||||||||
Three Months Ended March 31, | |||||||||
2014 | 2013 | ||||||||
Basic and diluted net income (loss) per common share: | |||||||||
Numerator: | |||||||||
Net income (loss) | $ | (6,113 | ) | $ | 12,425 | ||||
Preferred stock dividends | (5,250 | ) | (5,250 | ) | |||||
Less: Net income (loss) attributable to non-controlling interest | 108 | (25 | ) | ||||||
Net income (loss) available to common stockholders | $ | (11,471 | ) | $ | 7,200 | ||||
Denominator: | |||||||||
Weighted-average common shares outstanding—basic | 82,387 | 81,199 | |||||||
Effect of dilutive securities: | |||||||||
Stock options | — | 101 | |||||||
Weighted-average common shares outstanding—diluted | 82,387 | 81,300 | |||||||
Basic net income (loss) per common share attributable to Alere Inc. and Subsidiaries | $ | (0.14 | ) | $ | 0.09 | ||||
Diluted net income (loss) per common share attributable to Alere Inc. and Subsidiaries | $ | (0.14 | ) | $ | 0.09 | ||||
The following potential dilutive securities were not included in the calculation of diluted net income (loss) per common share because the inclusion thereof would be antidilutive (in thousands): | |||||||||
Three Months Ended March 31, | |||||||||
2014 | 2013 | ||||||||
Denominator: | |||||||||
Options to purchase shares of common stock | 11,143 | 9,987 | |||||||
Warrants | 4 | 4 | |||||||
Conversion shares related to 3% convertible senior subordinated notes | 3,411 | 3,411 | |||||||
Conversion shares related to subordinated convertible promissory notes | 27 | 27 | |||||||
Conversion shares related to Series B convertible preferred stock | 10,239 | 10,239 | |||||||
Common stock equivalents related to the settlement of a contingent consideration obligation | 358 | — | |||||||
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding | 25,182 | 23,668 | |||||||
Stockholders_Equity_and_NonCon
Stockholders' Equity and Non-Controlling Interests | 3 Months Ended | ||||||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||||||
Equity [Abstract] | ' | ||||||||||||||||||||||||
Stockholders' Equity and Non-Controlling Interests | ' | ||||||||||||||||||||||||
(7) Stockholders’ Equity and Non-controlling Interests | |||||||||||||||||||||||||
(a) Preferred Stock | |||||||||||||||||||||||||
For both the three months ended March 31, 2014 and 2013, Series B preferred stock dividends amounted to $5.3 million, which reduced earnings available to common stockholders for purposes of calculating net income (loss) per common share for each of the periods. As of March 31, 2014, $5.3 million of Series B preferred stock dividends was accrued. As of April 15, 2014, payments have been made covering all dividend periods through March 31, 2014. | |||||||||||||||||||||||||
The Series B preferred stock dividends for the three months ended March 31, 2014 and 2013 were paid in cash. | |||||||||||||||||||||||||
(b) Changes in Stockholders’ Equity and Non-controlling Interests | |||||||||||||||||||||||||
A summary of the changes in stockholders’ equity and non-controlling interests comprising total equity for the three months ended March 31, 2014 and 2013 is provided below (in thousands): | |||||||||||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||||||||||
2014 | 2013 | ||||||||||||||||||||||||
Total | Non- | Total | Total | Non- | Total | ||||||||||||||||||||
Stockholders’ | controlling | Equity | Stockholders’ | controlling | Equity | ||||||||||||||||||||
Equity | Interests | Equity | Interests | ||||||||||||||||||||||
Equity, beginning of period | $ | 2,077,966 | $ | 4,882 | $ | 2,082,848 | $ | 2,180,422 | $ | 2,282 | $ | 2,182,704 | |||||||||||||
Issuance of common stock under employee compensation plans | 14,698 | — | 14,698 | 6,135 | — | 6,135 | |||||||||||||||||||
Preferred stock dividends | (5,323 | ) | — | (5,323 | ) | (5,323 | ) | — | (5,323 | ) | |||||||||||||||
Stock-based compensation expense | 5,704 | — | 5,704 | 4,123 | — | 4,123 | |||||||||||||||||||
Excess tax benefits on exercised stock options | 17 | — | 17 | (422 | ) | — | (422 | ) | |||||||||||||||||
Net income (loss) | (6,221 | ) | 108 | (6,113 | ) | 12,450 | (25 | ) | 12,425 | ||||||||||||||||
Total other comprehensive loss | (11,275 | ) | — | (11,275 | ) | (74,739 | ) | — | (74,739 | ) | |||||||||||||||
Equity, end of period | $ | 2,075,566 | $ | 4,990 | $ | 2,080,556 | $ | 2,122,646 | $ | 2,257 | $ | 2,124,903 | |||||||||||||
Business_Combinations
Business Combinations | 3 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Business Combinations [Abstract] | ' | ||||||||||||||||
Business Combinations | ' | ||||||||||||||||
(8) Business Combinations | |||||||||||||||||
Acquisitions are accounted for using the acquisition method and the acquired companies’ results have been included in the accompanying Consolidated Financial Statements from their respective dates of acquisition. During the three months ended March 31, 2014 and 2013, we expensed acquisition-related costs of $0.3 million and $0.9 million, respectively, in general and administrative expense. | |||||||||||||||||
Our business acquisitions have historically been made at prices above the fair value of the assets acquired and liabilities assumed, resulting in goodwill, based on our expectations of synergies and other benefits of combining the businesses. These synergies and benefits include elimination of redundant facilities, functions and staffing; use of our existing commercial infrastructure to expand sales of the products of the acquired businesses; and use of the commercial infrastructure of the acquired businesses to expand product sales in a cost-efficient manner. | |||||||||||||||||
Net assets acquired are recorded at their fair value and are subject to adjustment upon finalization of the fair value analysis. We are not aware of any information that indicates the final fair value analysis will differ materially from the preliminary estimates. The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the intangible assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets based on patterns on which the respective economic benefits are expected to be realized. | |||||||||||||||||
Acquisitions in 2013 | |||||||||||||||||
(a) Epocal | |||||||||||||||||
On February 1, 2013, we acquired Epocal, Inc., or Epocal, located in Ottawa, Canada, a provider of technologies that support blood gas and electrolyte testing at the point of care. The aggregate purchase price was approximately $248.5 million, which consisted of $151.4 million in cash, a $22.1 million settlement of a pre-existing arrangement and a contingent consideration obligation with an aggregate acquisition date fair value of $75.0 million. The operating results of Epocal are included in our professional diagnostics reporting unit and business segment. The amount allocated to goodwill from this acquisition is not deductible for tax purposes. | |||||||||||||||||
(b) Other acquisitions in 2013 | |||||||||||||||||
During the year ended December 31, 2013, we acquired the following businesses for a preliminary aggregate purchase price of $57.6 million, which included cash payments totaling $28.2 million, a $17.5 million settlement of a pre-existing arrangement, contingent consideration obligations with an aggregate acquisition date fair value of $1.3 million, deferred purchase price consideration with an acquisition date fair value of $0.8 million and an $8.0 million bargain purchase gain. | |||||||||||||||||
• | certain assets of PT Mega Medika Mandiri, or Mega Medika, located in South Jakarta, Indonesia, a distributor of infectious disease products to the Indonesian marketplace as well as materials for vaccines to a pharmaceutical customer (Acquired January 2013) | ||||||||||||||||
• | Discount Diabetic, LLC, or Discount Diabetic, located in Phoenix, Arizona, a provider of blood glucose monitoring products, including diabetes testing systems and test strips and other products (Acquired April 2013) | ||||||||||||||||
• | the Medicare fee-for-service assets of Liberty Medical, or the Liberty business, located in Port St. Lucie, Florida, a leading mail order provider of diabetes testing supplies serving the needs of both Type 1 and Type 2 diabetic patients (Acquired April 2013) | ||||||||||||||||
• | 51% share in Cardio Selfcare B.V., subsequently renamed Alere Health Services B.V., or Alere Health Services, located in Ede, the Netherlands, a developer of innovative software for the healthcare industry that develops and licenses software and sells medical devices to enable patients to perform medical self-care, including thrombosis self-care (Acquired May 2013) | ||||||||||||||||
• | 74.9% interest in Pantech Proprietary Limited, or Pantech, located in Durban, South Africa, a supplier of rapid diagnostic test kits, including HIV, malaria, syphilis, drugs of abuse, 10 parameter urine sticks, glucometers and glucose sticks (Acquired July 2013) | ||||||||||||||||
• | Certain assets of Simplex Healthcare, Inc. and its subsidiaries, or Simplex, located in Tennessee, a provider of home delivery of diabetes-related medical supplies and products (Acquired November 2013) | ||||||||||||||||
The operating results of Mega Medika, Discount Diabetic, the Liberty business, Alere Health Services, Pantech, and Simplex are included in our professional diagnostics reporting unit and business segment. | |||||||||||||||||
Our Consolidated Statement of Operations for the three months ended March 31, 2014 included revenue totaling approximately $23.8 million related to these businesses. Goodwill has been recognized in the Mega Medika, Alere Health Services, Pantech, and Simplex acquisitions and amounted to approximately $2.5 million. The goodwill related to the Mega Medika and Simplex acquisitions is deductible for tax purposes, but the goodwill related to the Pantech and Alere Health Services acquisitions is not. | |||||||||||||||||
With respect to our acquisition of the Liberty business, the purchase price of the acquisition has been allocated to the net tangible and intangible assets acquired, with the excess of the fair value of assets acquired over the purchase price recorded as a bargain purchase gain. The $8.0 million bargain purchase gain has been recorded in other income (expense), net in our consolidated statement of operations and is not recognized for tax purposes. The bargain purchase gain resulted from our operating cost structure which we believe will allow us to operate this business more cost effectively than the sellers. | |||||||||||||||||
A summary of the preliminary fair values of the net assets acquired for the acquisitions consummated in 2013 is as follows (in thousands): | |||||||||||||||||
Epocal | Other | Total | |||||||||||||||
Current assets (1) | $ | 12,536 | $ | 13,702 | $ | 26,238 | |||||||||||
Property, plant and equipment | 1,267 | 1,669 | 2,936 | ||||||||||||||
Goodwill | 98,454 | 2,543 | 100,997 | ||||||||||||||
Intangible assets | 164,400 | 51,180 | 215,580 | ||||||||||||||
Other non-current assets | 18,158 | 29 | 18,187 | ||||||||||||||
Total assets acquired | 294,815 | 69,123 | 363,938 | ||||||||||||||
Current liabilities | 2,627 | 5,398 | 8,025 | ||||||||||||||
Non-current liabilities | 43,727 | 6,175 | 49,902 | ||||||||||||||
Total liabilities assumed | 46,354 | 11,573 | 57,927 | ||||||||||||||
Net assets acquired | 248,461 | 57,550 | 306,011 | ||||||||||||||
Less: | |||||||||||||||||
Contingent consideration | 75,000 | 1,264 | 76,264 | ||||||||||||||
Settlement of pre-existing arrangements | 22,088 | 17,500 | 39,588 | ||||||||||||||
Non-controlling interest | — | 1,774 | 1,774 | ||||||||||||||
Bargain purchase gain | — | 8,023 | 8,023 | ||||||||||||||
Deferred purchase price consideration | — | 768 | 768 | ||||||||||||||
Cash paid | $ | 151,373 | $ | 28,221 | $ | 179,594 | |||||||||||
(1) | Includes approximately $3.3 million of acquired cash. | ||||||||||||||||
The following are the intangible assets acquired and their respective fair values and weighted-average useful lives (dollars in thousands): | |||||||||||||||||
Epocal | Other | Total | Weighted- | ||||||||||||||
average | |||||||||||||||||
Useful Life | |||||||||||||||||
Core technology and patents | $ | 119,700 | $ | — | $ | 119,700 | 20.0 years | ||||||||||
Software | — | 2,154 | 2,154 | 5.7 years | |||||||||||||
Trademarks and trade names | 20,500 | 80 | 20,580 | 19.1 years | |||||||||||||
License agreements | — | 620 | 620 | 1.5 years | |||||||||||||
Customer relationships | — | 42,510 | 42,510 | 11.5 years | |||||||||||||
Other | — | 5,816 | 5,816 | 3.0 years | |||||||||||||
In-process research and development | 24,200 | — | 24,200 | N/A | |||||||||||||
Total intangible assets | $ | 164,400 | $ | 51,180 | $ | 215,580 | |||||||||||
Restructuring
Restructuring | 3 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Restructuring And Related Activities [Abstract] | ' | ||||||||||||||||
Restructuring | ' | ||||||||||||||||
(9) Restructuring | |||||||||||||||||
The following table sets forth aggregate restructuring charges recorded in our Consolidated Statements of Operations for the three months ended March 31, 2014 and 2013 (in thousands): | |||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||
Statement of Operations Caption | 2014 | 2013 | |||||||||||||||
Cost of net revenue | $ | 875 | $ | 623 | |||||||||||||
Research and development | — | — | |||||||||||||||
Sales and marketing | 1,557 | 1,099 | |||||||||||||||
General and administrative | 4,783 | 2,170 | |||||||||||||||
Total operating expenses | 7,215 | 3,892 | |||||||||||||||
Interest expense, including amortization of original issue discounts and deferred financing costs | 125 | 55 | |||||||||||||||
Total charges | $ | 7,340 | $ | 3,947 | |||||||||||||
(a) 2014 Restructuring Plans | |||||||||||||||||
In 2014, management developed cost reduction efforts within our professional diagnostics and corporate and other business segments, including our U.S. sales force, our global information technology group, and certain businesses in Europe. The following table summarizes the restructuring activities related to our 2014 restructuring plans for the three months ended March 31, 2014 (in thousands): | |||||||||||||||||
Professional Diagnostics | Corporate and Other | Total | |||||||||||||||
Severance-related costs | $ | 2,364 | $ | 87 | $ | 2,451 | |||||||||||
Facility and transition costs | 34 | 8 | 42 | ||||||||||||||
Cash charges | 2,398 | 95 | 2,493 | ||||||||||||||
Fixed asset and inventory impairments | 750 | — | 750 | ||||||||||||||
Total charges | $ | 3,148 | $ | 95 | $ | 3,243 | |||||||||||
We anticipate incurring approximately $3.9 million and $1.3 million in additional costs under our 2014 restructuring plans related to our professional diagnostics and corporate and other business segments, respectively, in the U.S. and Europe and may develop additional plans over the remainder of 2014. As of March 31, 2014, $0.7 million in severance costs arising under our 2014 restructuring plans remain unpaid. | |||||||||||||||||
(b) 2013 Restructuring Plans | |||||||||||||||||
In 2013, management developed cost reduction efforts within our professional diagnostics business segment, including businesses in our United States, Europe and Asia Pacific regions. Additionally, management took steps to improve efficiencies within our health information solutions business segment, including winding down a small portion of this business, which resulted in charges associated with the impairment of related fixed and intangible assets. The following table summarizes the restructuring activities in our professional diagnostics and health information solutions business segments related to our 2013 restructuring plans for the three months ended March 31, 2014 and 2013 and since inception (in thousands): | |||||||||||||||||
Three Months Ended March 31, | Since | ||||||||||||||||
Professional Diagnostics | 2014 | 2013 | Inception | ||||||||||||||
Severance-related costs | $ | 838 | $ | 833 | $ | 7,964 | |||||||||||
Facility and transition costs | 174 | 13 | 2,755 | ||||||||||||||
Cash charges | 1,012 | 846 | 10,719 | ||||||||||||||
Fixed asset and inventory impairments | — | — | 743 | ||||||||||||||
Total charges | $ | 1,012 | $ | 846 | $ | 11,462 | |||||||||||
Three Months Ended March 31, | Since | ||||||||||||||||
Health Information Solutions | 2014 | 2013 | Inception | ||||||||||||||
Severance-related costs | $ | 89 | $ | 69 | $ | 3,356 | |||||||||||
Facility and transition costs | 3,227 | — | 6,182 | ||||||||||||||
Other exit costs | 33 | — | 50 | ||||||||||||||
Cash charges | 3,349 | 69 | 9,588 | ||||||||||||||
Fixed asset and inventory impairments | — | — | 1,089 | ||||||||||||||
Intangible asset impairments | — | — | 2,596 | ||||||||||||||
Other non-cash (recoveries) | (854 | ) | — | (1,757 | ) | ||||||||||||
Total charges | $ | 2,495 | $ | 69 | $ | 11,516 | |||||||||||
We anticipate incurring approximately $2.4 million in additional costs under our 2013 restructuring plans related to our professional diagnostics business segment in the United States and Europe and approximately $0.7 million in additional facility costs under our 2013 restructuring plans related to our health information solutions segment. As of March 31, 2014, $7.4 million in severance and facility costs arising under our 2013 restructuring plans remain unpaid. | |||||||||||||||||
(c) Restructuring Plans Prior to 2013 | |||||||||||||||||
In 2012, management developed cost reduction plans within our professional diagnostics business segment, including the integration of our businesses in Brazil, Europe and the United States. Additionally, management developed new plans to continue our efforts to reduce costs within our health information solutions business segment, including the termination of certain projects, which resulted in charges for the impairment of related fixed and intangible assets. | |||||||||||||||||
In 2011, management executed a company-wide cost reduction plan, which impacted our corporate and other business segment, as well as the health information solutions and professional diagnostics business segments. Management also developed plans within our professional diagnostics business segment to consolidate operating activities among certain of our U.S., European and Asia Pacific subsidiaries, including transferring the manufacturing of our Panbio products from Australia to our Standard Diagnostics facility in South Korea and eliminating redundant costs among our newly acquired Axis-Shield subsidiaries. Additionally, within our health information solutions business segment, management executed plans to further reduce costs and improve efficiencies, as well as cease operations at our GeneCare Medical Genetics Center, Inc., facility in Chapel Hill, North Carolina and transfer the majority of our Quality Assured Services, Inc. operation in Orlando, Florida to our facility in Livermore, California. | |||||||||||||||||
In 2010, management developed several plans to reduce costs and improve efficiencies within our health information solutions and professional diagnostics business segments. Additionally in 2008, management developed and initiated plans to transition the businesses of Cholestech Corporation to our San Diego, California facility. | |||||||||||||||||
The following table summarizes the restructuring activities related to our active 2012, 2011, 2010 and 2008 restructuring plans for the three months ended March 31, 2014 and 2013 and since inception (in thousands): | |||||||||||||||||
Three Months Ended March 31, | Since | ||||||||||||||||
Professional Diagnostics | 2014 | 2013 | Inception | ||||||||||||||
Severance-related costs | $ | 59 | $ | 312 | $ | 24,251 | |||||||||||
Facility and transition costs | 84 | 232 | 8,846 | ||||||||||||||
Other exit costs | 12 | 16 | 768 | ||||||||||||||
Cash charges | 155 | 560 | 33,865 | ||||||||||||||
Fixed asset and inventory impairments | — | — | 6,922 | ||||||||||||||
Intangible asset impairments | — | — | 686 | ||||||||||||||
Other non-cash charges | — | — | 64 | ||||||||||||||
Total charges | $ | 155 | $ | 560 | $ | 41,537 | |||||||||||
Three Months Ended March 31, | Since | ||||||||||||||||
Health Information Solutions | 2014 | 2013 | Inception | ||||||||||||||
Severance-related costs | $ | — | $ | 1,819 | $ | 12,308 | |||||||||||
Facility and transition costs (recoveries) | 355 | 659 | 13,870 | ||||||||||||||
Other exit costs | 80 | 39 | 843 | ||||||||||||||
Cash charges (recoveries) | 435 | 2,517 | 27,021 | ||||||||||||||
Fixed asset and inventory impairments | — | — | 3,878 | ||||||||||||||
Intangible asset impairments | — | — | 5,923 | ||||||||||||||
Other non-cash charges | — | (45 | ) | (223 | ) | ||||||||||||
Total charges (recoveries) | $ | 435 | $ | 2,472 | $ | 36,599 | |||||||||||
We anticipate incurring approximately $0.8 million in additional facility costs under these plans related to our professional diagnostics and health information solutions business segments. As of March 31, 2014, $4.9 million in cash charges remain unpaid, primarily related to facility lease obligations, which are anticipated to continue through 2020. | |||||||||||||||||
(d) Restructuring Reserves | |||||||||||||||||
The following table summarizes our restructuring reserves related to the plans described above, of which $7.7 million is included in accrued expenses and other current liabilities and $5.3 million is included in other long-term liabilities on our accompanying Consolidated Balance Sheets (in thousands): | |||||||||||||||||
Severance- | Facility and | Other Exit | Total | ||||||||||||||
related | Transition | Costs | |||||||||||||||
Costs | Costs | ||||||||||||||||
Balance, December 31, 2013 | $ | 2,708 | $ | 7,830 | $ | 609 | $ | 11,147 | |||||||||
Cash charges | 3,437 | 3,882 | 125 | 7,444 | |||||||||||||
Payments | (4,063 | ) | (1,459 | ) | (73 | ) | (5,595 | ) | |||||||||
Currency adjustments | 5 | 35 | (9 | ) | 31 | ||||||||||||
Balance, March 31, 2014 | $ | 2,087 | $ | 10,288 | $ | 652 | $ | 13,027 | |||||||||
LongTerm_Debt
Long-Term Debt | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Debt Disclosure [Abstract] | ' | ||||||||
Long-Term Debt | ' | ||||||||
(10) Long-term Debt | |||||||||
We had the following long-term debt balances outstanding (in thousands): | |||||||||
March 31, | December 31, | ||||||||
2014 | 2013 | ||||||||
A term loans(1) (2) | $ | 820,625 | $ | 832,188 | |||||
B term loans(1) | 901,875 | 904,188 | |||||||
Incremental B-1 term loans(1) | 244,375 | 245,000 | |||||||
Incremental B-2 term loans(1) | 194,629 | 195,050 | |||||||
Revolving line of credit(1) | 170,000 | 170,000 | |||||||
7.25% Senior notes | 450,000 | 450,000 | |||||||
6.5% Senior subordinated notes | 425,000 | 425,000 | |||||||
8.625% Senior subordinated notes | 400,000 | 400,000 | |||||||
3% Convertible senior subordinated notes | 150,000 | 150,000 | |||||||
Other lines of credit | 581 | 355 | |||||||
Other | 53,963 | 50,119 | |||||||
3,811,048 | 3,821,900 | ||||||||
Less: Current portion | (65,252 | ) | (49,112 | ) | |||||
$ | 3,745,796 | $ | 3,772,788 | ||||||
(1) | Incurred under our secured credit facility. | ||||||||
(2) | Includes “A” term loans and “Delayed Draw” term loans under our secured credit facility. | ||||||||
In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying Consolidated Statements of Operations for the three months ended March 31, 2014 and 2013, respectively, as follows (in thousands): | |||||||||
Three Months Ended March 31, | |||||||||
2014 | 2013 | ||||||||
Secured credit facility (1) | $ | 24,762 | $ | 27,275 | |||||
7.25% Senior notes | 8,525 | 8,356 | |||||||
7.875% Senior notes | — | (27 | ) | ||||||
6.5% Senior subordinated notes | 7,178 | — | |||||||
9% Senior subordinated notes | — | 10,394 | |||||||
8.625% Senior subordinated notes | 9,273 | 9,273 | |||||||
3% Convertible senior subordinated notes | 1,246 | 1,246 | |||||||
$ | 50,984 | $ | 56,517 | ||||||
(1) | Includes “A” term loans, including the “Delayed-Draw” term loans; “B” term loans; “Incremental B-1” term loans; “Incremental B-2” term loans; and revolving line of credit loans. For the three months ended March 31, 2014 and 2013, the amounts include $0.4 million and $1.0 million, respectively, related to the amortization of fees paid for certain debt modifications. |
Fair_Value_Measurements
Fair Value Measurements | 3 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Fair Value Disclosures [Abstract] | ' | ||||||||||||||||
Fair Value Measurements | ' | ||||||||||||||||
(11) Fair Value Measurements | |||||||||||||||||
We apply fair value measurement accounting to value our financial assets and liabilities. Fair value measurement accounting provides a framework for measuring fair value under U.S. GAAP and requires expanded disclosures regarding fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. | |||||||||||||||||
Described below are the three levels of inputs that may be used to measure fair value: | |||||||||||||||||
Level 1—Quoted prices in active markets for identical assets or liabilities. | |||||||||||||||||
Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. | |||||||||||||||||
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. | |||||||||||||||||
The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): | |||||||||||||||||
Description | March 31, | Quoted Prices in | Significant Other | Unobservable Inputs | |||||||||||||
2014 | Active Markets | Observable Inputs | (Level 3) | ||||||||||||||
(Level 1) | (Level 2) | ||||||||||||||||
Assets: | |||||||||||||||||
Marketable securities | $ | 781 | $ | 781 | $ | — | $ | — | |||||||||
Total assets | $ | 781 | $ | 781 | $ | — | $ | — | |||||||||
Liabilities: | |||||||||||||||||
Contingent consideration obligations (1) | $ | 210,819 | $ | — | $ | — | $ | 210,819 | |||||||||
Total liabilities | $ | 210,819 | $ | — | $ | — | $ | 210,819 | |||||||||
Description | December 31, | Quoted Prices in | Significant Other | Unobservable Inputs | |||||||||||||
2013 | Active Markets | Observable Inputs | (Level 3) | ||||||||||||||
(Level 1) | (Level 2) | ||||||||||||||||
Assets: | |||||||||||||||||
Marketable securities | $ | 858 | $ | 858 | $ | — | $ | — | |||||||||
Total assets | $ | 858 | $ | 858 | $ | — | $ | — | |||||||||
Liabilities: | |||||||||||||||||
Contingent consideration obligations (1) | $ | 213,969 | $ | — | $ | — | $ | 213,969 | |||||||||
Total liabilities | $ | 213,969 | $ | — | $ | — | $ | 213,969 | |||||||||
(1) | We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our Consolidated Statements of Operations. See Note 16 for additional information on the valuation of our contingent consideration obligations. | ||||||||||||||||
Changes in the fair value of our Level 3 contingent consideration obligations during the three months ended March 31, 2014 were as follows (in thousands): | |||||||||||||||||
Fair value of contingent consideration obligations, January 1, 2014 | $ | 213,969 | |||||||||||||||
Payments | (7,710 | ) | |||||||||||||||
Present value accretion and adjustments | 4,550 | ||||||||||||||||
Foreign currency adjustments | 10 | ||||||||||||||||
Fair value of contingent consideration obligations, March 31, 2014 | $ | 210,819 | |||||||||||||||
At March 31, 2014 and December 31, 2013, the carrying amounts of cash and cash equivalents, restricted cash, receivables, accounts payable and other current liabilities approximated their estimated fair values. | |||||||||||||||||
The carrying amount and estimated fair value of our long-term debt were $3.8 billion and $3.9 billion, respectively, at March 31, 2014. The carrying amount and estimated fair value of our long-term debt were $3.8 billion and $3.9 billion, respectively, at December 31, 2013. The estimated fair value of our long-term debt was determined using market sources that were derived from available market information (Level 2 in the fair value hierarchy) and may not be representative of actual values that could have been or will be realized in the future. |
Defined_Benefit_Pension_Plan
Defined Benefit Pension Plan | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Compensation And Retirement Disclosure [Abstract] | ' | ||||||||
Defined Benefit Pension Plan | ' | ||||||||
(12) Defined Benefit Pension Plan | |||||||||
Our subsidiary in England, Unipath Ltd., has a defined benefit pension plan established for certain of its employees. The net periodic benefit costs are as follows (in thousands): | |||||||||
Three Months Ended March 31, | |||||||||
2014 | 2013 | ||||||||
Service cost | $ | — | $ | — | |||||
Interest cost | 199 | 182 | |||||||
Expected return on plan assets | (188 | ) | (156 | ) | |||||
Amortization of prior service cost | 110 | 103 | |||||||
Net periodic benefit cost | $ | 121 | $ | 129 | |||||
Financial_Information_by_Segme
Financial Information by Segment | 3 Months Ended | ||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||
Segment Reporting [Abstract] | ' | ||||||||||||||||||||
Financial Information by Segment | ' | ||||||||||||||||||||
(13) Financial Information by Segment | |||||||||||||||||||||
Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of the chief executive officer and members of senior management. Our reportable operating segments are professional diagnostics, health information solutions, consumer diagnostics and corporate and other. Our operating results include license and royalty revenue which are allocated to professional diagnostics and consumer diagnostics on the basis of the original license or royalty agreement. We evaluate performance of our operating segments based on revenue and operating income (loss). Segment information for the three months ended March 31, 2014 and 2013 is as follows (in thousands): | |||||||||||||||||||||
Professional | Health | Consumer | Corporate | Total | |||||||||||||||||
Diagnostics | Information | Diagnostics | and | ||||||||||||||||||
Solutions | Other | ||||||||||||||||||||
Three Months Ended March 31, 2014: | |||||||||||||||||||||
Net revenue | $ | 566,545 | $ | 123,668 | $ | 26,409 | $ | — | $ | 716,622 | |||||||||||
Operating income (loss) | $ | 51,326 | $ | (6,720 | ) | $ | 2,248 | $ | (20,914 | ) | $ | 25,940 | |||||||||
Depreciation and amortization | $ | 77,421 | $ | 19,111 | $ | 920 | $ | 634 | $ | 98,086 | |||||||||||
Restructuring charges | $ | 4,303 | $ | 2,817 | $ | — | $ | 95 | $ | 7,215 | |||||||||||
Stock-based compensation | $ | — | $ | — | $ | — | $ | 5,704 | $ | 5.704 | |||||||||||
Three Months Ended March 31, 2013: | |||||||||||||||||||||
Net revenue | $ | 582,492 | $ | 134,207 | $ | 22,550 | $ | — | $ | 739,249 | |||||||||||
Operating income (loss) | $ | 59,840 | $ | (13,893 | ) | $ | 2,280 | $ | (17,738 | ) | $ | 30,489 | |||||||||
Depreciation and amortization | $ | 82,794 | $ | 20,737 | $ | 1,153 | $ | 286 | $ | 104,970 | |||||||||||
Non-cash charge associated with acquired inventory | $ | 461 | $ | — | $ | — | $ | — | $ | 461 | |||||||||||
Restructuring charges | $ | 1,389 | $ | 2,503 | $ | — | $ | — | $ | 3,892 | |||||||||||
Stock-based compensation | $ | — | $ | — | $ | — | $ | 4,123 | $ | 4,123 | |||||||||||
Assets: | |||||||||||||||||||||
As of March 31, 2014 | $ | 5,697,874 | $ | 496,310 | $ | 205,105 | $ | 636,897 | $ | 7,036,186 | |||||||||||
As of December 31, 2013 | $ | 5,744,734 | $ | 504,645 | $ | 197,458 | $ | 613,977 | $ | 7,060,814 | |||||||||||
The following tables summarize our net revenue from the professional diagnostics and health information solutions reporting segments by groups of similar products and services for the three months ended March 31, 2014 and 2013 (in thousands): | |||||||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||||||
Professional Diagnostics Segment | 2014 | 2013 | |||||||||||||||||||
Infectious disease | $ | 164,030 | $ | 189,844 | |||||||||||||||||
Toxicology | 151,897 | 149,049 | |||||||||||||||||||
Cardiology | 121,633 | 114,933 | |||||||||||||||||||
Diabetes | 50,721 | 50,083 | |||||||||||||||||||
Other | 73,052 | 74,719 | |||||||||||||||||||
Professional diagnostics net product sales and services revenue | 561,333 | 578,628 | |||||||||||||||||||
License and royalty revenue | 5,212 | 3,864 | |||||||||||||||||||
Professional diagnostics net revenue | $ | 566,545 | $ | 582,492 | |||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||||||
Health Information Solutions Segment | 2014 | 2013 | |||||||||||||||||||
Condition and case management | $ | 49,319 | $ | 54,126 | |||||||||||||||||
Wellness | 24,950 | 26,300 | |||||||||||||||||||
Women’s & children’s health | 22,215 | 29,080 | |||||||||||||||||||
Patient self-testing services | 27,184 | 24,701 | |||||||||||||||||||
Health information solutions net revenue | $ | 123,668 | $ | 134,207 | |||||||||||||||||
Related_Party_Transactions
Related Party Transactions | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Related Party Transactions [Abstract] | ' | ||||||||
Related Party Transactions | ' | ||||||||
(14) Related Party Transactions | |||||||||
In May 2007, we completed the formation of Swiss Precision Diagnostics GmbH, or SPD, our 50/50 joint venture with Procter & Gamble, for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiology, diabetes and oral care fields. Upon completion of the arrangement to form the joint venture, we ceased to consolidate the operating results of our consumer diagnostic products business related to the joint venture and instead account for our 50% interest in the results of the joint venture under the equity method of accounting. | |||||||||
We had a net receivable from SPD of $0.2 million and $2.1 million as of March 31, 2014 and December 31, 2013, respectively. Included in the $0.2 million receivable balance as of March 31, 2014 is approximately $1.7 million of costs incurred in connection with our 2008 SPD-related restructuring plans. Included in the $2.1 million receivable balance as of December 31, 2013 is approximately $1.8 million of costs incurred in connection with our 2008 SPD-related restructuring plans. We have also recorded a long-term receivable totaling approximately $13.3 million and $13.2 million as of March 31, 2014 and December 31, 2013, respectively, related to the 2008 SPD-related restructuring plans. Additionally, customer receivables associated with revenue earned after the formation of the joint venture was completed have been classified as other receivables within prepaid and other current assets on our accompanying Consolidated Balance Sheets in the amount of $9.3 million and $12.4 million as of March 31, 2014 and December 31, 2013, respectively. In connection with the joint venture arrangement, the joint venture bears the collection risk associated with these receivables. Sales to the joint venture under our manufacturing agreement totaled $20.6 million and $17.1 million during the three-month periods ended March 31, 2014 and 2013, respectively. Additionally, services revenue generated pursuant to the long-term services agreement with the joint venture totaled $0.4 million and $0.3 million during the three-month periods ended March 31, 2014 and 2013, respectively. Sales under our manufacturing agreement and long-term services agreement are included in net product sales and services revenue, respectively, in our accompanying Consolidated Statements of Operations. | |||||||||
Under the terms of our product supply agreement, SPD purchases products from our manufacturing facilities in China. SPD in turn sells a portion of those tests back to us for final assembly and packaging. Once packaged, a portion of the tests are sold to P&G for distribution to third-party customers in North America. As a result of these related transactions, we have recorded $5.8 million and $9.4 million of trade receivables which are included in accounts receivable on our accompanying Consolidated Balance Sheets as of March 31, 2014 and December 31, 2013, respectively, and $22.2 million and $18.8 million of trade accounts payable which are included in accounts payable on our accompanying Consolidated Balance Sheets as of March 31, 2014 and December 31, 2013, respectively. During the three months ended March 31, 2013, we received $10.8 million in cash from SPD as a return of capital. | |||||||||
The following table summarizes our related party balances with SPD within our Consolidated Balance Sheets (in thousands): | |||||||||
Balance Sheet Caption | March 31, 2014 | December 31, 2013 | |||||||
Accounts receivable, net of allowances | $ | 5,753 | $ | 9,436 | |||||
Prepaid expenses and other current assets | $ | 9,469 | $ | 12,417 | |||||
Deferred financing costs, net, and other non-current assets | $ | 13,313 | $ | 13,249 | |||||
Accounts payable | $ | 22,215 | $ | 18,811 |
Other_Arrangements
Other Arrangements | 3 Months Ended |
Mar. 31, 2014 | |
Text Block [Abstract] | ' |
Other Arrangements | ' |
(15) Other Arrangements | |
On February 19, 2013, we entered into an agreement with the Bill and Melinda Gates Foundation, or the Gates Foundation, whereby we were awarded a grant by the Gates Foundation in the amount of $21.6 million to support the development and commercialization of a validated, low-cost, nucleic-acid assay for clinical Tuberculosis, or TB, detection and drug-resistance test cartridges and adaptation of an analyzer platform capable of operation in rudimentary laboratories in low-resource settings. In connection with this agreement, we also entered into a loan agreement with the Gates Foundation, or the Gates Loan Agreement, which provides for the making of subordinated term loans by the Gates Foundation to us from time to time, subject to the achievement of certain milestones, in an aggregate principal amount of up to $20.6 million. Funding under the Gates Loan Agreement will be used in connection with the purchase of equipment for an automated high-throughput manufacturing line and other uses as necessary for the manufacture of the TB and HIV-related products. All loans under the Gates Loan Agreement are evidenced by promissory notes that we have executed and delivered to the Gates Foundation, bear interest at the rate of 3% per annum and, except to the extent earlier repaid by us, mature and are required to be repaid in full on December 31, 2019. As of March 31, 2014, we had borrowed no amounts under the Gates Loan Agreement. As of March 31, 2014, we had received approximately $7.9 million in grant-related funding from the Gates Foundation, which was recorded as restricted cash and deferred grant funding. The deferred grant funding is classified within accrued expenses and other current liabilities on our accompanying Consolidated Balance Sheet. As qualified expenditures are incurred under the terms of the grant, we use the deferred funding to recognize a reduction of our related qualified research and development expenditures. For the three months ended March 31, 2014, we incurred $2.1 million of qualified expenditures, for which we reduced our deferred grant funding balance and recorded an offset to our research and development expenses. |
Material_Contingencies
Material Contingencies | 3 Months Ended | ||||||||||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||||||||||
Commitments And Contingencies Disclosure [Abstract] | ' | ||||||||||||||||||||||||||||
Material Contingencies | ' | ||||||||||||||||||||||||||||
(16) Material Contingencies | |||||||||||||||||||||||||||||
(a) Acquisition-related Contingent Consideration Obligations | |||||||||||||||||||||||||||||
We determine the acquisition date fair value of the contingent consideration obligations based on a probability-weighted approach derived from the overall likelihood of achieving certain performance targets, including product development milestones or financial metrics. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement, as defined in fair value measurement accounting. The resultant probability-weighted earn-out payments are discounted using a discount rate based upon the weighted-average cost of capital. At each reporting date, we revalue the contingent consideration obligations to the reporting date fair values and record increases and decreases in the fair values as income or expense in our Consolidated Statements of Operations. | |||||||||||||||||||||||||||||
Increases or decreases in the fair values of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of earn-out criteria and changes in probability assumptions with respect to the likelihood of achieving the various earn-out criteria. | |||||||||||||||||||||||||||||
We have contractual contingent purchase price consideration obligations related to certain of our acquisitions, as follows (in thousands): | |||||||||||||||||||||||||||||
Acquisition | Acquisition Date | Acquisition | Maximum | Remaining | Estimated | Estimated | Payments | ||||||||||||||||||||||
Date Fair | Remaining | Earn-out | Fair Value as | Fair Value as | Made | ||||||||||||||||||||||||
Value | Earn-out | Period as | of | of | during | ||||||||||||||||||||||||
Potential | of | March 31, | December 31, | 2014 | |||||||||||||||||||||||||
as of | March 31, | 2014 | 2013 | ||||||||||||||||||||||||||
March 31, | 2014 | ||||||||||||||||||||||||||||
2014 | |||||||||||||||||||||||||||||
TwistDx, Inc. | 11-Mar-10 | $ | 35,600 | $ | 123,888 | 2014 – 2025 | (1) | $ | 46,400 | $ | 45,502 | $ | 139 | ||||||||||||||||
Ionian Technologies, Inc. | 12-Jul-10 | $ | 24,500 | 57,500 | 2014 – 2015 | 29,400 | 29,000 | — | |||||||||||||||||||||
Laboratory Data Systems, Inc. | 29-Aug-11 | $ | 13,000 | 7,500 | 2013 | (2) | 7,500 | (2) | 7,400 | (2) | — | ||||||||||||||||||
Forensics Limited (ROAR) | September 22, 2011 | $ | 5,463 | 12,600 | 2014 | 3,328 | 2,484 | — | |||||||||||||||||||||
Method Factory Inc. (Wellogic) | December 9, 2011 | $ | 18,900 | — | (3) | 2014 – 2019 | 25,400 | 26,900 | 150 | ||||||||||||||||||||
MedApps. | 2-Jul-12 | $ | 13,100 | 8,600 | 2014 | 7,600 | 8,200 | 5,000 | |||||||||||||||||||||
Amedica Biotech, Inc. | 3-Jul-12 | $ | 8,900 | 8,100 | 2013 | (2) | 7,935 | (2) | 7,500 | (2) | — | ||||||||||||||||||
DiagnosisOne, Inc. | 31-Jul-12 | $ | 22,300 | 33,000 | 2014 – 2017 | 26,900 | 26,600 | — | |||||||||||||||||||||
Epocal. | 1-Feb-13 | $ | 75,000 | 65,500 | 2014 – 2018 | 45,600 | 47,200 | — | |||||||||||||||||||||
Other | Various | $ | 58,877 | 20,229 | 2014 – 2016 | 10,756 | 13,183 | 2,421 | |||||||||||||||||||||
$ | 210,819 | $ | 213,969 | $ | 7,710 | ||||||||||||||||||||||||
-1 | The maximum earn-out period ends on the fifteenth anniversary of the acquisition date. | ||||||||||||||||||||||||||||
-2 | The fair value of the maximum remaining earn-out was accrued as of March 31, 2014 and December 31, 2013. We expect to pay the maximum remaining earn-out during the second quarter of 2014. | ||||||||||||||||||||||||||||
(3) | The earn-out is comprised of three components of which two components have an aggregate maximum remaining earn-out potential of $49.9 million. There is no dollar cap on the third earn-out component, however, the earn-out potential is limited to the remaining earn-out period. |
Recent_Accounting_Pronouncemen
Recent Accounting Pronouncements | 3 Months Ended |
Mar. 31, 2014 | |
Accounting Policies [Abstract] | ' |
Recent Accounting Pronouncements | ' |
(17) Recent Accounting Pronouncements | |
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position, results of operations, comprehensive income or cash flows upon adoption. | |
Recently Adopted Standards | |
Effective January 1, 2014, we adopted Accounting Standards Update, or ASU, 2013-11, Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU 2013-11 clarifies guidance and eliminates diversity in practice on the presentation of unrecognized tax benefits when a net operating loss carryforward, similar tax loss or a tax credit carryforward exists, with limited exceptions. The adoption of this standard had no material impact on our Consolidated Financial Statements. |
Equity_Investments
Equity Investments | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Equity Method Investments And Joint Ventures [Abstract] | ' | ||||||||
Equity Investments | ' | ||||||||
(18) Equity Investments | |||||||||
We account for the results from our equity investments under the equity method of accounting in accordance with Accounting Standards Codification, or ASC, 323, Investments — Equity Method and Joint Ventures, based on the percentage of our ownership interest in the business. Our equity investments primarily include the following: | |||||||||
(a) SPD | |||||||||
We recorded earnings of $5.1 million and $2.5 million during the three months ended March 31, 2014 and 2013, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying Consolidated Statements of Operations, which represented our 50% share of SPD’s net income for the respective periods. | |||||||||
(b) TechLab | |||||||||
We own 49% of TechLab, Inc., or TechLab, a privately-held developer, manufacturer and distributor of rapid non-invasive intestinal diagnostics tests in the areas of intestinal inflammation, antibiotic-associated diarrhea and parasitology. We recorded earnings of $0.3 million and $0.2 million during the three months ended March 31, 2014 and 2013, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying Consolidated Statements of Operations, which represented our minority share of TechLab’s net income for the respective periods. | |||||||||
Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands): | |||||||||
Three Months Ended March 31, | |||||||||
Combined Condensed Results of Operations: | 2014 | 2013 | |||||||
Net revenue | $ | 48,933 | $ | 49,155 | |||||
Gross profit | $ | 42,980 | $ | 37,113 | |||||
Net income after taxes | $ | 10,830 | $ | 5,577 | |||||
Combined Condensed Balance Sheet: | March 31, 2014 | December 31, 2013 | |||||||
Current assets | $ | 72,582 | $ | 63,985 | |||||
Non-current assets | 38,376 | 38,541 | |||||||
Total assets | $ | 110,958 | $ | 102,526 | |||||
Current liabilities | $ | 38,524 | $ | 38,053 | |||||
Non-current liabilities | 6,430 | 6,175 | |||||||
Total liabilities | $ | 44,954 | $ | 44,228 |
Guarantor_Financial_Informatio
Guarantor Financial Information (Guarantor Subsidiaries [Member]) | 3 Months Ended | ||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||
Guarantor Subsidiaries [Member] | ' | ||||||||||||||||||||
Guarantor Financial Information | ' | ||||||||||||||||||||
(19) Guarantor Financial Information | |||||||||||||||||||||
Our 7.25% senior notes due 2018, our 8.625% senior subordinated notes due 2018, and our 6.5% senior subordinated notes due 2020 are guaranteed by certain of our consolidated wholly owned subsidiaries, or the Guarantor Subsidiaries. The guarantees are full and unconditional and joint and several. The following supplemental financial information sets forth, on a consolidating basis, balance sheets as of March 31, 2014 and December 31, 2013, the related statements of operations, statements of comprehensive income (loss) and cash flows for each of the three months ended March 31, 2014 and 2013, respectively, for Alere Inc., the Guarantor Subsidiaries and our other subsidiaries, or the Non-Guarantor Subsidiaries. The supplemental financial information reflects the investments of Alere Inc. and the Guarantor Subsidiaries in the Guarantor and Non-Guarantor Subsidiaries using the equity method of accounting. | |||||||||||||||||||||
We have extensive transactions and relationships between various members of the consolidated group. These transactions and relationships include intercompany pricing agreements, intellectual property royalty agreements and general and administrative and research and development cost-sharing agreements. Because of these relationships, it is possible that the terms of these transactions are not the same as those that would result from transactions among wholly unrelated parties. | |||||||||||||||||||||
For comparative purposes, certain amounts for prior periods have been reclassified to conform to the current period classification. | |||||||||||||||||||||
(19) Guarantor Financial Information (Continued) | |||||||||||||||||||||
CONSOLIDATING STATEMENT OF OPERATIONS | |||||||||||||||||||||
For the Three Months Ended March 31, 2014 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Non - | |||||||||||||||||||||
Guarantor | Guarantor | ||||||||||||||||||||
Issuer | Subsidiaries | Subsidiaries | Eliminations | Consolidated | |||||||||||||||||
Net product sales | $ | — | $ | 213,409 | $ | 336,037 | $ | (54,001 | ) | $ | 495,445 | ||||||||||
Services revenue | — | 197,908 | 18,057 | — | 215,965 | ||||||||||||||||
Net product sales and services revenue | — | 411,317 | 354,094 | (54,001 | ) | 711,410 | |||||||||||||||
License and royalty revenue | — | 3,485 | 5,018 | (3,291 | ) | 5,212 | |||||||||||||||
Net revenue | — | 414,802 | 359,112 | (57,292 | ) | 716,622 | |||||||||||||||
Cost of net product sales | 688 | 114,135 | 183,774 | (52,485 | ) | 246,112 | |||||||||||||||
Cost of services revenue | 73 | 115,325 | 8,054 | (5,720 | ) | 117,732 | |||||||||||||||
Cost of net product sales and services revenue | 761 | 229,460 | 191,828 | (58,205 | ) | 363,844 | |||||||||||||||
Cost of license and royalty revenue | — | 92 | 4,738 | (3,291 | ) | 1,539 | |||||||||||||||
Cost of net revenue | 761 | 229,552 | 196,566 | (61,496 | ) | 365,383 | |||||||||||||||
Gross profit (loss) | (761 | ) | 185,250 | 162,546 | 4,204 | 351,239 | |||||||||||||||
Operating expenses: | |||||||||||||||||||||
Research and development | 5,615 | 14,845 | 18,239 | — | 38,699 | ||||||||||||||||
Sales and marketing | 1,868 | 74,959 | 70,237 | — | 147,064 | ||||||||||||||||
General and administrative | 18,488 | 68,782 | 52,266 | — | 139,536 | ||||||||||||||||
Operating expenses | 25,971 | 158,586 | 140,742 | — | 325,299 | ||||||||||||||||
Operating income (loss) | (26,732 | ) | 26,664 | 21,804 | 4,204 | 25,940 | |||||||||||||||
Interest expense, including amortization of original issue discounts and deferred financing costs | (51,258 | ) | (5,628 | ) | (4,544 | ) | 9,386 | (52,044 | ) | ||||||||||||
Other income (expense), net | 4,694 | 3,648 | 5,825 | (9,445 | ) | 4,722 | |||||||||||||||
Income (loss) before provision (benefit) for income taxes | (73,296 | ) | 24,684 | 23,085 | 4,145 | (21,382 | ) | ||||||||||||||
Provision (benefit) for income taxes | (38,423 | ) | 17,367 | 9,681 | 1,458 | (9,917 | ) | ||||||||||||||
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax | (34,873 | ) | 7,317 | 13,404 | 2,687 | (11,465 | ) | ||||||||||||||
Equity in earnings of subsidiaries, net of tax | 28,355 | 68 | — | (28,423 | ) | — | |||||||||||||||
Equity earnings of unconsolidated entities, net of tax | 405 | — | 5,064 | (117 | ) | 5,352 | |||||||||||||||
Net income (loss) | (6,113 | ) | 7,385 | 18,468 | (25,853 | ) | (6,113 | ) | |||||||||||||
Less: Net income attributable to non-controlling interests | — | — | 108 | — | 108 | ||||||||||||||||
Net income (loss) attributable to Alere Inc. and Subsidiaries | (6,113 | ) | 7,385 | 18,360 | (25,853 | ) | (6,221 | ) | |||||||||||||
Preferred stock dividends | (5,250 | ) | — | — | — | (5,250 | ) | ||||||||||||||
Net income (loss) available to common stockholders | $ | (11,363 | ) | $ | 7,385 | $ | 18,360 | $ | (25,853 | ) | $ | (11,471 | ) | ||||||||
(19) Guarantor Financial Information (Continued) | |||||||||||||||||||||
CONSOLIDATING STATEMENT OF OPERATIONS | |||||||||||||||||||||
For the Three Months Ended March 31, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Non - | |||||||||||||||||||||
Guarantor | Guarantor | ||||||||||||||||||||
Issuer | Subsidiaries | Subsidiaries | Eliminations | Consolidated | |||||||||||||||||
Net product sales | $ | — | $ | 233,551 | $ | 320,839 | $ | (46,114 | ) | $ | 508,276 | ||||||||||
Services revenue | — | 207,749 | 19,160 | — | 226,909 | ||||||||||||||||
Net product sales and services revenue | — | 441,300 | 339,999 | (46,114 | ) | 735,185 | |||||||||||||||
License and royalty revenue | — | 3,035 | 3,533 | (2,504 | ) | 4,064 | |||||||||||||||
Net revenue | — | 444,335 | 343,532 | (48,618 | ) | 739,249 | |||||||||||||||
Cost of net product sales | 948 | 121,236 | 172,574 | (41,680 | ) | 253,078 | |||||||||||||||
Cost of services revenue | — | 115,971 | 8,142 | (3,955 | ) | 120,158 | |||||||||||||||
Cost of net product sales and services revenue | 948 | 237,207 | 180,716 | (45,635 | ) | 373,236 | |||||||||||||||
Cost of license and royalty revenue | — | 17 | 4,243 | (2,504 | ) | 1,756 | |||||||||||||||
Cost of net revenue | 948 | 237,224 | 184,959 | (48,139 | ) | 374,992 | |||||||||||||||
Gross profit (loss) | (948 | ) | 207,111 | 158,573 | (479 | ) | 364,257 | ||||||||||||||
Operating expenses: | |||||||||||||||||||||
Research and development | 4,423 | 18,100 | 18,931 | — | 41,454 | ||||||||||||||||
Sales and marketing | 1,392 | 83,431 | 71,633 | — | 156,456 | ||||||||||||||||
General and administrative | 14,027 | 67,146 | 54,685 | — | 135,858 | ||||||||||||||||
Operating expenses | 19,842 | 168,677 | 145,249 | — | 333,768 | ||||||||||||||||
Operating income (loss) | (20,790 | ) | 38,434 | 13,324 | (479 | ) | 30,489 | ||||||||||||||
Interest expense, including amortization of original issue discounts and deferred financing costs | (56,858 | ) | (7,021 | ) | (3,417 | ) | 9,897 | (57,399 | ) | ||||||||||||
Other income (expense), net | 4,770 | 6,259 | (1,603 | ) | (9,896 | ) | (470 | ) | |||||||||||||
Income (loss) before provision (benefit) for income taxes | (72,878 | ) | 37,672 | 8,304 | (478 | ) | (27,380 | ) | |||||||||||||
Provision (benefit) for income taxes | (62,811 | ) | 17,082 | 8,971 | (113 | ) | (36,871 | ) | |||||||||||||
Income (loss) before equity in earnings (losses) of subsidiaries and unconsolidated entities, net of tax | (10,067 | ) | 20,590 | (667 | ) | (365 | ) | 9,491 | |||||||||||||
Equity in earnings (losses) of subsidiaries, net of tax | 22,244 | (614 | ) | — | (21,630 | ) | — | ||||||||||||||
Equity earnings of unconsolidated entities, net of tax | 248 | — | 2,688 | (2 | ) | 2,934 | |||||||||||||||
Net income | 12,425 | 19,976 | 2,021 | (21,997 | ) | 12,425 | |||||||||||||||
Less: Net loss attributable to non-controlling interests | — | — | (25 | ) | — | (25 | ) | ||||||||||||||
Net income attributable to Alere Inc. and Subsidiaries | 12,425 | 19,976 | 2,046 | (21,997 | ) | 12,450 | |||||||||||||||
Preferred stock dividends | (5,250 | ) | — | — | — | (5,250 | ) | ||||||||||||||
Net income available to common stockholders | $ | 7,175 | $ | 19,976 | $ | 2,046 | $ | (21,997 | ) | $ | 7,200 | ||||||||||
(19) Guarantor Financial Information (Continued) | |||||||||||||||||||||
CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) | |||||||||||||||||||||
For the Three Months Ended March 31, 2014 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Non- | |||||||||||||||||||||
Guarantor | Guarantor | ||||||||||||||||||||
Issuer | Subsidiaries | Subsidiaries | Eliminations | Consolidated | |||||||||||||||||
Net income (loss) | $ | (6,113 | ) | $ | 7,386 | $ | 18,466 | $ | (25,852 | ) | $ | (6,113 | ) | ||||||||
Other comprehensive income (loss), before tax: | |||||||||||||||||||||
Changes in cumulative translation adjustment | 157 | (129 | ) | (11,368 | ) | — | (11,340 | ) | |||||||||||||
Unrealized losses on available for sale securities | — | (17 | ) | — | — | (17 | ) | ||||||||||||||
Unrealized gains on hedging instruments | — | — | 8 | — | 8 | ||||||||||||||||
Minimum pension liability adjustment | — | — | 74 | — | 74 | ||||||||||||||||
Other comprehensive income (loss), before tax | 157 | (146 | ) | (11,286 | ) | — | (11,275 | ) | |||||||||||||
Income tax benefit related to items of other comprehensive income (loss) | — | — | — | — | — | ||||||||||||||||
Other comprehensive income (loss), net of tax | 157 | (146 | ) | (11,286 | ) | — | (11,275 | ) | |||||||||||||
Comprehensive income (loss) | (5,956 | ) | 7,240 | 7,180 | (25,852 | ) | (17,388 | ) | |||||||||||||
Less: Comprehensive income attributable to non-controlling interests | — | — | 108 | — | 108 | ||||||||||||||||
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | $ | (5,956 | ) | $ | 7,240 | $ | 7,072 | $ | (25,852 | ) | $ | (17,496 | ) | ||||||||
(19) Guarantor Financial Information (Continued) | |||||||||||||||||||||
CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) | |||||||||||||||||||||
For the Three Months Ended March 31, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Non - | |||||||||||||||||||||
Guarantor | Guarantor | ||||||||||||||||||||
Issuer | Subsidiaries | Subsidiaries | Eliminations | Consolidated | |||||||||||||||||
Net income | $ | 12,425 | $ | 19,976 | $ | 2,021 | $ | (21,997 | ) | $ | 12,425 | ||||||||||
Other comprehensive loss, before tax: | |||||||||||||||||||||
Changes in cumulative translation adjustment | (201 | ) | — | (75,154 | ) | — | (75,355 | ) | |||||||||||||
Unrealized gains on hedging instruments | — | — | 11 | — | 11 | ||||||||||||||||
Minimum pension liability adjustment | — | — | 605 | — | 605 | ||||||||||||||||
Other comprehensive loss, before tax | (201 | ) | — | (74,538 | ) | — | (74,739 | ) | |||||||||||||
Income tax benefit related to items of other comprehensive loss | — | — | — | — | — | ||||||||||||||||
Other comprehensive loss, net of tax | (201 | ) | — | (74,538 | ) | — | (74,739 | ) | |||||||||||||
Comprehensive income (loss) | 12,224 | 19,976 | (72,517 | ) | (21,997 | ) | (62,314 | ) | |||||||||||||
Less: Comprehensive loss attributable to non-controlling interests | — | — | (25 | ) | — | (25 | ) | ||||||||||||||
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | $ | 12,224 | $ | 19,976 | $ | (72,492 | ) | $ | (21,997 | ) | $ | (62,289 | ) | ||||||||
(19) Guarantor Financial Information (Continued) | |||||||||||||||||||||
CONSOLIDATING BALANCE SHEET | |||||||||||||||||||||
March 31, 2014 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Guarantor | Non-Guarantor | ||||||||||||||||||||
Issuer | Subsidiaries | Subsidiaries | Eliminations | Consolidated | |||||||||||||||||
ASSETS | |||||||||||||||||||||
Current assets: | |||||||||||||||||||||
Cash and cash equivalents | $ | 13,020 | $ | 82,048 | $ | 337,958 | $ | — | $ | 433,026 | |||||||||||
Restricted cash | 84 | 2,915 | 1,223 | — | 4,222 | ||||||||||||||||
Marketable securities | — | 776 | 5 | — | 781 | ||||||||||||||||
Accounts receivable, net of allowances | — | 250,603 | 278,190 | — | 528,793 | ||||||||||||||||
Inventories, net | — | 170,165 | 218,246 | (17,275 | ) | 371,136 | |||||||||||||||
Deferred tax assets | 4,984 | 27,375 | 32,120 | (1,863 | ) | 62,616 | |||||||||||||||
Prepaid expenses and other current assets | 538,410 | (432,500 | ) | 10,713 | 3,906 | 120,529 | |||||||||||||||
Intercompany receivables | 304,817 | 715,596 | 69,903 | (1,090,316 | ) | — | |||||||||||||||
Total current assets | 861,315 | 816,978 | 948,358 | (1,105,548 | ) | 1,521,103 | |||||||||||||||
Property, plant and equipment, net | 19,312 | 286,490 | 239,523 | (274 | ) | 545,051 | |||||||||||||||
Goodwill | — | 1,842,309 | 1,247,747 | — | 3,090,056 | ||||||||||||||||
Other intangible assets with indefinite lives | — | 14,300 | 41,675 | (59 | ) | 55,916 | |||||||||||||||
Finite-lived intangible assets, net | 10,245 | 959,002 | 648,007 | — | 1,617,254 | ||||||||||||||||
Restricted cash | — | — | 28,856 | — | 28,856 | ||||||||||||||||
Deferred financing costs, net and other non-current assets | 51,746 | 7,586 | 20,764 | (40 | ) | 80,056 | |||||||||||||||
Investments in subsidiaries | 3,821,577 | 270,857 | 191,920 | (4,284,354 | ) | — | |||||||||||||||
Investments in unconsolidated entities | 30,174 | — | 49,510 | 10,761 | 90,445 | ||||||||||||||||
Deferred tax assets | — | — | 7,449 | — | 7,449 | ||||||||||||||||
Intercompany notes receivables | 1,099,817 | 720,017 | 48,779 | (1,868,613 | ) | — | |||||||||||||||
Total assets | $ | 5,894,186 | $ | 4,917,539 | $ | 3,472,588 | $ | (7,248,127 | ) | $ | 7,036,186 | ||||||||||
LIABILITIES AND EQUITY | |||||||||||||||||||||
Current liabilities: | |||||||||||||||||||||
Current portion of long-term debt | $ | 60,000 | $ | 962 | $ | 4,290 | $ | — | $ | 65,252 | |||||||||||
Current portion of capital lease obligations | — | 3,165 | 3,055 | — | 6,220 | ||||||||||||||||
Accounts payable | 8,280 | 79,319 | 102,849 | — | 190,448 | ||||||||||||||||
Accrued expenses and other current liabilities | 85,170 | 161,351 | 183,775 | (35 | ) | 430,261 | |||||||||||||||
Intercompany payables | 660,712 | 148,533 | 281,071 | (1,090,316 | ) | — | |||||||||||||||
Total current liabilities | 814,162 | 393,330 | 575,040 | (1,090,351 | ) | 692,181 | |||||||||||||||
Long-term liabilities: | |||||||||||||||||||||
Long-term debt, net of current portion | 3,705,215 | 100 | 40,481 | — | 3,745,796 | ||||||||||||||||
Capital lease obligations, net of current portion | — | 5,563 | 9,527 | — | 15,090 | ||||||||||||||||
Deferred tax liabilities | (65,370 | ) | 290,283 | 82,616 | 45 | 307,574 | |||||||||||||||
Other long-term liabilities | 25,384 | 61,026 | 108,619 | (40 | ) | 194,989 | |||||||||||||||
Intercompany notes payables (receivables) | (660,771 | ) | 1,419,782 | 1,109,602 | (1,868,613 | ) | — | ||||||||||||||
Total long-term liabilities | 3,004,458 | 1,776,754 | 1,350,845 | (1,868,608 | ) | 4,263,449 | |||||||||||||||
Stockholders’ equity | 2,075,566 | 2,747,455 | 1,541,713 | (4,289,168 | ) | 2,075,566 | |||||||||||||||
Non-controlling interests | — | — | 4,990 | — | 4,990 | ||||||||||||||||
Total equity | 2,075,566 | 2,747,455 | 1,546,703 | (4,289,168 | ) | 2,080,556 | |||||||||||||||
Total liabilities and equity | $ | 5,894,186 | $ | 4,917,539 | $ | 3,472,588 | $ | (7,248,127 | ) | $ | 7,036,186 | ||||||||||
(19) Guarantor Financial Information (Continued) | |||||||||||||||||||||
CONSOLIDATING BALANCE SHEET | |||||||||||||||||||||
December 31, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Guarantor | Non-Guarantor | ||||||||||||||||||||
Issuer | Subsidiaries | Subsidiaries | Eliminations | Consolidated | |||||||||||||||||
ASSETS | |||||||||||||||||||||
Current assets: | |||||||||||||||||||||
Cash and cash equivalents | $ | 14,801 | $ | 85,453 | $ | 261,654 | $ | — | $ | 361,908 | |||||||||||
Restricted cash | 2,221 | 2,915 | 1,237 | — | 6,373 | ||||||||||||||||
Marketable securities | — | 853 | 5 | — | 858 | ||||||||||||||||
Accounts receivable, net of allowances | — | 238,782 | 309,947 | — | 548,729 | ||||||||||||||||
Inventories, net | — | 168,058 | 219,892 | (23,765 | ) | 364,185 | |||||||||||||||
Deferred tax assets | 5,191 | 20,541 | 31,451 | 3,506 | 60,689 | ||||||||||||||||
Prepaid expenses and other current assets | 512,123 | (405,954 | ) | 23,547 | (44 | ) | 129,672 | ||||||||||||||
Intercompany receivables | 317,357 | 759,497 | 75,424 | (1,152,278 | ) | — | |||||||||||||||
Total current assets | 851,693 | 870,145 | 923,157 | (1,172,581 | ) | 1,472,414 | |||||||||||||||
Property, plant and equipment, net | 15,086 | 288,637 | 241,737 | (296 | ) | 545,164 | |||||||||||||||
Goodwill | — | 1,841,377 | 1,252,314 | — | 3,093,691 | ||||||||||||||||
Other intangible assets with indefinite lives | — | 14,300 | 42,402 | — | 56,702 | ||||||||||||||||
Finite-lived intangible assets, net | 11,006 | 995,868 | 677,737 | — | 1,684,611 | ||||||||||||||||
Restricted cash | — | — | 29,370 | — | 29,370 | ||||||||||||||||
Deferred financing costs, net and other non-current assets | 55,207 | 8,353 | 20,559 | (46 | ) | 84,073 | |||||||||||||||
Investments in subsidiaries | 3,802,475 | 267,824 | 191,947 | (4,262,246 | ) | — | |||||||||||||||
Investments in unconsolidated entities | 29,005 | — | 44,637 | 13,188 | 86,830 | ||||||||||||||||
Deferred tax assets | — | — | 7,959 | — | 7,959 | ||||||||||||||||
Intercompany notes receivables (payables) | 1,100,746 | 630,628 | (741,016 | ) | (990,358 | ) | — | ||||||||||||||
Total assets | $ | 5,865,218 | $ | 4,917,132 | $ | 2,690,803 | $ | (6,412,339 | ) | $ | 7,060,814 | ||||||||||
LIABILITIES AND EQUITY | |||||||||||||||||||||
Current liabilities: | |||||||||||||||||||||
Current portion of long-term debt | $ | 45,000 | $ | 323 | $ | 3,789 | $ | — | $ | 49,112 | |||||||||||
Current portion of capital lease obligations | — | 3,751 | 3,104 | — | 6,855 | ||||||||||||||||
Accounts payable | 12,584 | 69,076 | 105,711 | — | 187,371 | ||||||||||||||||
Accrued expenses and other current liabilities | 63,990 | 164,762 | 201,132 | (36 | ) | 429,848 | |||||||||||||||
Intercompany payables | 728,541 | 149,031 | 274,707 | (1,152,279 | ) | — | |||||||||||||||
Total current liabilities | 850,115 | 386,943 | 588,443 | (1,152,315 | ) | 673,186 | |||||||||||||||
Long-term liabilities: | |||||||||||||||||||||
Long-term debt, net of current portion | 3,735,137 | 100 | 37,551 | — | 3,772,788 | ||||||||||||||||
Capital lease obligations, net of current portion | — | 5,938 | 8,469 | — | 14,407 | ||||||||||||||||
Deferred tax liabilities | (43,246 | ) | 284,448 | 88,039 | 8 | 329,249 | |||||||||||||||
Other long-term liabilities | 19,753 | 58,823 | 109,806 | (46 | ) | 188,336 | |||||||||||||||
Intercompany notes payables (receivables) | (774,507 | ) | 1,444,741 | 320,125 | (990,359 | ) | — | ||||||||||||||
Total long-term liabilities | 2,937,137 | 1,794,050 | 563,990 | (990,397 | ) | 4,304,780 | |||||||||||||||
Stockholders’ equity | 2,077,966 | 2,736,139 | 1,533,488 | (4,269,627 | ) | 2,077,966 | |||||||||||||||
Non-controlling interests | — | — | 4,882 | — | 4,882 | ||||||||||||||||
Total equity | 2,077,966 | 2,736,139 | 1,538,370 | (4,269,627 | ) | 2,082,848 | |||||||||||||||
Total liabilities and equity | $ | 5,865,218 | $ | 4,917,132 | $ | 2,690,803 | $ | (6,412,339 | ) | $ | 7,060,814 | ||||||||||
(19) Guarantor Financial Information (Continued) | |||||||||||||||||||||
CONSOLIDATING STATEMENT OF CASH FLOWS | |||||||||||||||||||||
For the Three Months Ended March 31, 2014 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Guarantor | Non-Guarantor | ||||||||||||||||||||
Issuer | Subsidiaries | Subsidiaries | Eliminations | Consolidated | |||||||||||||||||
Cash Flows from Operating Activities: | |||||||||||||||||||||
Net income (loss) | $ | (6,113 | ) | $ | 7,385 | $ | 18,468 | $ | (25,853 | ) | $ | (6,113 | ) | ||||||||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||||||||||||||||||||
Equity in earnings of subsidiaries, net of tax | (28,355 | ) | (68 | ) | — | 28,423 | — | ||||||||||||||
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs | 3,857 | 125 | 159 | — | 4,141 | ||||||||||||||||
Depreciation and amortization | 1,399 | 58,445 | 38,166 | 76 | 98,086 | ||||||||||||||||
Non-cash stock-based compensation expense | 2,407 | 1,093 | 2,204 | — | 5,704 | ||||||||||||||||
Impairment of inventory | — | — | 589 | — | 589 | ||||||||||||||||
Impairment of long-lived assets | — | — | 161 | — | 161 | ||||||||||||||||
Loss on sale of fixed assets | — | 2,010 | 62 | — | 2,072 | ||||||||||||||||
Equity earnings of unconsolidated entities, net of tax | (405 | ) | — | (5,064 | ) | 117 | (5,352 | ) | |||||||||||||
Deferred income taxes | (21,658 | ) | (1,399 | ) | (3,037 | ) | 1,458 | (24,636 | ) | ||||||||||||
Other non-cash items | — | 1,197 | (4,856 | ) | — | (3,659 | ) | ||||||||||||||
Changes in assets and liabilities, net of acquisitions: | |||||||||||||||||||||
Accounts receivable, net | — | (11,821 | ) | 31,719 | — | 19,898 | |||||||||||||||
Inventories, net | — | (8,576 | ) | (105 | ) | (4,064 | ) | (12,745 | ) | ||||||||||||
Prepaid expenses and other current assets | (26,287 | ) | 23,130 | 11,790 | (4,303 | ) | 4,330 | ||||||||||||||
Accounts payable | (4,305 | ) | 11,975 | (2,439 | ) | — | 5,231 | ||||||||||||||
Accrued expenses and other current liabilities | 18,625 | (3,339 | ) | (7,278 | ) | 355 | 8,363 | ||||||||||||||
Other non-current liabilities | 9,106 | 2,148 | (1,895 | ) | 3,954 | 13,313 | |||||||||||||||
Cash paid for contingent consideration | (3,417 | ) | — | (58 | ) | — | (3,475 | ) | |||||||||||||
Intercompany payable (receivable) | 67,749 | (70,945 | ) | 3,196 | — | — | |||||||||||||||
Net cash provided by operating activities | 12,603 | 11,360 | 81,782 | 163 | 105,908 | ||||||||||||||||
Cash Flows from Investing Activities: | |||||||||||||||||||||
Decrease in restricted cash | 2,125 | — | 26 | — | 2,151 | ||||||||||||||||
Purchases of property, plant and equipment | (6,323 | ) | (12,941 | ) | (9,093 | ) | 817 | (27,540 | ) | ||||||||||||
Proceeds from sale of property, plant and equipment | 269 | 664 | 112 | (916 | ) | 129 | |||||||||||||||
Cash received from disposition | — | — | 4,373 | — | 4,373 | ||||||||||||||||
Cash paid for investments | (504 | ) | — | (3 | ) | — | (507 | ) | |||||||||||||
Cash received from sales of marketable securities | — | 60 | — | — | 60 | ||||||||||||||||
Increase in other assets | (311 | ) | (2,185 | ) | (482 | ) | 53 | (2,925 | ) | ||||||||||||
Net cash used in investing activities | (4,744 | ) | (14,402 | ) | (5,067 | ) | (46 | ) | (24,259 | ) | |||||||||||
Cash Flows from Financing Activities: | |||||||||||||||||||||
Cash paid for financing costs | (7 | ) | — | — | — | (7 | ) | ||||||||||||||
Cash paid for contingent purchase price consideration | (4,072 | ) | — | (123 | ) | — | (4,195 | ) | |||||||||||||
Proceeds from issuance of common stock, net of issuance costs | 14,698 | — | — | — | 14,698 | ||||||||||||||||
Proceeds from issuance of long-term debt | — | 939 | — | — | 939 | ||||||||||||||||
Payments on long-term debt | (15,000 | ) | (301 | ) | (522 | ) | — | (15,823 | ) | ||||||||||||
Net proceeds under revolving credit facilities | — | — | 233 | — | 233 | ||||||||||||||||
Cash paid for dividends | (5,323 | ) | — | — | — | (5,323 | ) | ||||||||||||||
Excess tax benefits on exercised stock options | 53 | 207 | 32 | — | 292 | ||||||||||||||||
Principal payments on capital lease obligations | — | (1,080 | ) | (760 | ) | — | (1,840 | ) | |||||||||||||
Net cash used in financing activities | (9,651 | ) | (235 | ) | (1,140 | ) | — | (11,026 | ) | ||||||||||||
Foreign exchange effect on cash and cash equivalents | 11 | (128 | ) | 729 | (117 | ) | 495 | ||||||||||||||
Net increase (decrease) in cash and cash equivalents | (1,781 | ) | (3,405 | ) | 76,304 | — | 71,118 | ||||||||||||||
Cash and cash equivalents, beginning of period | 14,801 | 85,453 | 261,654 | — | 361,908 | ||||||||||||||||
Cash and cash equivalents, end of period | $ | 13,020 | $ | 82,048 | $ | 337,958 | $ | — | $ | 433,026 | |||||||||||
(19) Guarantor Financial Information (Continued) | |||||||||||||||||||||
CONSOLIDATING STATEMENT OF CASH FLOWS | |||||||||||||||||||||
For the Three Months Ended March 31, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Guarantor | Non-Guarantor | ||||||||||||||||||||
Issuer | Subsidiaries | Subsidiaries | Eliminations | Consolidated | |||||||||||||||||
Cash Flows from Operating Activities: | |||||||||||||||||||||
Net income | $ | 12,425 | $ | 19,976 | $ | 2,021 | $ | (21,997 | ) | $ | 12,425 | ||||||||||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||||||||||||||||||||
Equity in earnings (losses) of subsidiaries, net of tax | (22,244 | ) | 614 | — | 21,630 | — | |||||||||||||||
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs | 5,153 | 55 | 9 | — | 5,217 | ||||||||||||||||
Depreciation and amortization | 1,287 | 62,711 | 41,001 | (29 | ) | 104,970 | |||||||||||||||
Non-cash charges for sale of inventories revalued at the date of acquisition | — | — | 461 | — | 461 | ||||||||||||||||
Non-cash stock-based compensation expense | 1,660 | 1,096 | 1,367 | — | 4,123 | ||||||||||||||||
(Gain) loss on sale of fixed assets | — | 227 | (55 | ) | — | 172 | |||||||||||||||
Equity earnings of unconsolidated entities, net of tax | (248 | ) | — | (2,688 | ) | 2 | (2,934 | ) | |||||||||||||
Deferred income taxes | (30,889 | ) | (10,300 | ) | (9,605 | ) | (113 | ) | (50,907 | ) | |||||||||||
Other non-cash items | (762 | ) | 275 | 2,428 | — | 1,941 | |||||||||||||||
Changes in assets and liabilities, net of acquisitions: | |||||||||||||||||||||
Accounts receivable, net | — | (1,968 | ) | (18,199 | ) | — | (20,167 | ) | |||||||||||||
Inventories, net | — | (10,617 | ) | (7,129 | ) | 575 | (17,171 | ) | |||||||||||||
Prepaid expenses and other current assets | (473,927 | ) | 413,274 | 35,633 | 19,187 | (5,833 | ) | ||||||||||||||
Accounts payable | (604 | ) | (7,823 | ) | 6,439 | — | (1,988 | ) | |||||||||||||
Accrued expenses and other current liabilities | 478,784 | (387,671 | ) | (29,830 | ) | (19,187 | ) | 42,096 | |||||||||||||
Other non-current liabilities | (126 | ) | (2,959 | ) | 3,880 | — | 795 | ||||||||||||||
Cash paid for contingent consideration | (2,139 | ) | — | — | — | (2,139 | ) | ||||||||||||||
Intercompany payable (receivable) | 64,910 | (77,486 | ) | 12,576 | — | — | |||||||||||||||
Net cash provided by (used in) operating activities | 33,280 | (596 | ) | 38,309 | 68 | 71,061 | |||||||||||||||
Cash Flows from Investing Activities: | |||||||||||||||||||||
Increase in restricted cash | (7,933 | ) | (630 | ) | (10 | ) | — | (8,573 | ) | ||||||||||||
Purchases of property, plant and equipment | (37 | ) | (14,732 | ) | (26,358 | ) | 5,022 | (36,105 | ) | ||||||||||||
Proceeds from sale of property, plant and equipment | — | 2,106 | 4,085 | (5,048 | ) | 1,143 | |||||||||||||||
Cash paid for acquisitions, net of cash acquired | (151,372 | ) | — | (7,049 | ) | — | (158,421 | ) | |||||||||||||
Cash received from investments | — | — | 10,771 | — | 10,771 | ||||||||||||||||
Increase in other assets | (3,210 | ) | (881 | ) | (1,478 | ) | — | (5,569 | ) | ||||||||||||
Net cash used in investing activities | (162,552 | ) | (14,137 | ) | (20,039 | ) | (26 | ) | (196,754 | ) | |||||||||||
Cash Flows from Financing Activities: | |||||||||||||||||||||
Cash paid for financing costs | (1,427 | ) | — | — | — | (1,427 | ) | ||||||||||||||
Cash paid for contingent purchase price consideration | (19,098 | ) | — | — | — | (19,098 | ) | ||||||||||||||
Proceeds from issuance of common stock, net of issuance costs | 6,135 | — | — | — | 6,135 | ||||||||||||||||
Proceeds from issuance of long-term debt | — | 1,007 | 9,046 | — | 10,053 | ||||||||||||||||
Payments on long-term debt | (16,845 | ) | (445 | ) | (2,348 | ) | — | (19,638 | ) | ||||||||||||
Net proceeds (payments) under revolving credit facilities | 170,000 | — | (7,517 | ) | — | 162,483 | |||||||||||||||
Cash paid for dividends | (5,323 | ) | — | — | — | (5,323 | ) | ||||||||||||||
Excess tax benefits on exercised stock options | 71 | 17 | 16 | — | 104 | ||||||||||||||||
Principal payments on capital lease obligations | — | (817 | ) | (904 | ) | — | (1,721 | ) | |||||||||||||
Net cash provided by (used in) financing activities | 133,513 | (238 | ) | (1,707 | ) | — | 131,568 | ||||||||||||||
Foreign exchange effect on cash and cash equivalents | 762 | 16 | (7,724 | ) | (42 | ) | (6,988 | ) | |||||||||||||
Net increase (decrease) in cash and cash equivalents | 5,003 | (14,955 | ) | 8,839 | — | (1,113 | ) | ||||||||||||||
Cash and cash equivalents, beginning of period | 3,623 | 67,941 | 256,782 | — | 328,346 | ||||||||||||||||
Cash and cash equivalents, end of period | $ | 8,626 | $ | 52,986 | $ | 265,621 | $ | — | $ | 327,233 |
Basis_of_Presentation_of_Finan1
Basis of Presentation of Financial Information (Policies) | 3 Months Ended |
Mar. 31, 2014 | |
Cash And Cash Equivalents [Abstract] | ' |
Basis of Presentation of Financial Information | ' |
The accompanying Consolidated Financial Statements of Alere Inc. are unaudited. In the opinion of management, the unaudited Consolidated Financial Statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these Consolidated Financial Statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations, comprehensive income and cash flows. Our audited Consolidated Financial Statements for the year ended December 31, 2013 included information and footnotes necessary for such presentation and were included in our Annual Report on Form 10-K, as amended, filed with the Securities and Exchange Commission, or SEC, on March 3, 2014. These unaudited Consolidated Financial Statements should be read in conjunction with our audited Consolidated Financial Statements and notes thereto for the year ended December 31, 2013. | |
Certain reclassifications of prior period amounts have been made to conform to current period presentation. These reclassifications had no effect on net income or equity. | |
During the three months ended March 31, 2014, we recorded net after-tax expense charges of $1.3 million to correct prior period items, including a net after-tax charge of $2.8 million related to the fair value of the MedApps Holding Company, Inc., or MedApps, contingent consideration obligations. We consider the adjustments to be immaterial to both the prior period and the current period financial statements. | |
Certain amounts presented may not recalculate directly, due to rounding. | |
Cash and Cash Equivalents | ' |
Cash and Cash Equivalents | |
We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At March 31, 2014, our cash equivalents consisted of money market funds. | |
Presentation of Unrecognized Tax Benefit | ' |
Recently Adopted Standards | |
Effective January 1, 2014, we adopted Accounting Standards Update, or ASU, 2013-11, Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU 2013-11 clarifies guidance and eliminates diversity in practice on the presentation of unrecognized tax benefits when a net operating loss carryforward, similar tax loss or a tax credit carryforward exists, with limited exceptions. The adoption of this standard had no material impact on our Consolidated Financial Statements. |
Inventories_Tables
Inventories (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Inventory Disclosure [Abstract] | ' | ||||||||
Inventories are Stated at Lower of Cost (First In, First Out) or Market | ' | ||||||||
Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands): | |||||||||
March 31, 2014 | December 31, 2013 | ||||||||
Raw materials | $ | 124,020 | $ | 118,571 | |||||
Work-in-process | 73,848 | 79,559 | |||||||
Finished goods | 173,268 | 166,055 | |||||||
$ | 371,136 | $ | 364,185 | ||||||
StockBased_Compensation_Tables
Stock-Based Compensation (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ' | ||||||||
Stock-Based Compensation Expense | ' | ||||||||
We recorded stock-based compensation expense in our Consolidated Statements of Operations for the three months ended March 31, 2014 and 2013, respectively, as follows (in thousands): | |||||||||
Three Months Ended March 31, | |||||||||
2014 | 2013 | ||||||||
Cost of net revenue | $ | 287 | $ | 232 | |||||
Research and development | 1,191 | 747 | |||||||
Sales and marketing | 891 | 716 | |||||||
General and administrative | 3,335 | 2,428 | |||||||
5,704 | 4,123 | ||||||||
Benefit for income taxes | (1,778 | ) | (862 | ) | |||||
$ | 3,926 | $ | 3,261 | ||||||
Net_Income_Loss_Per_Common_Sha1
Net Income (Loss) Per Common Share (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Earnings Per Share [Abstract] | ' | ||||||||
Computation of Basic and Diluted Net Income (Loss) Per Common Share | ' | ||||||||
The following table sets forth the computation of basic and diluted net income (loss) per common share for the three months ended March 31, 2014 and 2013 (in thousands, except per share amounts): | |||||||||
Three Months Ended March 31, | |||||||||
2014 | 2013 | ||||||||
Basic and diluted net income (loss) per common share: | |||||||||
Numerator: | |||||||||
Net income (loss) | $ | (6,113 | ) | $ | 12,425 | ||||
Preferred stock dividends | (5,250 | ) | (5,250 | ) | |||||
Less: Net income (loss) attributable to non-controlling interest | 108 | (25 | ) | ||||||
Net income (loss) available to common stockholders | $ | (11,471 | ) | $ | 7,200 | ||||
Denominator: | |||||||||
Weighted-average common shares outstanding—basic | 82,387 | 81,199 | |||||||
Effect of dilutive securities: | |||||||||
Stock options | — | 101 | |||||||
Weighted-average common shares outstanding—diluted | 82,387 | 81,300 | |||||||
Basic net income (loss) per common share attributable to Alere Inc. and Subsidiaries | $ | (0.14 | ) | $ | 0.09 | ||||
Diluted net income (loss) per common share attributable to Alere Inc. and Subsidiaries | $ | (0.14 | ) | $ | 0.09 | ||||
Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share | ' | ||||||||
The following potential dilutive securities were not included in the calculation of diluted net income (loss) per common share because the inclusion thereof would be antidilutive (in thousands): | |||||||||
Three Months Ended March 31, | |||||||||
2014 | 2013 | ||||||||
Denominator: | |||||||||
Options to purchase shares of common stock | 11,143 | 9,987 | |||||||
Warrants | 4 | 4 | |||||||
Conversion shares related to 3% convertible senior subordinated notes | 3,411 | 3,411 | |||||||
Conversion shares related to subordinated convertible promissory notes | 27 | 27 | |||||||
Conversion shares related to Series B convertible preferred stock | 10,239 | 10,239 | |||||||
Common stock equivalents related to the settlement of a contingent consideration obligation | 358 | — | |||||||
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding | 25,182 | 23,668 | |||||||
Stockholders_Equity_and_NonCon1
Stockholders' Equity and Non-Controlling Interests (Tables) | 3 Months Ended | ||||||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||||||
Equity [Abstract] | ' | ||||||||||||||||||||||||
Summary of Changes in Stockholders' Equity and Non-Controlling Interests Comprising Total Equity | ' | ||||||||||||||||||||||||
A summary of the changes in stockholders’ equity and non-controlling interests comprising total equity for the three months ended March 31, 2014 and 2013 is provided below (in thousands): | |||||||||||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||||||||||
2014 | 2013 | ||||||||||||||||||||||||
Total | Non- | Total | Total | Non- | Total | ||||||||||||||||||||
Stockholders’ | controlling | Equity | Stockholders’ | controlling | Equity | ||||||||||||||||||||
Equity | Interests | Equity | Interests | ||||||||||||||||||||||
Equity, beginning of period | $ | 2,077,966 | $ | 4,882 | $ | 2,082,848 | $ | 2,180,422 | $ | 2,282 | $ | 2,182,704 | |||||||||||||
Issuance of common stock under employee compensation plans | 14,698 | — | 14,698 | 6,135 | — | 6,135 | |||||||||||||||||||
Preferred stock dividends | (5,323 | ) | — | (5,323 | ) | (5,323 | ) | — | (5,323 | ) | |||||||||||||||
Stock-based compensation expense | 5,704 | — | 5,704 | 4,123 | — | 4,123 | |||||||||||||||||||
Excess tax benefits on exercised stock options | 17 | — | 17 | (422 | ) | — | (422 | ) | |||||||||||||||||
Net income (loss) | (6,221 | ) | 108 | (6,113 | ) | 12,450 | (25 | ) | 12,425 | ||||||||||||||||
Total other comprehensive loss | (11,275 | ) | — | (11,275 | ) | (74,739 | ) | — | (74,739 | ) | |||||||||||||||
Equity, end of period | $ | 2,075,566 | $ | 4,990 | $ | 2,080,556 | $ | 2,122,646 | $ | 2,257 | $ | 2,124,903 | |||||||||||||
Business_Combinations_Tables
Business Combinations (Tables) | 3 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Business Combinations [Abstract] | ' | ||||||||||||||||
Summary of Aggregate Purchase Price Allocation | ' | ||||||||||||||||
A summary of the preliminary fair values of the net assets acquired for the acquisitions consummated in 2013 is as follows (in thousands): | |||||||||||||||||
Epocal | Other | Total | |||||||||||||||
Current assets(1) | $ | 12,536 | $ | 13,702 | $ | 26,238 | |||||||||||
Property, plant and equipment | 1,267 | 1,669 | 2,936 | ||||||||||||||
Goodwill | 98,454 | 2,543 | 100,997 | ||||||||||||||
Intangible assets | 164,400 | 51,180 | 215,580 | ||||||||||||||
Other non-current assets | 18,158 | 29 | 18,187 | ||||||||||||||
Total assets acquired | 294,815 | 69,123 | 363,938 | ||||||||||||||
Current liabilities | 2,627 | 5,398 | 8,025 | ||||||||||||||
Non-current liabilities | 43,727 | 6,175 | 49,902 | ||||||||||||||
Total liabilities assumed | 46,354 | 11,573 | 57,927 | ||||||||||||||
Net assets acquired | 248,461 | 57,550 | 306,011 | ||||||||||||||
Less: | |||||||||||||||||
Contingent consideration | 75,000 | 1,264 | 76,264 | ||||||||||||||
Settlement of pre-existing arrangements | 22,088 | 17,500 | 39,588 | ||||||||||||||
Non-controlling interest | — | 1,774 | 1,774 | ||||||||||||||
Bargain purchase gain | — | 8,023 | 8,023 | ||||||||||||||
Deferred purchase price consideration | — | 768 | 768 | ||||||||||||||
Cash paid | $ | 151,373 | $ | 28,221 | $ | 179,594 | |||||||||||
-1 | Includes approximately $3.3 million of acquired cash. | ||||||||||||||||
Intangible Assets Acquired and Their Respective Fair Values and Weighted-Average Useful Lives | ' | ||||||||||||||||
The following are the intangible assets acquired and their respective fair values and weighted-average useful lives (dollars in thousands): | |||||||||||||||||
Epocal | Other | Total | Weighted- | ||||||||||||||
average | |||||||||||||||||
Useful Life | |||||||||||||||||
Core technology and patents | $ | 119,700 | $ | — | $ | 119,700 | 20.0 years | ||||||||||
Software | — | 2,154 | 2,154 | 5.7 years | |||||||||||||
Trademarks and trade names | 20,500 | 80 | 20,580 | 19.1 years | |||||||||||||
License agreements | — | 620 | 620 | 1.5 years | |||||||||||||
Customer relationships | — | 42,510 | 42,510 | 11.5 years | |||||||||||||
Other | — | 5,816 | 5,816 | 3.0 years | |||||||||||||
In-process research and development | 24,200 | — | 24,200 | N/A | |||||||||||||
Total intangible assets | $ | 164,400 | $ | 51,180 | $ | 215,580 | |||||||||||
Restructuring_Tables
Restructuring (Tables) | 3 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Restructuring And Related Activities [Abstract] | ' | ||||||||||||||||
Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income | ' | ||||||||||||||||
The following table sets forth aggregate restructuring charges recorded in our Consolidated Statements of Operations for the three months ended March 31, 2014 and 2013 (in thousands): | |||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||
Statement of Operations Caption | 2014 | 2013 | |||||||||||||||
Cost of net revenue | $ | 875 | $ | 623 | |||||||||||||
Research and development | — | — | |||||||||||||||
Sales and marketing | 1,557 | 1,099 | |||||||||||||||
General and administrative | 4,783 | 2,170 | |||||||||||||||
Total operating expenses | 7,215 | 3,892 | |||||||||||||||
Interest expense, including amortization of original issue discounts and deferred financing costs | 125 | 55 | |||||||||||||||
Total charges | $ | 7,340 | $ | 3,947 | |||||||||||||
Restructuring Activities Related to Restructuring Plans | ' | ||||||||||||||||
The following table summarizes the restructuring activities related to our 2014 restructuring plans for the three months ended March 31, 2014 (in thousands): | |||||||||||||||||
Professional Diagnostics | Corporate and Other | Total | |||||||||||||||
Severance-related costs | $ | 2,364 | $ | 87 | $ | 2,451 | |||||||||||
Facility and transition costs | 34 | 8 | 42 | ||||||||||||||
Cash charges | 2,398 | 95 | 2,493 | ||||||||||||||
Fixed asset and inventory impairments | 750 | — | 750 | ||||||||||||||
Total charges | $ | 3,148 | $ | 95 | $ | 3,243 | |||||||||||
The following tables summarizes the restructuring activities in our professional diagnostics and health information solutions business segments related to our 2013 restructuring plans for the three months ended March 31, 2014 and 2013 and since inception (in thousands): | |||||||||||||||||
Three Months Ended March 31, | Since | ||||||||||||||||
Professional Diagnostics | 2014 | 2013 | Inception | ||||||||||||||
Severance-related costs | $ | 838 | $ | 833 | $ | 7,964 | |||||||||||
Facility and transition costs | 174 | 13 | 2,755 | ||||||||||||||
Cash charges | 1,012 | 846 | 10,719 | ||||||||||||||
Fixed asset and inventory impairments | — | — | 743 | ||||||||||||||
Total charges | $ | 1,012 | $ | 846 | $ | 11,462 | |||||||||||
Three Months Ended March 31, | Since | ||||||||||||||||
Health Information Solutions | 2014 | 2013 | Inception | ||||||||||||||
Severance-related costs | $ | 89 | $ | 69 | $ | 3,356 | |||||||||||
Facility and transition costs | 3,227 | — | 6,182 | ||||||||||||||
Other exit costs | 33 | — | 50 | ||||||||||||||
Cash charges | 3,349 | 69 | 9,588 | ||||||||||||||
Fixed asset and inventory impairments | — | — | 1,089 | ||||||||||||||
Intangible asset impairments | — | — | 2,596 | ||||||||||||||
Other non-cash (recoveries) | (854 | ) | — | (1,757 | ) | ||||||||||||
Total charges | $ | 2,495 | $ | 69 | $ | 11,516 | |||||||||||
The following table summarizes the restructuring activities related to our active 2012, 2011, 2010 and 2008 restructuring plans for the three months ended March 31, 2014 and 2013 and since inception (in thousands): | |||||||||||||||||
Three Months Ended March 31, | Since | ||||||||||||||||
Professional Diagnostics | 2014 | 2013 | Inception | ||||||||||||||
Severance-related costs | $ | 59 | $ | 312 | $ | 24,251 | |||||||||||
Facility and transition costs | 84 | 232 | 8,846 | ||||||||||||||
Other exit costs | 12 | 16 | 768 | ||||||||||||||
Cash charges | 155 | 560 | 33,865 | ||||||||||||||
Fixed asset and inventory impairments | — | — | 6,922 | ||||||||||||||
Intangible asset impairments | — | — | 686 | ||||||||||||||
Other non-cash charges | — | — | 64 | ||||||||||||||
Total charges | $ | 155 | $ | 560 | $ | 41,537 | |||||||||||
Three Months Ended March 31, | Since | ||||||||||||||||
Health Information Solutions | 2014 | 2013 | Inception | ||||||||||||||
Severance-related costs | $ | — | $ | 1,819 | $ | 12,308 | |||||||||||
Facility and transition costs (recoveries) | 355 | 659 | 13,870 | ||||||||||||||
Other exit costs | 80 | 39 | 843 | ||||||||||||||
Cash charges (recoveries) | 435 | 2,517 | 27,021 | ||||||||||||||
Fixed asset and inventory impairments | — | — | 3,878 | ||||||||||||||
Intangible asset impairments | — | — | 5,923 | ||||||||||||||
Other non-cash charges | — | (45 | ) | (223 | ) | ||||||||||||
Total charges (recoveries) | $ | 435 | $ | 2,472 | $ | 36,599 | |||||||||||
Cash Activity for Restructuring Reserves | ' | ||||||||||||||||
The following table summarizes our restructuring reserves related to the plans described above, of which $7.7 million is included in accrued expenses and other current liabilities and $5.3 million is included in other long-term liabilities on our accompanying Consolidated Balance Sheets (in thousands): | |||||||||||||||||
Severance- | Facility and | Other Exit | Total | ||||||||||||||
related | Transition | Costs | |||||||||||||||
Costs | Costs | ||||||||||||||||
Balance, December 31, 2013 | $ | 2,708 | $ | 7,830 | $ | 609 | $ | 11,147 | |||||||||
Cash charges | 3,437 | 3,882 | 125 | 7,444 | |||||||||||||
Payments | (4,063 | ) | (1,459 | ) | (73 | ) | (5,595 | ) | |||||||||
Currency adjustments | 5 | 35 | (9 | ) | 31 | ||||||||||||
Balance, March 31, 2014 | $ | 2,087 | $ | 10,288 | $ | 652 | $ | 13,027 | |||||||||
LongTerm_Debt_Tables
Long-Term Debt (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Debt Disclosure [Abstract] | ' | ||||||||
Long-Term Debt Balances Outstanding | ' | ||||||||
We had the following long-term debt balances outstanding (in thousands): | |||||||||
March 31, | December 31, | ||||||||
2014 | 2013 | ||||||||
A term loans(1) (2) | $ | 820,625 | $ | 832,188 | |||||
B term loans(1) | 901,875 | 904,188 | |||||||
Incremental B-1 term loans(1) | 244,375 | 245,000 | |||||||
Incremental B-2 term loans(1) | 194,629 | 195,050 | |||||||
Revolving line of credit(1) | 170,000 | 170,000 | |||||||
7.25% Senior notes | 450,000 | 450,000 | |||||||
6.5% Senior subordinated notes | 425,000 | 425,000 | |||||||
8.625% Senior subordinated notes | 400,000 | 400,000 | |||||||
3% Convertible senior subordinated notes | 150,000 | 150,000 | |||||||
Other lines of credit | 581 | 355 | |||||||
Other | 53,963 | 50,119 | |||||||
3,811,048 | 3,821,900 | ||||||||
Less: Current portion | (65,252 | ) | (49,112 | ) | |||||
$ | 3,745,796 | $ | 3,772,788 | ||||||
(1) | Incurred under our secured credit facility. | ||||||||
(2) | Includes “A” term loans and “Delayed Draw” term loans under our secured credit facility. | ||||||||
Long-Term Debt Interest Expense | ' | ||||||||
In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying Consolidated Statements of Operations for the three months ended March 31, 2014 and 2013, respectively, as follows (in thousands): | |||||||||
Three Months Ended March 31, | |||||||||
2014 | 2013 | ||||||||
Secured credit facility (1) | $ | 24,762 | $ | 27,275 | |||||
7.25% Senior notes | 8,525 | 8,356 | |||||||
7.875% Senior notes | — | (27 | ) | ||||||
6.5% Senior subordinated notes | 7,178 | — | |||||||
9% Senior subordinated notes | — | 10,394 | |||||||
8.625% Senior subordinated notes | 9,273 | 9,273 | |||||||
3% Convertible senior subordinated notes | 1,246 | 1,246 | |||||||
$ | 50,984 | $ | 56,517 | ||||||
-1 | Includes “A” term loans, including the “Delayed-Draw” term loans; “B” term loans; “Incremental B-1” term loans; “Incremental B-2” term loans; and revolving line of credit loans. For the three months ended March 31, 2014 and 2013, the amounts include $0.4 million and $1.0 million, respectively, related to the amortization of fees paid for certain debt modifications. |
Fair_Value_Measurements_Tables
Fair Value Measurements (Tables) | 3 Months Ended | ||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||
Fair Value Disclosures [Abstract] | ' | ||||||||||||||||
Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques | ' | ||||||||||||||||
The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): | |||||||||||||||||
Description | March 31, | Quoted Prices in | Significant Other | Unobservable Inputs | |||||||||||||
2014 | Active Markets | Observable Inputs | (Level 3) | ||||||||||||||
(Level 1) | (Level 2) | ||||||||||||||||
Assets: | |||||||||||||||||
Marketable securities | $ | 781 | $ | 781 | $ | — | $ | — | |||||||||
Total assets | $ | 781 | $ | 781 | $ | — | $ | — | |||||||||
Liabilities: | |||||||||||||||||
Contingent consideration obligations (1) | $ | 210,819 | $ | — | $ | — | $ | 210,819 | |||||||||
Total liabilities | $ | 210,819 | $ | — | $ | — | $ | 210,819 | |||||||||
Description | December 31, | Quoted Prices in | Significant Other | Unobservable Inputs | |||||||||||||
2013 | Active Markets | Observable Inputs | (Level 3) | ||||||||||||||
(Level 1) | (Level 2) | ||||||||||||||||
Assets: | |||||||||||||||||
Marketable securities | $ | 858 | $ | 858 | $ | — | $ | — | |||||||||
Total assets | $ | 858 | $ | 858 | $ | — | $ | — | |||||||||
Liabilities: | |||||||||||||||||
Contingent consideration obligations (1) | $ | 213,969 | $ | — | $ | — | $ | 213,969 | |||||||||
Total liabilities | $ | 213,969 | $ | — | $ | — | $ | 213,969 | |||||||||
(1) | We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our Consolidated Statements of Operations. See Note 16 for additional information on the valuation of our contingent consideration obligations. | ||||||||||||||||
Changes in Fair Value of Contingent Consideration Obligations | ' | ||||||||||||||||
Changes in the fair value of our Level 3 contingent consideration obligations during the three months ended March 31, 2014 were as follows (in thousands): | |||||||||||||||||
Fair value of contingent consideration obligations, January 1, 2014 | $ | 213,969 | |||||||||||||||
Payments | (7,710 | ) | |||||||||||||||
Present value accretion and adjustments | 4,550 | ||||||||||||||||
Foreign currency adjustments | 10 | ||||||||||||||||
Fair value of contingent consideration obligations, March 31, 2014 | $ | 210,819 | |||||||||||||||
Defined_Benefit_Pension_Plan_T
Defined Benefit Pension Plan (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Compensation And Retirement Disclosure [Abstract] | ' | ||||||||
Net Periodic Benefit Costs | ' | ||||||||
The net periodic benefit costs are as follows (in thousands): | |||||||||
Three Months Ended March 31, | |||||||||
2014 | 2013 | ||||||||
Service cost | $ | — | $ | — | |||||
Interest cost | 199 | 182 | |||||||
Expected return on plan assets | (188 | ) | (156 | ) | |||||
Amortization of prior service cost | 110 | 103 | |||||||
Net periodic benefit cost | $ | 121 | $ | 129 | |||||
Financial_Information_by_Segme1
Financial Information by Segment (Tables) | 3 Months Ended | ||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||
Segment Reporting [Abstract] | ' | ||||||||||||||||||||
Performance of Our Operating Segments Based on Revenue and Operating Income (Loss) | ' | ||||||||||||||||||||
Segment information for the three months ended March 31, 2014 and 2013 is as follows (in thousands): | |||||||||||||||||||||
Professional | Health | Consumer | Corporate | Total | |||||||||||||||||
Diagnostics | Information | Diagnostics | and | ||||||||||||||||||
Solutions | Other | ||||||||||||||||||||
Three Months Ended March 31, 2014: | |||||||||||||||||||||
Net revenue | $ | 566,545 | $ | 123,668 | $ | 26,409 | $ | — | $ | 716,622 | |||||||||||
Operating income (loss) | $ | 51,326 | $ | (6,720 | ) | $ | 2,248 | $ | (20,914 | ) | $ | 25,940 | |||||||||
Depreciation and amortization | $ | 77,421 | $ | 19,111 | $ | 920 | $ | 634 | $ | 98,086 | |||||||||||
Restructuring charges | $ | 4,303 | $ | 2,817 | $ | — | $ | 95 | $ | 7,215 | |||||||||||
Stock-based compensation | $ | — | $ | — | $ | — | $ | 5,704 | $ | 5.704 | |||||||||||
Three Months Ended March 31, 2013: | |||||||||||||||||||||
Net revenue | $ | 582,492 | $ | 134,207 | $ | 22,550 | $ | — | $ | 739,249 | |||||||||||
Operating income (loss) | $ | 59,840 | $ | (13,893 | ) | $ | 2,280 | $ | (17,738 | ) | $ | 30,489 | |||||||||
Depreciation and amortization | $ | 82,794 | $ | 20,737 | $ | 1,153 | $ | 286 | $ | 104,970 | |||||||||||
Non-cash charge associated with acquired inventory | $ | 461 | $ | — | $ | — | $ | — | $ | 461 | |||||||||||
Restructuring charges | $ | 1,389 | $ | 2,503 | $ | — | $ | — | $ | 3,892 | |||||||||||
Stock-based compensation | $ | — | $ | — | $ | — | $ | 4,123 | $ | 4,123 | |||||||||||
Assets: | |||||||||||||||||||||
As of March 31, 2014 | $ | 5,697,874 | $ | 496,310 | $ | 205,105 | $ | 636,897 | $ | 7,036,186 | |||||||||||
As of December 31, 2013 | $ | 5,744,734 | $ | 504,645 | $ | 197,458 | $ | 613,977 | $ | 7,060,814 | |||||||||||
Summary of Company's Net Revenue from Professional Diagnostics and Health Information Solutions Reporting Segments by Groups of Similar Products and Services | ' | ||||||||||||||||||||
The following tables summarize our net revenue from the professional diagnostics and health information solutions reporting segments by groups of similar products and services for the three months ended March 31, 2014 and 2013 (in thousands): | |||||||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||||||
Professional Diagnostics Segment | 2014 | 2013 | |||||||||||||||||||
Infectious disease | $ | 164,030 | $ | 189,844 | |||||||||||||||||
Toxicology | 151,897 | 149,049 | |||||||||||||||||||
Cardiology | 121,633 | 114,933 | |||||||||||||||||||
Diabetes | 50,721 | 50,083 | |||||||||||||||||||
Other | 73,052 | 74,719 | |||||||||||||||||||
Professional diagnostics net product sales and services revenue | 561,333 | 578,628 | |||||||||||||||||||
License and royalty revenue | 5,212 | 3,864 | |||||||||||||||||||
Professional diagnostics net revenue | $ | 566,545 | $ | 582,492 | |||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||||||
Health Information Solutions Segment | 2014 | 2013 | |||||||||||||||||||
Condition and case management | $ | 49,319 | $ | 54,126 | |||||||||||||||||
Wellness | 24,950 | 26,300 | |||||||||||||||||||
Women’s & children’s health | 22,215 | 29,080 | |||||||||||||||||||
Patient self-testing services | 27,184 | 24,701 | |||||||||||||||||||
Health information solutions net revenue | $ | 123,668 | $ | 134,207 | |||||||||||||||||
Related_Party_Transactions_Tab
Related Party Transactions (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Related Party Transactions [Abstract] | ' | ||||||||
Related Party Balances with SPD within Consolidated Balance Sheets | ' | ||||||||
The following table summarizes our related party balances with SPD within our Consolidated Balance Sheets (in thousands): | |||||||||
Balance Sheet Caption | March 31, 2014 | December 31, 2013 | |||||||
Accounts receivable, net of allowances | $ | 5,753 | $ | 9,436 | |||||
Prepaid expenses and other current assets | $ | 9,469 | $ | 12,417 | |||||
Deferred financing costs, net, and other non-current assets | $ | 13,313 | $ | 13,249 | |||||
Accounts payable | $ | 22,215 | $ | 18,811 |
Material_Contingencies_Tables
Material Contingencies (Tables) | 3 Months Ended | ||||||||||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||||||||||
Commitments And Contingencies Disclosure [Abstract] | ' | ||||||||||||||||||||||||||||
Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions | ' | ||||||||||||||||||||||||||||
We have contractual contingent purchase price consideration obligations related to certain of our acquisitions, as follows (in thousands): | |||||||||||||||||||||||||||||
Acquisition | Acquisition Date | Acquisition | Maximum | Remaining | Estimated | Estimated | Payments | ||||||||||||||||||||||
Date Fair | Remaining | Earn-out | Fair Value as | Fair Value as | Made | ||||||||||||||||||||||||
Value | Earn-out | Period as | of | of | during | ||||||||||||||||||||||||
Potential | of | March 31, | December 31, | 2014 | |||||||||||||||||||||||||
as of | March 31, | 2014 | 2013 | ||||||||||||||||||||||||||
March 31, | 2014 | ||||||||||||||||||||||||||||
2014 | |||||||||||||||||||||||||||||
TwistDx, Inc. | 11-Mar-10 | $ | 35,600 | $ | 123,888 | 2014 – 2025 | (1) | $ | 46,400 | $ | 45,502 | $ | 139 | ||||||||||||||||
Ionian Technologies, Inc. | 12-Jul-10 | $ | 24,500 | 57,500 | 2014 – 2015 | 29,400 | 29,000 | — | |||||||||||||||||||||
Laboratory Data Systems, Inc. | 29-Aug-11 | $ | 13,000 | 7,500 | 2013 | (2) | 7,500 | (2) | 7,400 | (2) | — | ||||||||||||||||||
Forensics Limited (ROAR) | September 22, 2011 | $ | 5,463 | 12,600 | 2014 | 3,328 | 2,484 | — | |||||||||||||||||||||
Method Factory Inc. (Wellogic) | December 9, 2011 | $ | 18,900 | — | (3) | 2014 – 2019 | 25,400 | 26,900 | 150 | ||||||||||||||||||||
MedApps. | 2-Jul-12 | $ | 13,100 | 8,600 | 2014 | 7,600 | 8,200 | 5,000 | |||||||||||||||||||||
Amedica Biotech, Inc. | 3-Jul-12 | $ | 8,900 | 8,100 | 2013 | (2) | 7,935 | (2) | 7,500 | (2) | — | ||||||||||||||||||
DiagnosisOne, Inc. | 31-Jul-12 | $ | 22,300 | 33,000 | 2014 – 2017 | 26,900 | 26,600 | — | |||||||||||||||||||||
Epocal. | 1-Feb-13 | $ | 75,000 | 65,500 | 2014 – 2018 | 45,600 | 47,200 | — | |||||||||||||||||||||
Other | Various | $ | 58,877 | 20,229 | 2014 – 2016 | 10,756 | 13,183 | 2,421 | |||||||||||||||||||||
$ | 210,819 | $ | 213,969 | $ | 7,710 | ||||||||||||||||||||||||
-1 | The maximum earn-out period ends on the fifteenth anniversary of the acquisition date. | ||||||||||||||||||||||||||||
-2 | The fair value of the maximum remaining earn-out was accrued as of March 31, 2014 and December 31, 2013. We expect to pay the maximum remaining earn-out during the second quarter of 2014. | ||||||||||||||||||||||||||||
(3) | The earn-out is comprised of three components of which two components have an aggregate maximum remaining earn-out potential of $49.9 million. There is no dollar cap on the third earn-out component, however, the earn-out potential is limited to the remaining earn-out period. |
Equity_Investments_Tables
Equity Investments (Tables) | 3 Months Ended | ||||||||
Mar. 31, 2014 | |||||||||
Equity Method Investments And Joint Ventures [Abstract] | ' | ||||||||
Financial Information for SPD and TechLab on Combined Condensed Results of Operations | ' | ||||||||
Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands): | |||||||||
Three Months Ended March 31, | |||||||||
Combined Condensed Results of Operations: | 2014 | 2013 | |||||||
Net revenue | $ | 48,933 | $ | 49,155 | |||||
Gross profit | $ | 42,980 | $ | 37,113 | |||||
Net income after taxes | $ | 10,830 | $ | 5,577 | |||||
Financial Information for SPD and TechLab on Combined Condensed Balance Sheet | ' | ||||||||
Combined Condensed Balance Sheet: | March 31, 2014 | December 31, 2013 | |||||||
Current assets | $ | 72,582 | $ | 63,985 | |||||
Non-current assets | 38,376 | 38,541 | |||||||
Total assets | $ | 110,958 | $ | 102,526 | |||||
Current liabilities | $ | 38,524 | $ | 38,053 | |||||
Non-current liabilities | 6,430 | 6,175 | |||||||
Total liabilities | $ | 44,954 | $ | 44,228 | |||||
Guarantor_Financial_Informatio1
Guarantor Financial Information (Tables) | 3 Months Ended | ||||||||||||||||||||
Mar. 31, 2014 | |||||||||||||||||||||
Quarterly Financial Information Disclosure [Abstract] | ' | ||||||||||||||||||||
Guarantor Financial Information Consolidating Statement of Operations | ' | ||||||||||||||||||||
CONSOLIDATING STATEMENT OF OPERATIONS | |||||||||||||||||||||
For the Three Months Ended March 31, 2014 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Non - | |||||||||||||||||||||
Guarantor | Guarantor | ||||||||||||||||||||
Issuer | Subsidiaries | Subsidiaries | Eliminations | Consolidated | |||||||||||||||||
Net product sales | $ | — | $ | 213,409 | $ | 336,037 | $ | (54,001 | ) | $ | 495,445 | ||||||||||
Services revenue | — | 197,908 | 18,057 | — | 215,965 | ||||||||||||||||
Net product sales and services revenue | — | 411,317 | 354,094 | (54,001 | ) | 711,410 | |||||||||||||||
License and royalty revenue | — | 3,485 | 5,018 | (3,291 | ) | 5,212 | |||||||||||||||
Net revenue | — | 414,802 | 359,112 | (57,292 | ) | 716,622 | |||||||||||||||
Cost of net product sales | 688 | 114,135 | 183,774 | (52,485 | ) | 246,112 | |||||||||||||||
Cost of services revenue | 73 | 115,325 | 8,054 | (5,720 | ) | 117,732 | |||||||||||||||
Cost of net product sales and services revenue | 761 | 229,460 | 191,828 | (58,205 | ) | 363,844 | |||||||||||||||
Cost of license and royalty revenue | — | 92 | 4,738 | (3,291 | ) | 1,539 | |||||||||||||||
Cost of net revenue | 761 | 229,552 | 196,566 | (61,496 | ) | 365,383 | |||||||||||||||
Gross profit (loss) | (761 | ) | 185,250 | 162,546 | 4,204 | 351,239 | |||||||||||||||
Operating expenses: | |||||||||||||||||||||
Research and development | 5,615 | 14,845 | 18,239 | — | 38,699 | ||||||||||||||||
Sales and marketing | 1,868 | 74,959 | 70,237 | — | 147,064 | ||||||||||||||||
General and administrative | 18,488 | 68,782 | 52,266 | — | 139,536 | ||||||||||||||||
Operating expenses | 25,971 | 158,586 | 140,742 | — | 325,299 | ||||||||||||||||
Operating income (loss) | (26,732 | ) | 26,664 | 21,804 | 4,204 | 25,940 | |||||||||||||||
Interest expense, including amortization of original issue discounts and deferred financing costs | (51,258 | ) | (5,628 | ) | (4,544 | ) | 9,386 | (52,044 | ) | ||||||||||||
Other income (expense), net | 4,694 | 3,648 | 5,825 | (9,445 | ) | 4,722 | |||||||||||||||
Income (loss) before provision (benefit) for income taxes | (73,296 | ) | 24,684 | 23,085 | 4,145 | (21,382 | ) | ||||||||||||||
Provision (benefit) for income taxes | (38,423 | ) | 17,367 | 9,681 | 1,458 | (9,917 | ) | ||||||||||||||
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax | (34,873 | ) | 7,317 | 13,404 | 2,687 | (11,465 | ) | ||||||||||||||
Equity in earnings of subsidiaries, net of tax | 28,355 | 68 | — | (28,423 | ) | — | |||||||||||||||
Equity earnings of unconsolidated entities, net of tax | 405 | — | 5,064 | (117 | ) | 5,352 | |||||||||||||||
Net income (loss) | (6,113 | ) | 7,385 | 18,468 | (25,853 | ) | (6,113 | ) | |||||||||||||
Less: Net income attributable to non-controlling interests | — | — | 108 | — | 108 | ||||||||||||||||
Net income (loss) attributable to Alere Inc. and Subsidiaries | (6,113 | ) | 7,385 | 18,360 | (25,853 | ) | (6,221 | ) | |||||||||||||
Preferred stock dividends | (5,250 | ) | — | — | — | (5,250 | ) | ||||||||||||||
Net income (loss) available to common stockholders | $ | (11,363 | ) | $ | 7,385 | $ | 18,360 | $ | (25,853 | ) | $ | (11,471 | ) | ||||||||
(19) Guarantor Financial Information (Continued) | |||||||||||||||||||||
CONSOLIDATING STATEMENT OF OPERATIONS | |||||||||||||||||||||
For the Three Months Ended March 31, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Non - | |||||||||||||||||||||
Guarantor | Guarantor | ||||||||||||||||||||
Issuer | Subsidiaries | Subsidiaries | Eliminations | Consolidated | |||||||||||||||||
Net product sales | $ | — | $ | 233,551 | $ | 320,839 | $ | (46,114 | ) | $ | 508,276 | ||||||||||
Services revenue | — | 207,749 | 19,160 | — | 226,909 | ||||||||||||||||
Net product sales and services revenue | — | 441,300 | 339,999 | (46,114 | ) | 735,185 | |||||||||||||||
License and royalty revenue | — | 3,035 | 3,533 | (2,504 | ) | 4,064 | |||||||||||||||
Net revenue | — | 444,335 | 343,532 | (48,618 | ) | 739,249 | |||||||||||||||
Cost of net product sales | 948 | 121,236 | 172,574 | (41,680 | ) | 253,078 | |||||||||||||||
Cost of services revenue | — | 115,971 | 8,142 | (3,955 | ) | 120,158 | |||||||||||||||
Cost of net product sales and services revenue | 948 | 237,207 | 180,716 | (45,635 | ) | 373,236 | |||||||||||||||
Cost of license and royalty revenue | — | 17 | 4,243 | (2,504 | ) | 1,756 | |||||||||||||||
Cost of net revenue | 948 | 237,224 | 184,959 | (48,139 | ) | 374,992 | |||||||||||||||
Gross profit (loss) | (948 | ) | 207,111 | 158,573 | (479 | ) | 364,257 | ||||||||||||||
Operating expenses: | |||||||||||||||||||||
Research and development | 4,423 | 18,100 | 18,931 | — | 41,454 | ||||||||||||||||
Sales and marketing | 1,392 | 83,431 | 71,633 | — | 156,456 | ||||||||||||||||
General and administrative | 14,027 | 67,146 | 54,685 | — | 135,858 | ||||||||||||||||
Operating expenses | 19,842 | 168,677 | 145,249 | — | 333,768 | ||||||||||||||||
Operating income (loss) | (20,790 | ) | 38,434 | 13,324 | (479 | ) | 30,489 | ||||||||||||||
Interest expense, including amortization of original issue discounts and deferred financing costs | (56,858 | ) | (7,021 | ) | (3,417 | ) | 9,897 | (57,399 | ) | ||||||||||||
Other income (expense), net | 4,770 | 6,259 | (1,603 | ) | (9,896 | ) | (470 | ) | |||||||||||||
Income (loss) before provision (benefit) for income taxes | (72,878 | ) | 37,672 | 8,304 | (478 | ) | (27,380 | ) | |||||||||||||
Provision (benefit) for income taxes | (62,811 | ) | 17,082 | 8,971 | (113 | ) | (36,871 | ) | |||||||||||||
Income (loss) before equity in earnings (losses) of subsidiaries and unconsolidated entities, net of tax | (10,067 | ) | 20,590 | (667 | ) | (365 | ) | 9,491 | |||||||||||||
Equity in earnings (losses) of subsidiaries, net of tax | 22,244 | (614 | ) | — | (21,630 | ) | — | ||||||||||||||
Equity earnings of unconsolidated entities, net of tax | 248 | — | 2,688 | (2 | ) | 2,934 | |||||||||||||||
Net income | 12,425 | 19,976 | 2,021 | (21,997 | ) | 12,425 | |||||||||||||||
Less: Net loss attributable to non-controlling interests | — | — | (25 | ) | — | (25 | ) | ||||||||||||||
Net income attributable to Alere Inc. and Subsidiaries | 12,425 | 19,976 | 2,046 | (21,997 | ) | 12,450 | |||||||||||||||
Preferred stock dividends | (5,250 | ) | — | — | — | (5,250 | ) | ||||||||||||||
Net income available to common stockholders | $ | 7,175 | $ | 19,976 | $ | 2,046 | $ | (21,997 | ) | $ | 7,200 | ||||||||||
Guarantor Financial Information Consolidating Statement of Comprehensive Income (Loss) | ' | ||||||||||||||||||||
CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) | |||||||||||||||||||||
For the Three Months Ended March 31, 2014 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Non- | |||||||||||||||||||||
Guarantor | Guarantor | ||||||||||||||||||||
Issuer | Subsidiaries | Subsidiaries | Eliminations | Consolidated | |||||||||||||||||
Net income (loss) | $ | (6,113 | ) | $ | 7,386 | $ | 18,466 | $ | (25,852 | ) | $ | (6,113 | ) | ||||||||
Other comprehensive income (loss), before tax: | |||||||||||||||||||||
Changes in cumulative translation adjustment | 157 | (129 | ) | (11,368 | ) | — | (11,340 | ) | |||||||||||||
Unrealized losses on available for sale securities | — | (17 | ) | — | — | (17 | ) | ||||||||||||||
Unrealized gains on hedging instruments | — | — | 8 | — | 8 | ||||||||||||||||
Minimum pension liability adjustment | — | — | 74 | — | 74 | ||||||||||||||||
Other comprehensive income (loss), before tax | 157 | (146 | ) | (11,286 | ) | — | (11,275 | ) | |||||||||||||
Income tax benefit related to items of other comprehensive income (loss) | — | — | — | — | — | ||||||||||||||||
Other comprehensive income (loss), net of tax | 157 | (146 | ) | (11,286 | ) | — | (11,275 | ) | |||||||||||||
Comprehensive income (loss) | (5,956 | ) | 7,240 | 7,180 | (25,852 | ) | (17,388 | ) | |||||||||||||
Less: Comprehensive income attributable to non-controlling interests | — | — | 108 | — | 108 | ||||||||||||||||
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | $ | (5,956 | ) | $ | 7,240 | $ | 7,072 | $ | (25,852 | ) | $ | (17,496 | ) | ||||||||
(19) Guarantor Financial Information (Continued) | |||||||||||||||||||||
CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) | |||||||||||||||||||||
For the Three Months Ended March 31, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Non - | |||||||||||||||||||||
Guarantor | Guarantor | ||||||||||||||||||||
Issuer | Subsidiaries | Subsidiaries | Eliminations | Consolidated | |||||||||||||||||
Net income | $ | 12,425 | $ | 19,976 | $ | 2,021 | $ | (21,997 | ) | $ | 12,425 | ||||||||||
Other comprehensive loss, before tax: | |||||||||||||||||||||
Changes in cumulative translation adjustment | (201 | ) | — | (75,154 | ) | — | (75,355 | ) | |||||||||||||
Unrealized gains on hedging instruments | — | — | 11 | — | 11 | ||||||||||||||||
Minimum pension liability adjustment | — | — | 605 | — | 605 | ||||||||||||||||
Other comprehensive loss, before tax | (201 | ) | — | (74,538 | ) | — | (74,739 | ) | |||||||||||||
Income tax benefit related to items of other comprehensive loss | — | — | — | — | — | ||||||||||||||||
Other comprehensive loss, net of tax | (201 | ) | — | (74,538 | ) | — | (74,739 | ) | |||||||||||||
Comprehensive income (loss) | 12,224 | 19,976 | (72,517 | ) | (21,997 | ) | (62,314 | ) | |||||||||||||
Less: Comprehensive loss attributable to non-controlling interests | — | — | (25 | ) | — | (25 | ) | ||||||||||||||
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | $ | 12,224 | $ | 19,976 | $ | (72,492 | ) | $ | (21,997 | ) | $ | (62,289 | ) | ||||||||
Guarantor Financial Information Consolidating Balance Sheet | ' | ||||||||||||||||||||
CONSOLIDATING BALANCE SHEET | |||||||||||||||||||||
March 31, 2014 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Guarantor | Non-Guarantor | ||||||||||||||||||||
Issuer | Subsidiaries | Subsidiaries | Eliminations | Consolidated | |||||||||||||||||
ASSETS | |||||||||||||||||||||
Current assets: | |||||||||||||||||||||
Cash and cash equivalents | $ | 13,020 | $ | 82,048 | $ | 337,958 | $ | — | $ | 433,026 | |||||||||||
Restricted cash | 84 | 2,915 | 1,223 | — | 4,222 | ||||||||||||||||
Marketable securities | — | 776 | 5 | — | 781 | ||||||||||||||||
Accounts receivable, net of allowances | — | 250,603 | 278,190 | — | 528,793 | ||||||||||||||||
Inventories, net | — | 170,165 | 218,246 | (17,275 | ) | 371,136 | |||||||||||||||
Deferred tax assets | 4,984 | 27,375 | 32,120 | (1,863 | ) | 62,616 | |||||||||||||||
Prepaid expenses and other current assets | 538,410 | (432,500 | ) | 10,713 | 3,906 | 120,529 | |||||||||||||||
Intercompany receivables | 304,817 | 715,596 | 69,903 | (1,090,316 | ) | — | |||||||||||||||
Total current assets | 861,315 | 816,978 | 948,358 | (1,105,548 | ) | 1,521,103 | |||||||||||||||
Property, plant and equipment, net | 19,312 | 286,490 | 239,523 | (274 | ) | 545,051 | |||||||||||||||
Goodwill | — | 1,842,309 | 1,247,747 | — | 3,090,056 | ||||||||||||||||
Other intangible assets with indefinite lives | — | 14,300 | 41,675 | (59 | ) | 55,916 | |||||||||||||||
Finite-lived intangible assets, net | 10,245 | 959,002 | 648,007 | — | 1,617,254 | ||||||||||||||||
Restricted cash | — | — | 28,856 | — | 28,856 | ||||||||||||||||
Deferred financing costs, net and other non-current assets | 51,746 | 7,586 | 20,764 | (40 | ) | 80,056 | |||||||||||||||
Investments in subsidiaries | 3,821,577 | 270,857 | 191,920 | (4,284,354 | ) | — | |||||||||||||||
Investments in unconsolidated entities | 30,174 | — | 49,510 | 10,761 | 90,445 | ||||||||||||||||
Deferred tax assets | — | — | 7,449 | — | 7,449 | ||||||||||||||||
Intercompany notes receivables | 1,099,817 | 720,017 | 48,779 | (1,868,613 | ) | — | |||||||||||||||
Total assets | $ | 5,894,186 | $ | 4,917,539 | $ | 3,472,588 | $ | (7,248,127 | ) | $ | 7,036,186 | ||||||||||
LIABILITIES AND EQUITY | |||||||||||||||||||||
Current liabilities: | |||||||||||||||||||||
Current portion of long-term debt | $ | 60,000 | $ | 962 | $ | 4,290 | $ | — | $ | 65,252 | |||||||||||
Current portion of capital lease obligations | — | 3,165 | 3,055 | — | 6,220 | ||||||||||||||||
Accounts payable | 8,280 | 79,319 | 102,849 | — | 190,448 | ||||||||||||||||
Accrued expenses and other current liabilities | 85,170 | 161,351 | 183,775 | (35 | ) | 430,261 | |||||||||||||||
Intercompany payables | 660,712 | 148,533 | 281,071 | (1,090,316 | ) | — | |||||||||||||||
Total current liabilities | 814,162 | 393,330 | 575,040 | (1,090,351 | ) | 692,181 | |||||||||||||||
Long-term liabilities: | |||||||||||||||||||||
Long-term debt, net of current portion | 3,705,215 | 100 | 40,481 | — | 3,745,796 | ||||||||||||||||
Capital lease obligations, net of current portion | — | 5,563 | 9,527 | — | 15,090 | ||||||||||||||||
Deferred tax liabilities | (65,370 | ) | 290,283 | 82,616 | 45 | 307,574 | |||||||||||||||
Other long-term liabilities | 25,384 | 61,026 | 108,619 | (40 | ) | 194,989 | |||||||||||||||
Intercompany notes payables (receivables) | (660,771 | ) | 1,419,782 | 1,109,602 | (1,868,613 | ) | — | ||||||||||||||
Total long-term liabilities | 3,004,458 | 1,776,754 | 1,350,845 | (1,868,608 | ) | 4,263,449 | |||||||||||||||
Stockholders’ equity | 2,075,566 | 2,747,455 | 1,541,713 | (4,289,168 | ) | 2,075,566 | |||||||||||||||
Non-controlling interests | — | — | 4,990 | — | 4,990 | ||||||||||||||||
Total equity | 2,075,566 | 2,747,455 | 1,546,703 | (4,289,168 | ) | 2,080,556 | |||||||||||||||
Total liabilities and equity | $ | 5,894,186 | $ | 4,917,539 | $ | 3,472,588 | $ | (7,248,127 | ) | $ | 7,036,186 | ||||||||||
(19) Guarantor Financial Information (Continued) | |||||||||||||||||||||
CONSOLIDATING BALANCE SHEET | |||||||||||||||||||||
December 31, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Guarantor | Non-Guarantor | ||||||||||||||||||||
Issuer | Subsidiaries | Subsidiaries | Eliminations | Consolidated | |||||||||||||||||
ASSETS | |||||||||||||||||||||
Current assets: | |||||||||||||||||||||
Cash and cash equivalents | $ | 14,801 | $ | 85,453 | $ | 261,654 | $ | — | $ | 361,908 | |||||||||||
Restricted cash | 2,221 | 2,915 | 1,237 | — | 6,373 | ||||||||||||||||
Marketable securities | — | 853 | 5 | — | 858 | ||||||||||||||||
Accounts receivable, net of allowances | — | 238,782 | 309,947 | — | 548,729 | ||||||||||||||||
Inventories, net | — | 168,058 | 219,892 | (23,765 | ) | 364,185 | |||||||||||||||
Deferred tax assets | 5,191 | 20,541 | 31,451 | 3,506 | 60,689 | ||||||||||||||||
Prepaid expenses and other current assets | 512,123 | (405,954 | ) | 23,547 | (44 | ) | 129,672 | ||||||||||||||
Intercompany receivables | 317,357 | 759,497 | 75,424 | (1,152,278 | ) | — | |||||||||||||||
Total current assets | 851,693 | 870,145 | 923,157 | (1,172,581 | ) | 1,472,414 | |||||||||||||||
Property, plant and equipment, net | 15,086 | 288,637 | 241,737 | (296 | ) | 545,164 | |||||||||||||||
Goodwill | — | 1,841,377 | 1,252,314 | — | 3,093,691 | ||||||||||||||||
Other intangible assets with indefinite lives | — | 14,300 | 42,402 | — | 56,702 | ||||||||||||||||
Finite-lived intangible assets, net | 11,006 | 995,868 | 677,737 | — | 1,684,611 | ||||||||||||||||
Restricted cash | — | — | 29,370 | — | 29,370 | ||||||||||||||||
Deferred financing costs, net and other non-current assets | 55,207 | 8,353 | 20,559 | (46 | ) | 84,073 | |||||||||||||||
Investments in subsidiaries | 3,802,475 | 267,824 | 191,947 | (4,262,246 | ) | — | |||||||||||||||
Investments in unconsolidated entities | 29,005 | — | 44,637 | 13,188 | 86,830 | ||||||||||||||||
Deferred tax assets | — | — | 7,959 | — | 7,959 | ||||||||||||||||
Intercompany notes receivables (payables) | 1,100,746 | 630,628 | (741,016 | ) | (990,358 | ) | — | ||||||||||||||
Total assets | $ | 5,865,218 | $ | 4,917,132 | $ | 2,690,803 | $ | (6,412,339 | ) | $ | 7,060,814 | ||||||||||
LIABILITIES AND EQUITY | |||||||||||||||||||||
Current liabilities: | |||||||||||||||||||||
Current portion of long-term debt | $ | 45,000 | $ | 323 | $ | 3,789 | $ | — | $ | 49,112 | |||||||||||
Current portion of capital lease obligations | — | 3,751 | 3,104 | — | 6,855 | ||||||||||||||||
Accounts payable | 12,584 | 69,076 | 105,711 | — | 187,371 | ||||||||||||||||
Accrued expenses and other current liabilities | 63,990 | 164,762 | 201,132 | (36 | ) | 429,848 | |||||||||||||||
Intercompany payables | 728,541 | 149,031 | 274,707 | (1,152,279 | ) | — | |||||||||||||||
Total current liabilities | 850,115 | 386,943 | 588,443 | (1,152,315 | ) | 673,186 | |||||||||||||||
Long-term liabilities: | |||||||||||||||||||||
Long-term debt, net of current portion | 3,735,137 | 100 | 37,551 | — | 3,772,788 | ||||||||||||||||
Capital lease obligations, net of current portion | — | 5,938 | 8,469 | — | 14,407 | ||||||||||||||||
Deferred tax liabilities | (43,246 | ) | 284,448 | 88,039 | 8 | 329,249 | |||||||||||||||
Other long-term liabilities | 19,753 | 58,823 | 109,806 | (46 | ) | 188,336 | |||||||||||||||
Intercompany notes payables (receivables) | (774,507 | ) | 1,444,741 | 320,125 | (990,359 | ) | — | ||||||||||||||
Total long-term liabilities | 2,937,137 | 1,794,050 | 563,990 | (990,397 | ) | 4,304,780 | |||||||||||||||
Stockholders’ equity | 2,077,966 | 2,736,139 | 1,533,488 | (4,269,627 | ) | 2,077,966 | |||||||||||||||
Non-controlling interests | — | — | 4,882 | — | 4,882 | ||||||||||||||||
Total equity | 2,077,966 | 2,736,139 | 1,538,370 | (4,269,627 | ) | 2,082,848 | |||||||||||||||
Total liabilities and equity | $ | 5,865,218 | $ | 4,917,132 | $ | 2,690,803 | $ | (6,412,339 | ) | $ | 7,060,814 | ||||||||||
Guarantor Financial Information Consolidating Statement of Cash Flows | ' | ||||||||||||||||||||
CONSOLIDATING STATEMENT OF CASH FLOWS | |||||||||||||||||||||
For the Three Months Ended March 31, 2014 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Guarantor | Non-Guarantor | ||||||||||||||||||||
Issuer | Subsidiaries | Subsidiaries | Eliminations | Consolidated | |||||||||||||||||
Cash Flows from Operating Activities: | |||||||||||||||||||||
Net income (loss) | $ | (6,113 | ) | $ | 7,385 | $ | 18,468 | $ | (25,853 | ) | $ | (6,113 | ) | ||||||||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||||||||||||||||||||
Equity in earnings of subsidiaries, net of tax | (28,355 | ) | (68 | ) | — | 28,423 | — | ||||||||||||||
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs | 3,857 | 125 | 159 | — | 4,141 | ||||||||||||||||
Depreciation and amortization | 1,399 | 58,445 | 38,166 | 76 | 98,086 | ||||||||||||||||
Non-cash stock-based compensation expense | 2,407 | 1,093 | 2,204 | — | 5,704 | ||||||||||||||||
Impairment of inventory | — | — | 589 | — | 589 | ||||||||||||||||
Impairment of long-lived assets | — | — | 161 | — | 161 | ||||||||||||||||
Loss on sale of fixed assets | — | 2,010 | 62 | — | 2,072 | ||||||||||||||||
Equity earnings of unconsolidated entities, net of tax | (405 | ) | — | (5,064 | ) | 117 | (5,352 | ) | |||||||||||||
Deferred income taxes | (21,658 | ) | (1,399 | ) | (3,037 | ) | 1,458 | (24,636 | ) | ||||||||||||
Other non-cash items | — | 1,197 | (4,856 | ) | — | (3,659 | ) | ||||||||||||||
Changes in assets and liabilities, net of acquisitions: | |||||||||||||||||||||
Accounts receivable, net | — | (11,821 | ) | 31,719 | — | 19,898 | |||||||||||||||
Inventories, net | — | (8,576 | ) | (105 | ) | (4,064 | ) | (12,745 | ) | ||||||||||||
Prepaid expenses and other current assets | (26,287 | ) | 23,130 | 11,790 | (4,303 | ) | 4,330 | ||||||||||||||
Accounts payable | (4,305 | ) | 11,975 | (2,439 | ) | — | 5,231 | ||||||||||||||
Accrued expenses and other current liabilities | 18,625 | (3,339 | ) | (7,278 | ) | 355 | 8,363 | ||||||||||||||
Other non-current liabilities | 9,106 | 2,148 | (1,895 | ) | 3,954 | 13,313 | |||||||||||||||
Cash paid for contingent consideration | (3,417 | ) | — | (58 | ) | — | (3,475 | ) | |||||||||||||
Intercompany payable (receivable) | 67,749 | (70,945 | ) | 3,196 | — | — | |||||||||||||||
Net cash provided by operating activities | 12,603 | 11,360 | 81,782 | 163 | 105,908 | ||||||||||||||||
Cash Flows from Investing Activities: | |||||||||||||||||||||
Decrease in restricted cash | 2,125 | — | 26 | — | 2,151 | ||||||||||||||||
Purchases of property, plant and equipment | (6,323 | ) | (12,941 | ) | (9,093 | ) | 817 | (27,540 | ) | ||||||||||||
Proceeds from sale of property, plant and equipment | 269 | 664 | 112 | (916 | ) | 129 | |||||||||||||||
Cash received from disposition | — | — | 4,373 | — | 4,373 | ||||||||||||||||
Cash paid for investments | (504 | ) | — | (3 | ) | — | (507 | ) | |||||||||||||
Cash received from sales of marketable securities | — | 60 | — | — | 60 | ||||||||||||||||
Increase in other assets | (311 | ) | (2,185 | ) | (482 | ) | 53 | (2,925 | ) | ||||||||||||
Net cash used in investing activities | (4,744 | ) | (14,402 | ) | (5,067 | ) | (46 | ) | (24,259 | ) | |||||||||||
Cash Flows from Financing Activities: | |||||||||||||||||||||
Cash paid for financing costs | (7 | ) | — | — | — | (7 | ) | ||||||||||||||
Cash paid for contingent purchase price consideration | (4,072 | ) | — | (123 | ) | — | (4,195 | ) | |||||||||||||
Proceeds from issuance of common stock, net of issuance costs | 14,698 | — | — | — | 14,698 | ||||||||||||||||
Proceeds from issuance of long-term debt | — | 939 | — | — | 939 | ||||||||||||||||
Payments on long-term debt | (15,000 | ) | (301 | ) | (522 | ) | — | (15,823 | ) | ||||||||||||
Net proceeds under revolving credit facilities | — | — | 233 | — | 233 | ||||||||||||||||
Cash paid for dividends | (5,323 | ) | — | — | — | (5,323 | ) | ||||||||||||||
Excess tax benefits on exercised stock options | 53 | 207 | 32 | — | 292 | ||||||||||||||||
Principal payments on capital lease obligations | — | (1,080 | ) | (760 | ) | — | (1,840 | ) | |||||||||||||
Net cash used in financing activities | (9,651 | ) | (235 | ) | (1,140 | ) | — | (11,026 | ) | ||||||||||||
Foreign exchange effect on cash and cash equivalents | 11 | (128 | ) | 729 | (117 | ) | 495 | ||||||||||||||
Net increase (decrease) in cash and cash equivalents | (1,781 | ) | (3,405 | ) | 76,304 | — | 71,118 | ||||||||||||||
Cash and cash equivalents, beginning of period | 14,801 | 85,453 | 261,654 | — | 361,908 | ||||||||||||||||
Cash and cash equivalents, end of period | $ | 13,020 | $ | 82,048 | $ | 337,958 | $ | — | $ | 433,026 | |||||||||||
(19) Guarantor Financial Information (Continued) | |||||||||||||||||||||
CONSOLIDATING STATEMENT OF CASH FLOWS | |||||||||||||||||||||
For the Three Months Ended March 31, 2013 | |||||||||||||||||||||
(in thousands) | |||||||||||||||||||||
Guarantor | Non-Guarantor | ||||||||||||||||||||
Issuer | Subsidiaries | Subsidiaries | Eliminations | Consolidated | |||||||||||||||||
Cash Flows from Operating Activities: | |||||||||||||||||||||
Net income | $ | 12,425 | $ | 19,976 | $ | 2,021 | $ | (21,997 | ) | $ | 12,425 | ||||||||||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||||||||||||||||||||
Equity in earnings (losses) of subsidiaries, net of tax | (22,244 | ) | 614 | — | 21,630 | — | |||||||||||||||
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs | 5,153 | 55 | 9 | — | 5,217 | ||||||||||||||||
Depreciation and amortization | 1,287 | 62,711 | 41,001 | (29 | ) | 104,970 | |||||||||||||||
Non-cash charges for sale of inventories revalued at the date of acquisition | — | — | 461 | — | 461 | ||||||||||||||||
Non-cash stock-based compensation expense | 1,660 | 1,096 | 1,367 | — | 4,123 | ||||||||||||||||
(Gain) loss on sale of fixed assets | — | 227 | (55 | ) | — | 172 | |||||||||||||||
Equity earnings of unconsolidated entities, net of tax | (248 | ) | — | (2,688 | ) | 2 | (2,934 | ) | |||||||||||||
Deferred income taxes | (30,889 | ) | (10,300 | ) | (9,605 | ) | (113 | ) | (50,907 | ) | |||||||||||
Other non-cash items | (762 | ) | 275 | 2,428 | — | 1,941 | |||||||||||||||
Changes in assets and liabilities, net of acquisitions: | |||||||||||||||||||||
Accounts receivable, net | — | (1,968 | ) | (18,199 | ) | — | (20,167 | ) | |||||||||||||
Inventories, net | — | (10,617 | ) | (7,129 | ) | 575 | (17,171 | ) | |||||||||||||
Prepaid expenses and other current assets | (473,927 | ) | 413,274 | 35,633 | 19,187 | (5,833 | ) | ||||||||||||||
Accounts payable | (604 | ) | (7,823 | ) | 6,439 | — | (1,988 | ) | |||||||||||||
Accrued expenses and other current liabilities | 478,784 | (387,671 | ) | (29,830 | ) | (19,187 | ) | 42,096 | |||||||||||||
Other non-current liabilities | (126 | ) | (2,959 | ) | 3,880 | — | 795 | ||||||||||||||
Cash paid for contingent consideration | (2,139 | ) | — | — | — | (2,139 | ) | ||||||||||||||
Intercompany payable (receivable) | 64,910 | (77,486 | ) | 12,576 | — | — | |||||||||||||||
Net cash provided by (used in) operating activities | 33,280 | (596 | ) | 38,309 | 68 | 71,061 | |||||||||||||||
Cash Flows from Investing Activities: | |||||||||||||||||||||
Increase in restricted cash | (7,933 | ) | (630 | ) | (10 | ) | — | (8,573 | ) | ||||||||||||
Purchases of property, plant and equipment | (37 | ) | (14,732 | ) | (26,358 | ) | 5,022 | (36,105 | ) | ||||||||||||
Proceeds from sale of property, plant and equipment | — | 2,106 | 4,085 | (5,048 | ) | 1,143 | |||||||||||||||
Cash paid for acquisitions, net of cash acquired | (151,372 | ) | — | (7,049 | ) | — | (158,421 | ) | |||||||||||||
Cash received from investments | — | — | 10,771 | — | 10,771 | ||||||||||||||||
Increase in other assets | (3,210 | ) | (881 | ) | (1,478 | ) | — | (5,569 | ) | ||||||||||||
Net cash used in investing activities | (162,552 | ) | (14,137 | ) | (20,039 | ) | (26 | ) | (196,754 | ) | |||||||||||
Cash Flows from Financing Activities: | |||||||||||||||||||||
Cash paid for financing costs | (1,427 | ) | — | — | — | (1,427 | ) | ||||||||||||||
Cash paid for contingent purchase price consideration | (19,098 | ) | — | — | — | (19,098 | ) | ||||||||||||||
Proceeds from issuance of common stock, net of issuance costs | 6,135 | — | — | — | 6,135 | ||||||||||||||||
Proceeds from issuance of long-term debt | — | 1,007 | 9,046 | — | 10,053 | ||||||||||||||||
Payments on long-term debt | (16,845 | ) | (445 | ) | (2,348 | ) | — | (19,638 | ) | ||||||||||||
Net proceeds (payments) under revolving credit facilities | 170,000 | — | (7,517 | ) | — | 162,483 | |||||||||||||||
Cash paid for dividends | (5,323 | ) | — | — | — | (5,323 | ) | ||||||||||||||
Excess tax benefits on exercised stock options | 71 | 17 | 16 | — | 104 | ||||||||||||||||
Principal payments on capital lease obligations | — | (817 | ) | (904 | ) | — | (1,721 | ) | |||||||||||||
Net cash provided by (used in) financing activities | 133,513 | (238 | ) | (1,707 | ) | — | 131,568 | ||||||||||||||
Foreign exchange effect on cash and cash equivalents | 762 | 16 | (7,724 | ) | (42 | ) | (6,988 | ) | |||||||||||||
Net increase (decrease) in cash and cash equivalents | 5,003 | (14,955 | ) | 8,839 | — | (1,113 | ) | ||||||||||||||
Cash and cash equivalents, beginning of period | 3,623 | 67,941 | 256,782 | — | 328,346 | ||||||||||||||||
Cash and cash equivalents, end of period | $ | 8,626 | $ | 52,986 | $ | 265,621 | $ | — | $ | 327,233 |
Basis_of_Presentation_of_Finan2
Basis of Presentation of Financial Information - Additional Information (Detail) (USD $) | 3 Months Ended |
In Millions, unless otherwise specified | Mar. 31, 2014 |
Schedule Of Description Of Business [Line Items] | ' |
Net after-tax expense charges corrected amount | $1.30 |
MedApps [Member] | ' |
Schedule Of Description Of Business [Line Items] | ' |
Net after-tax expense charges corrected amount | $2.80 |
Cash_and_Cash_Equivalents_Addi
Cash and Cash Equivalents - Additional Information (Detail) | 3 Months Ended |
Mar. 31, 2014 | |
Cash And Cash Equivalents [Abstract] | ' |
Cash investments maturity period | 'Three months or less |
Restricted_Cash_Additional_Inf
Restricted Cash - Additional Information (Detail) (USD $) | 3 Months Ended | |
Mar. 31, 2014 | Dec. 31, 2013 | |
Cash And Cash Equivalents [Abstract] | ' | ' |
Restricted cash | $33,100,000 | $35,700,000 |
Restricted cash, non-current | $28,856,000 | $29,370,000 |
Deposit period of restricted cash | '2 years | ' |
Inventories_Inventories_are_St
Inventories - Inventories are Stated at Lower of Cost (First In, First Out) or Market (Detail) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Inventory Disclosure [Abstract] | ' | ' |
Raw materials | $124,020 | $118,571 |
Work-in-process | 73,848 | 79,559 |
Finished goods | 173,268 | 166,055 |
Inventories, net | $371,136 | $364,185 |
StockBased_Compensation_StockB
Stock-Based Compensation - Stock-Based Compensation Expense (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' |
Stock-based compensation | $5,704 | $4,123 |
Benefit for income taxes | -1,778 | -862 |
Stock-based compensation, net of tax | 3,926 | 3,261 |
Cost of Net Revenue [Member] | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' |
Stock-based compensation | 287 | 232 |
Research and Development [Member] | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' |
Stock-based compensation | 1,191 | 747 |
Sales and Marketing [Member] | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' |
Stock-based compensation | 891 | 716 |
General and Administrative [Member] | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' |
Stock-based compensation | $3,335 | $2,428 |
Net_Income_Loss_Per_Common_Sha2
Net Income (Loss) Per Common Share - Computation of Basic and Diluted Net Income (Loss) Per Common Share (Detail) (USD $) | 3 Months Ended | |
In Thousands, except Per Share data, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Numerator: | ' | ' |
Net income (loss) | ($6,113) | $12,425 |
Preferred stock dividends | -5,250 | -5,250 |
Less: Net income (loss) attributable to non-controlling interest | 108 | -25 |
Net income (loss) available to common stockholders | ($11,471) | $7,200 |
Denominator: | ' | ' |
Weighted-average common shares outstanding-basic | 82,387 | 81,199 |
Effect of dilutive securities: | ' | ' |
Stock options | 0 | 101 |
Weighted-average common shares outstanding-diluted | 82,387 | 81,300 |
Basic net income (loss) per common share attributable to Alere Inc. and Subsidiaries | ($0.14) | $0.09 |
Diluted net income (loss) per common share attributable to Alere Inc. and Subsidiaries | ($0.14) | $0.09 |
Net_Income_Loss_Per_Common_Sha3
Net Income (Loss) Per Common Share - Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share (Detail) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Denominator: | ' | ' |
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding | 25,182 | 23,668 |
Options to Purchase Shares of Common Stock [Member] | ' | ' |
Denominator: | ' | ' |
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding | 11,143 | 9,987 |
Warrants [Member] | ' | ' |
Denominator: | ' | ' |
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding | 4 | 4 |
Conversion Shares Related to 3% Convertible Senior Subordinated Notes [Member] | ' | ' |
Denominator: | ' | ' |
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding | 3,411 | 3,411 |
Conversion Shares Related to Subordinated Convertible Promissory Notes [Member] | ' | ' |
Denominator: | ' | ' |
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding | 27 | 27 |
Conversion Shares Related to Series B Convertible Preferred Stock [Member] | ' | ' |
Denominator: | ' | ' |
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding | 10,239 | 10,239 |
Common Stock Equivalents Related to the Settlement of a Contingent Consideration Obligation [Member] | ' | ' |
Denominator: | ' | ' |
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding | 358 | 0 |
Net_Income_Loss_Per_Common_Sha4
Net Income (Loss) Per Common Share - Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share (Parenthetical) (Detail) (Conversion Shares Related to 3% Convertible Senior Subordinated Notes [Member]) | Mar. 31, 2014 | Mar. 31, 2013 |
Conversion Shares Related to 3% Convertible Senior Subordinated Notes [Member] | ' | ' |
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' |
Interest rate of debt instrument | 3.00% | 3.00% |
Stockholders_Equity_and_NonCon2
Stockholders' Equity and Non-Controlling Interests - Additional Information (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Class of Stock [Line Items] | ' | ' |
Preferred stock dividends | $5,250 | $5,250 |
Series B Preferred Stock [Member] | ' | ' |
Class of Stock [Line Items] | ' | ' |
Preferred stock dividends | 5,250 | 5,250 |
Preferred stock dividends accrued | $5,323 | ' |
Stockholders_Equity_and_NonCon3
Stockholders' Equity and Non-Controlling Interests - Summary of Changes in Stockholders' Equity and Non-Controlling Interests Comprising Total Equity (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Equity And Noncontrolling Interests [Line Items] | ' | ' |
Equity, beginning of period | $2,082,848 | $2,182,704 |
Issuance of common stock under employee compensation plans | 14,698 | 6,135 |
Preferred stock dividends | -5,323 | -5,323 |
Stock-based compensation expense | 5,704 | 4,123 |
Excess tax benefits on exercised stock options | 17 | -422 |
Net income (loss) | -6,113 | 12,425 |
Total other comprehensive loss | -11,275 | -74,739 |
Equity, end of period | 2,080,556 | 2,124,903 |
Issuer [Member] | ' | ' |
Equity And Noncontrolling Interests [Line Items] | ' | ' |
Equity, beginning of period | 2,077,966 | 2,180,422 |
Issuance of common stock under employee compensation plans | 14,698 | 6,135 |
Preferred stock dividends | -5,323 | -5,323 |
Stock-based compensation expense | 5,704 | 4,123 |
Excess tax benefits on exercised stock options | 17 | -422 |
Net income (loss) | -6,221 | 12,450 |
Total other comprehensive loss | -11,275 | -74,739 |
Equity, end of period | 2,075,566 | 2,122,646 |
Non-controlling Interests [Member] | ' | ' |
Equity And Noncontrolling Interests [Line Items] | ' | ' |
Equity, beginning of period | 4,882 | 2,282 |
Issuance of common stock under employee compensation plans | 0 | 0 |
Preferred stock dividends | 0 | 0 |
Stock-based compensation expense | 0 | 0 |
Excess tax benefits on exercised stock options | 0 | 0 |
Net income (loss) | 108 | -25 |
Total other comprehensive loss | 0 | 0 |
Equity, end of period | $4,990 | $2,257 |
Business_Combinations_Addition
Business Combinations - Additional Information (Detail) (USD $) | 3 Months Ended | 12 Months Ended | 3 Months Ended | 1 Months Ended | 12 Months Ended | |||||
Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | Mar. 31, 2014 | 31-May-13 | Jul. 31, 2013 | Mar. 31, 2014 | Feb. 01, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | |
Liberty Business [Member] | Cardio Selfcare [Member] | Pantech Proprietary [Member] | Mega Medika, Alere Health Services and Pantech [Member] | Epocal. [Member] | Epocal. [Member] | Other [Member] | ||||
Business Acquisition [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
General and administrative expense related to acquisition | $300,000 | $900,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Preliminary aggregate purchase price | ' | ' | ' | ' | ' | ' | ' | 248,500,000 | ' | 57,600,000 |
Total cash payments | ' | ' | ' | ' | ' | ' | ' | 151,400,000 | ' | 28,221,000 |
Acquisition date fair value investment | ' | ' | 76,264,000 | ' | ' | ' | ' | 75,000,000 | 75,000,000 | 1,264,000 |
Settlement of pre-existing arrangements | ' | ' | 39,588,000 | ' | ' | ' | ' | 22,100,000 | 22,088,000 | 17,500,000 |
Deferred purchase price consideration | ' | ' | 768,000 | ' | ' | ' | ' | ' | 0 | 768,000 |
Bargain purchase gain | ' | ' | 8,023,000 | 8,000,000 | ' | ' | ' | ' | 0 | 8,023,000 |
Percentage of incremental ownership interest | ' | ' | ' | ' | 51.00% | ' | ' | ' | ' | ' |
Interest in Pantech Proprietary Limited | ' | ' | ' | ' | ' | 74.90% | ' | ' | ' | ' |
Total revenue related to acquisition | 23,800,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Goodwill | $3,090,056,000 | ' | $3,093,691,000 | ' | ' | ' | $2,500,000 | ' | ' | ' |
Business_Combinations_Summary_
Business Combinations - Summary of Aggregate Purchase Price Allocation (Detail) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Dec. 31, 2013 | Feb. 01, 2013 |
Loans At Acquisition Date [Line Items] | ' | ' |
Current assets | $26,238 | ' |
Property, plant and equipment | 2,936 | ' |
Goodwill | 100,997 | ' |
Intangible assets | 215,580 | ' |
Other non-current assets | 18,187 | ' |
Total assets acquired | 363,938 | ' |
Current liabilities | 8,025 | ' |
Non-current liabilities | 49,902 | ' |
Total liabilities assumed | 57,927 | ' |
Net assets acquired | 306,011 | ' |
Contingent consideration | 76,264 | ' |
Settlement of pre-existing arrangements | 39,588 | ' |
Non-controlling interest | 1,774 | ' |
Bargain purchase gain | 8,023 | ' |
Deferred purchase price consideration | 768 | ' |
Cash paid | 179,594 | ' |
Epocal. [Member] | ' | ' |
Loans At Acquisition Date [Line Items] | ' | ' |
Current assets | 12,536 | ' |
Property, plant and equipment | 1,267 | ' |
Goodwill | 98,454 | ' |
Intangible assets | 164,400 | ' |
Other non-current assets | 18,158 | ' |
Total assets acquired | 294,815 | ' |
Current liabilities | 2,627 | ' |
Non-current liabilities | 43,727 | ' |
Total liabilities assumed | 46,354 | ' |
Net assets acquired | 248,461 | ' |
Contingent consideration | 75,000 | 75,000 |
Settlement of pre-existing arrangements | 22,088 | 22,100 |
Non-controlling interest | 0 | ' |
Bargain purchase gain | 0 | ' |
Deferred purchase price consideration | 0 | ' |
Cash paid | 151,373 | ' |
Other [Member] | ' | ' |
Loans At Acquisition Date [Line Items] | ' | ' |
Current assets | 13,702 | ' |
Property, plant and equipment | 1,669 | ' |
Goodwill | 2,543 | ' |
Intangible assets | 51,180 | ' |
Other non-current assets | 29 | ' |
Total assets acquired | 69,123 | ' |
Current liabilities | 5,398 | ' |
Non-current liabilities | 6,175 | ' |
Total liabilities assumed | 11,573 | ' |
Net assets acquired | 57,550 | ' |
Contingent consideration | 1,264 | ' |
Settlement of pre-existing arrangements | 17,500 | ' |
Non-controlling interest | 1,774 | ' |
Bargain purchase gain | 8,023 | ' |
Deferred purchase price consideration | 768 | ' |
Cash paid | $28,221 | ' |
Business_Combinations_Summary_1
Business Combinations - Summary of Aggregate Purchase Price Allocation (Parenthetical) (Detail) (USD $) | Dec. 31, 2013 |
In Millions, unless otherwise specified | |
Business Combinations [Abstract] | ' |
Cash acquired | $3.30 |
Business_Combinations_Intangib
Business Combinations - Intangible Assets Acquired and Their Respective Fair Values and Weighted-Average Useful Lives (Detail) (USD $) | 12 Months Ended |
In Thousands, unless otherwise specified | Dec. 31, 2013 |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Total intangible assets | $215,580 |
In-Process Research and Development [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired indefinite-lived intangible asset, amount | 24,200 |
Epocal. [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Total intangible assets | 164,400 |
Epocal. [Member] | In-Process Research and Development [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired indefinite-lived intangible asset, amount | 24,200 |
Other [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Total intangible assets | 51,180 |
Other [Member] | In-Process Research and Development [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired indefinite-lived intangible asset, amount | 0 |
Core Technology and Patents [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | 119,700 |
Weighted-average Useful Life | '20 years |
Core Technology and Patents [Member] | Epocal. [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | 119,700 |
Core Technology and Patents [Member] | Other [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | 0 |
Software [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | 2,154 |
Weighted-average Useful Life | '5 years 8 months 12 days |
Software [Member] | Epocal. [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | 0 |
Software [Member] | Other [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | 2,154 |
Trademarks and Trade Names [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | 20,580 |
Weighted-average Useful Life | '19 years 1 month 6 days |
Trademarks and Trade Names [Member] | Epocal. [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | 20,500 |
Trademarks and Trade Names [Member] | Other [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | 80 |
License Agreements [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | 620 |
Weighted-average Useful Life | '1 year 6 months |
License Agreements [Member] | Epocal. [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | 0 |
License Agreements [Member] | Other [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | 620 |
Customer Relationships [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | 42,510 |
Weighted-average Useful Life | '11 years 6 months |
Customer Relationships [Member] | Epocal. [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | 0 |
Customer Relationships [Member] | Other [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | 42,510 |
Other [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | 5,816 |
Weighted-average Useful Life | '3 years |
Other [Member] | Epocal. [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | 0 |
Other [Member] | Other [Member] | ' |
Finite And Infinite Lived Intangible Assets [Line Items] | ' |
Acquired finite-lived intangible asset, amount | $5,816 |
Restructuring_Aggregate_Charge
Restructuring - Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Restructuring Cost and Reserve [Line Items] | ' | ' |
Restructuring charges | $7,215 | $3,892 |
Total Operating Expenses [Member] | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' |
Restructuring charges | 7,215 | 3,892 |
Interest Expense, Including Amortization of Original Issue Discounts and Deferred Financing Costs [Member] | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' |
Restructuring charges | 125 | 55 |
Cost of Net Revenue [Member] | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' |
Restructuring charges | 875 | 623 |
Research and Development [Member] | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' |
Restructuring charges | 0 | 0 |
Sales and Marketing [Member] | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' |
Restructuring charges | 1,557 | 1,099 |
General and Administrative [Member] | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' |
Restructuring charges | 4,783 | 2,170 |
Total Charges [Member] | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' |
Restructuring charges | $7,340 | $3,947 |
Restructuring_Restructuring_Ac
Restructuring - Restructuring Activities Related to Restructuring Plans (Detail) (USD $) | 3 Months Ended | 75 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | $7,215 | $3,892 | ' |
Professional Diagnostics [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 4,303 | 1,389 | ' |
Corporate and Other [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 95 | 0 | ' |
Health Information Solutions [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 2,817 | 2,503 | ' |
2014 Restructuring Plans [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 3,243 | ' | ' |
2014 Restructuring Plans [Member] | Severance-Related Costs [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 2,451 | ' | ' |
2014 Restructuring Plans [Member] | Facility and Transition Costs [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 42 | ' | ' |
2014 Restructuring Plans [Member] | Cash Charges [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 2,493 | ' | ' |
2014 Restructuring Plans [Member] | Fixed Asset and Inventory Impairments [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 750 | ' | ' |
2014 Restructuring Plans [Member] | Professional Diagnostics [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 3,148 | ' | ' |
2014 Restructuring Plans [Member] | Professional Diagnostics [Member] | Severance-Related Costs [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 2,364 | ' | ' |
2014 Restructuring Plans [Member] | Professional Diagnostics [Member] | Facility and Transition Costs [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 34 | ' | ' |
2014 Restructuring Plans [Member] | Professional Diagnostics [Member] | Cash Charges [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 2,398 | ' | ' |
2014 Restructuring Plans [Member] | Professional Diagnostics [Member] | Fixed Asset and Inventory Impairments [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 750 | ' | ' |
2014 Restructuring Plans [Member] | Corporate and Other [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 95 | ' | ' |
2014 Restructuring Plans [Member] | Corporate and Other [Member] | Severance-Related Costs [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 87 | ' | ' |
2014 Restructuring Plans [Member] | Corporate and Other [Member] | Facility and Transition Costs [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 8 | ' | ' |
2014 Restructuring Plans [Member] | Corporate and Other [Member] | Cash Charges [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 95 | ' | ' |
2014 Restructuring Plans [Member] | Corporate and Other [Member] | Fixed Asset and Inventory Impairments [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 0 | ' | ' |
2011, 2010 and 2008 Restructuring Plans [Member] | Professional Diagnostics [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 155 | 560 | 41,537 |
2011, 2010 and 2008 Restructuring Plans [Member] | Professional Diagnostics [Member] | Severance-Related Costs [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 59 | 312 | 24,251 |
2011, 2010 and 2008 Restructuring Plans [Member] | Professional Diagnostics [Member] | Facility and Transition Costs [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 84 | 232 | 8,846 |
2011, 2010 and 2008 Restructuring Plans [Member] | Professional Diagnostics [Member] | Cash Charges [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 155 | 560 | 33,865 |
2011, 2010 and 2008 Restructuring Plans [Member] | Professional Diagnostics [Member] | Fixed Asset and Inventory Impairments [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 0 | 0 | 6,922 |
2011, 2010 and 2008 Restructuring Plans [Member] | Professional Diagnostics [Member] | Other Exit Costs [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 12 | 16 | 768 |
2011, 2010 and 2008 Restructuring Plans [Member] | Professional Diagnostics [Member] | Intangible Asset Impairments [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 0 | 0 | 686 |
2011, 2010 and 2008 Restructuring Plans [Member] | Professional Diagnostics [Member] | Other Non-Cash Charges [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 0 | 0 | 64 |
2011, 2010 and 2008 Restructuring Plans [Member] | Health Information Solutions [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 435 | 2,472 | 36,599 |
2011, 2010 and 2008 Restructuring Plans [Member] | Health Information Solutions [Member] | Severance-Related Costs [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 0 | 1,819 | 12,308 |
2011, 2010 and 2008 Restructuring Plans [Member] | Health Information Solutions [Member] | Facility and Transition Costs [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 355 | 659 | 13,870 |
2011, 2010 and 2008 Restructuring Plans [Member] | Health Information Solutions [Member] | Cash Charges [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 435 | 2,517 | 27,021 |
2011, 2010 and 2008 Restructuring Plans [Member] | Health Information Solutions [Member] | Fixed Asset and Inventory Impairments [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 0 | 0 | 3,878 |
2011, 2010 and 2008 Restructuring Plans [Member] | Health Information Solutions [Member] | Other Exit Costs [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 80 | 39 | 843 |
2011, 2010 and 2008 Restructuring Plans [Member] | Health Information Solutions [Member] | Intangible Asset Impairments [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 0 | 0 | 5,923 |
2011, 2010 and 2008 Restructuring Plans [Member] | Health Information Solutions [Member] | Other Non-Cash Charges [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 0 | -45 | -223 |
2013 Restructuring Plans [Member] | Professional Diagnostics [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 1,012 | 846 | 11,462 |
2013 Restructuring Plans [Member] | Professional Diagnostics [Member] | Severance-Related Costs [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 838 | 833 | 7,964 |
2013 Restructuring Plans [Member] | Professional Diagnostics [Member] | Facility and Transition Costs [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 174 | 13 | 2,755 |
2013 Restructuring Plans [Member] | Professional Diagnostics [Member] | Cash Charges [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 1,012 | 846 | 10,719 |
2013 Restructuring Plans [Member] | Professional Diagnostics [Member] | Fixed Asset and Inventory Impairments [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 0 | 0 | 743 |
2013 Restructuring Plans [Member] | Health Information Solutions [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 2,495 | 69 | 11,516 |
2013 Restructuring Plans [Member] | Health Information Solutions [Member] | Severance-Related Costs [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 89 | 69 | 3,356 |
2013 Restructuring Plans [Member] | Health Information Solutions [Member] | Facility and Transition Costs [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 3,227 | 0 | 6,182 |
2013 Restructuring Plans [Member] | Health Information Solutions [Member] | Cash Charges [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 3,349 | 69 | 9,588 |
2013 Restructuring Plans [Member] | Health Information Solutions [Member] | Fixed Asset and Inventory Impairments [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 0 | 0 | 1,089 |
2013 Restructuring Plans [Member] | Health Information Solutions [Member] | Other Exit Costs [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 33 | 0 | 50 |
2013 Restructuring Plans [Member] | Health Information Solutions [Member] | Intangible Asset Impairments [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | 0 | 0 | 2,596 |
2013 Restructuring Plans [Member] | Health Information Solutions [Member] | Other Non-Cash Charges [Member] | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' |
Cash charges | ($854) | $0 | ($1,757) |
Restructuring_Additional_Infor
Restructuring - Additional Information (Detail) (USD $) | 3 Months Ended |
In Millions, unless otherwise specified | Mar. 31, 2014 |
Restructuring Cost and Reserve [Line Items] | ' |
Restructuring reserves included in accrued expenses and other current liabilities | $7.70 |
Restructuring reserves included in other long-term liabilities | 5.3 |
2014 Restructuring Plans [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Cash charges remain unpaid | 0.7 |
2013 Restructuring Plans [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Cash charges remain unpaid | 7.4 |
2011, 2010 and 2008 Restructuring Plans [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Cash charges remain unpaid | 4.9 |
Professional Diagnostics [Member] | 2014 Restructuring Plans [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Additional costs | 3.9 |
Professional Diagnostics [Member] | 2013 Restructuring Plans [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Additional costs | 2.4 |
Professional Diagnostics [Member] | 2011, 2010 and 2008 Restructuring Plans [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Additional costs | 0.8 |
Corporate and Other [Member] | 2014 Restructuring Plans [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Additional costs | 1.43 |
Health Information Solutions [Member] | 2013 Restructuring Plans [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Additional costs | $0.70 |
Restructuring_Cash_Activity_fo
Restructuring - Cash Activity for Restructuring Reserves (Detail) (USD $) | 3 Months Ended |
In Thousands, unless otherwise specified | Mar. 31, 2014 |
Restructuring Cost and Reserve [Line Items] | ' |
Restructuring Reserve, Beginning Balance | $11,147 |
Cash charges | 7,444 |
Payments | -5,595 |
Currency adjustments | 31 |
Restructuring Reserve, Ending Balance | 13,027 |
Severance-Related Costs [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Restructuring Reserve, Beginning Balance | 2,708 |
Cash charges | 3,437 |
Payments | -4,063 |
Currency adjustments | 5 |
Restructuring Reserve, Ending Balance | 2,087 |
Facility and Transition Costs [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Restructuring Reserve, Beginning Balance | 7,830 |
Cash charges | 3,882 |
Payments | -1,459 |
Currency adjustments | 35 |
Restructuring Reserve, Ending Balance | 10,288 |
Other Exit Costs [Member] | ' |
Restructuring Cost and Reserve [Line Items] | ' |
Restructuring Reserve, Beginning Balance | 609 |
Cash charges | 125 |
Payments | -73 |
Currency adjustments | -9 |
Restructuring Reserve, Ending Balance | $652 |
LongTerm_Debt_LongTerm_Debt_Ba
Long-Term Debt - Long-Term Debt Balances Outstanding (Detail) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Debt Instrument [Line Items] | ' | ' |
Long-term debt, Total | $3,811,048 | $3,821,900 |
Less: Current portion | -65,252 | -49,112 |
Long-term debt, after discount, Total | 3,745,796 | 3,772,788 |
A term loans [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt, Total | 820,625 | 832,188 |
B term loans [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt, Total | 901,875 | 904,188 |
Incremental B-1 term loans [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt, Total | 244,375 | 245,000 |
Incremental B-2 term loans [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt, Total | 194,629 | 195,050 |
Revolving line of credit [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt, Total | 170,000 | 170,000 |
7.25% Senior notes [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt, Total | 450,000 | 450,000 |
6.5% Senior subordinated notes [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt, Total | 425,000 | 425,000 |
8.625% Senior subordinated notes [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt, Total | 400,000 | 400,000 |
3% Convertible senior subordinated notes [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt, Total | 150,000 | 150,000 |
Other lines of credit [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt, Total | 581 | 355 |
Other [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt, Total | $53,963 | $50,119 |
LongTerm_Debt_LongTerm_Debt_Ba1
Long-Term Debt - Long-Term Debt Balances Outstanding (Parenthetical) (Detail) | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2013 |
7.25% Senior notes [Member] | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' |
Long-term debt, Interest rate | 7.25% | 7.25% | 7.25% |
6.5% Senior subordinated notes [Member] | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' |
Long-term debt, Interest rate | 6.50% | 6.50% | 6.50% |
8.625% Senior subordinated notes [Member] | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' |
Long-term debt, Interest rate | 8.63% | 8.63% | 8.63% |
3% Convertible senior subordinated notes [Member] | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' |
Long-term debt, Interest rate | 3.00% | 3.00% | 3.00% |
LongTerm_Debt_LongTerm_Debt_In
Long-Term Debt - Long-Term Debt Interest Expense (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Debt Instrument [Line Items] | ' | ' |
Long-term debt issuance cost | $50,984 | $56,517 |
Secured credit facility [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt issuance cost | 24,762 | 27,275 |
7.25% Senior notes [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt issuance cost | 8,525 | 8,356 |
7.875% Senior notes [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt issuance cost | 0 | -27 |
6.5% Senior subordinated notes [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt issuance cost | 7,178 | 0 |
9% Senior subordinated notes [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt issuance cost | 0 | 10,394 |
8.625% Senior subordinated notes [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt issuance cost | 9,273 | 9,273 |
3% Convertible senior subordinated notes [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term debt issuance cost | $1,246 | $1,246 |
LongTerm_Debt_LongTerm_Debt_In1
Long-Term Debt - Long-Term Debt Interest Expense (Parenthetical) (Detail) (USD $) | 3 Months Ended | |||||||||||||||||
In Millions, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2013 |
7.25% Senior notes [Member] | 7.25% Senior notes [Member] | 7.25% Senior notes [Member] | 7.875% Senior notes [Member] | 7.875% Senior notes [Member] | 6.5% Senior subordinated notes [Member] | 6.5% Senior subordinated notes [Member] | 6.5% Senior subordinated notes [Member] | 9% Senior subordinated notes [Member] | 9% Senior subordinated notes [Member] | 8.625% Senior subordinated notes [Member] | 8.625% Senior subordinated notes [Member] | 8.625% Senior subordinated notes [Member] | 3% Convertible senior subordinated notes [Member] | 3% Convertible senior subordinated notes [Member] | 3% Convertible senior subordinated notes [Member] | |||
Debt Instrument [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long-term debt issuance cost | ' | ' | 7.25% | 7.25% | 7.25% | 7.88% | 7.88% | 6.50% | 6.50% | 6.50% | 9.00% | 9.00% | 8.63% | 8.63% | 8.63% | 3.00% | 3.00% | 3.00% |
Amortization fee | $0.40 | $1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair_Value_Measurements_Fair_V
Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques (Detail) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Fair Value, Measurements, Recurring [Member] | ' | ' |
Assets: | ' | ' |
Marketable securities | $781 | $858 |
Total assets | 781 | 858 |
Liabilities: | ' | ' |
Contingent consideration obligations | 210,819 | 213,969 |
Total liabilities | 210,819 | 213,969 |
Quoted Prices in Active Markets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member] | ' | ' |
Assets: | ' | ' |
Marketable securities | 781 | 858 |
Total assets | 781 | 858 |
Liabilities: | ' | ' |
Contingent consideration obligations | 0 | 0 |
Total liabilities | 0 | 0 |
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | ' | ' |
Assets: | ' | ' |
Marketable securities | 0 | 0 |
Total assets | 0 | 0 |
Liabilities: | ' | ' |
Contingent consideration obligations | 0 | 0 |
Total liabilities | 0 | 0 |
Unobservable Inputs (Level 3) [Member] | ' | ' |
Liabilities: | ' | ' |
Contingent consideration obligations | 210,819 | 213,969 |
Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member] | ' | ' |
Assets: | ' | ' |
Marketable securities | 0 | 0 |
Total assets | 0 | 0 |
Liabilities: | ' | ' |
Contingent consideration obligations | 210,819 | 213,969 |
Total liabilities | $210,819 | $213,969 |
Fair_Value_Measurements_Change
Fair Value Measurements - Changes in Fair Value of Contingent Consideration Obligations (Detail) (Unobservable Inputs (Level 3) [Member], USD $) | 3 Months Ended |
In Thousands, unless otherwise specified | Mar. 31, 2014 |
Unobservable Inputs (Level 3) [Member] | ' |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ' |
Fair value of contingent consideration obligations, January 1, 2014 | $213,969 |
Payments | -7,710 |
Present value accretion and adjustments | 4,550 |
Foreign currency adjustments | 10 |
Fair value of contingent consideration obligations, March 31, 2014 | $210,819 |
Fair_Value_Measurements_Additi
Fair Value Measurements - Additional Information (Detail) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Billions, unless otherwise specified | ||
Debt Disclosure [Abstract] | ' | ' |
Estimated fair value of our long-term debt | $3.90 | $3.90 |
Long-term debt, Total | $3.80 | $3.80 |
Defined_Benefit_Pension_Plan_N
Defined Benefit Pension Plan - Net Periodic Benefit Costs (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Compensation And Retirement Disclosure [Abstract] | ' | ' |
Service cost | $0 | $0 |
Interest cost | 199 | 182 |
Expected return on plan assets | -188 | -156 |
Amortization of prior service cost | 110 | 103 |
Net periodic benefit cost | $121 | $129 |
Financial_Information_by_Segme2
Financial Information by Segment - Performance of Our Operating Segments Based on Revenue and Operating Income (Loss) (Detail) (USD $) | 3 Months Ended | ||
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 |
Segment Reporting Information [Line Items] | ' | ' | ' |
Net revenue | $716,622 | $739,249 | ' |
Operating income (loss) | 25,940 | 30,489 | ' |
Depreciation and amortization | 98,086 | 104,970 | ' |
Non-cash charge associated with acquired inventory | 0 | 461 | ' |
Restructuring charges | 7,215 | 3,892 | ' |
Stock-based compensation | 5,704 | 4,123 | ' |
Assets | 7,036,186 | ' | 7,060,814 |
Professional Diagnostics [Member] | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' |
Net revenue | 566,545 | 582,492 | ' |
Operating income (loss) | 51,326 | 59,840 | ' |
Depreciation and amortization | 77,421 | 82,794 | ' |
Non-cash charge associated with acquired inventory | ' | 461 | ' |
Restructuring charges | 4,303 | 1,389 | ' |
Stock-based compensation | 0 | 0 | ' |
Assets | 5,697,874 | ' | 5,744,734 |
Health Information Solutions [Member] | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' |
Net revenue | 123,668 | 134,207 | ' |
Operating income (loss) | -6,720 | -13,893 | ' |
Depreciation and amortization | 19,111 | 20,737 | ' |
Non-cash charge associated with acquired inventory | ' | 0 | ' |
Restructuring charges | 2,817 | 2,503 | ' |
Stock-based compensation | 0 | 0 | ' |
Assets | 496,310 | ' | 504,645 |
Consumer Diagnostics [Member] | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' |
Net revenue | 26,409 | 22,550 | ' |
Operating income (loss) | 2,248 | 2,280 | ' |
Depreciation and amortization | 920 | 1,153 | ' |
Non-cash charge associated with acquired inventory | ' | 0 | ' |
Restructuring charges | 0 | 0 | ' |
Stock-based compensation | 0 | 0 | ' |
Assets | 205,105 | ' | 197,458 |
Corporate and Other [Member] | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' |
Net revenue | 0 | 0 | ' |
Operating income (loss) | -20,914 | -17,738 | ' |
Depreciation and amortization | 634 | 286 | ' |
Non-cash charge associated with acquired inventory | ' | 0 | ' |
Restructuring charges | 95 | 0 | ' |
Stock-based compensation | 5,704 | 4,123 | ' |
Assets | $636,897 | ' | $613,977 |
Financial_Information_by_Segme3
Financial Information by Segment - Summary of Company's Net Revenue from Professional Diagnostics and Health Information Solutions Reporting Segments by Groups of Similar Products and Services (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Segment Reporting Information [Line Items] | ' | ' |
Net product sales and services revenue | $711,410 | $735,185 |
License and royalty revenue | 5,212 | 4,064 |
Net revenue | 716,622 | 739,249 |
Health Information Solutions [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Net revenue | 123,668 | 134,207 |
Health Information Solutions [Member] | Condition and Case Management [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Net product sales and services revenue | 49,319 | 54,126 |
Health Information Solutions [Member] | Wellness [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Net product sales and services revenue | 24,950 | 26,300 |
Health Information Solutions [Member] | Women's & Children's Health [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Net product sales and services revenue | 22,215 | 29,080 |
Health Information Solutions [Member] | Patient Self-testing Services [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Net product sales and services revenue | 27,184 | 24,701 |
Professional Diagnostics [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Net product sales and services revenue | 561,333 | 578,628 |
License and royalty revenue | 5,212 | 3,864 |
Net revenue | 566,545 | 582,492 |
Professional Diagnostics [Member] | Infectious Disease [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Net product sales and services revenue | 164,030 | 189,844 |
Professional Diagnostics [Member] | Toxicology [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Net product sales and services revenue | 151,897 | 149,049 |
Professional Diagnostics [Member] | Cardiology [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Net product sales and services revenue | 121,633 | 114,933 |
Professional Diagnostics [Member] | Diabetes [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Net product sales and services revenue | 50,721 | 50,083 |
Professional Diagnostics [Member] | Other [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Net product sales and services revenue | $73,052 | $74,719 |
Related_Party_Transactions_Add
Related Party Transactions - Additional Information (Detail) (USD $) | 3 Months Ended | 3 Months Ended | 12 Months Ended | |||||||
Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | 31-May-07 | |
Sales Revenue Goods [Member] | Sales Revenue Goods [Member] | Sales Revenue Services [Member] | Sales Revenue Services [Member] | SPD [Member] | SPD [Member] | SPD [Member] | ||||
Related Party Transaction [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Joint venture ownership percentage with Procter & Gamble | ' | ' | ' | ' | ' | ' | ' | ' | ' | 50.00% |
Net receivable from SPD | ' | ' | ' | ' | ' | ' | ' | $200,000 | $2,100,000 | ' |
Restructuring charges | 7,215,000 | 3,892,000 | ' | ' | ' | ' | ' | 1,700,000 | 1,800,000 | ' |
Long-term receivables cost related to restructuring plan | ' | ' | ' | ' | ' | ' | ' | 13,300,000 | 13,200,000 | ' |
Customer receivables associated with revenue earned after SPD was completed have been classified as other receivables | 9,300,000 | ' | 12,400,000 | ' | ' | ' | ' | ' | ' | ' |
Revenue from joint venture | ' | ' | ' | 20,600,000 | 17,100,000 | 400,000 | 300,000 | ' | ' | ' |
Trade receivables from SPD | 5,800,000 | ' | 9,400,000 | ' | ' | ' | ' | ' | ' | ' |
Trade payable to SPD | 22,200,000 | ' | 18,800,000 | ' | ' | ' | ' | ' | ' | ' |
Cash (return of investment) from SPD | ' | $10,800,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Related_Party_Transactions_Rel
Related Party Transactions - Related Party Balances with SPD within Consolidated Balance Sheets (Detail) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Related Party Transaction [Line Items] | ' | ' |
Accounts receivable, net of allowances | $528,793 | $548,729 |
Prepaid expenses and other current assets | 120,529 | 129,672 |
Deferred financing costs, net, and other non-current assets | 80,056 | 84,073 |
Accounts payable | 190,448 | 187,371 |
Related Party Transaction [Member] | ' | ' |
Related Party Transaction [Line Items] | ' | ' |
Accounts receivable, net of allowances | 5,753 | 9,436 |
Prepaid expenses and other current assets | 9,469 | 12,417 |
Deferred financing costs, net, and other non-current assets | 13,313 | 13,249 |
Accounts payable | $22,215 | $18,811 |
Other_Arrangements_Additional_
Other Arrangements - Additional Information (Detail) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 | Feb. 19, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Feb. 19, 2013 |
In Millions, unless otherwise specified | Gates Foundation [Member] | Gates Foundation [Member] | Gates Loan Agreement [Member] | Gates Loan Agreement [Member] | ||
Agreements [Line Items] | ' | ' | ' | ' | ' | ' |
Revenue from grant awarded | ' | ' | $21.60 | ' | ' | ' |
Aggregate principal amount of subordinated term loan | ' | ' | ' | ' | ' | 20.6 |
Loan bearing interest rate | ' | ' | ' | ' | 3.00% | ' |
Maturity date | ' | ' | ' | ' | 31-Dec-19 | ' |
Cash received from grant-related funding | ' | ' | ' | 7.9 | ' | ' |
Qualified expenditures | ' | ' | ' | 2.1 | ' | ' |
Amount borrowed under agreement | $3,800 | $3,800 | ' | ' | $0 | ' |
Material_Contingencies_Contrac
Material Contingencies - Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Dec. 31, 2013 |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Estimated Fair Value | $210,819 | $213,969 |
Payments made during 2014 | 7,710 | ' |
TwistDx, Inc [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Acquisition Date | 11-Mar-10 | ' |
Acquisition Date Fair Value | 35,600 | ' |
Maximum Remaining Earn-out Potential | 123,888 | ' |
Estimated Fair Value | 46,400 | 45,502 |
Payments made during 2014 | 139 | ' |
Ionian Technologies, Inc [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Acquisition Date | 12-Jul-10 | ' |
Acquisition Date Fair Value | 24,500 | ' |
Maximum Remaining Earn-out Potential | 57,500 | ' |
Estimated Fair Value | 29,400 | 29,000 |
Payments made during 2014 | 0 | ' |
Laboratory Data Systems, Inc. [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Acquisition Date | 29-Aug-11 | ' |
Acquisition Date Fair Value | 13,000 | ' |
Maximum Remaining Earn-out Potential | 7,500 | ' |
Remaining Earn-out Period | '2013 | ' |
Estimated Fair Value | 7,500 | 7,400 |
Payments made during 2014 | 0 | ' |
Forensics Limited (ROAR) [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Acquisition Date | 22-Sep-11 | ' |
Acquisition Date Fair Value | 5,463 | ' |
Maximum Remaining Earn-out Potential | 12,600 | ' |
Remaining Earn-out Period | '2014 | ' |
Estimated Fair Value | 3,328 | 2,484 |
Payments made during 2014 | 0 | ' |
Method Factory Inc. (Wellogic) [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Acquisition Date | 9-Dec-11 | ' |
Acquisition Date Fair Value | 18,900 | ' |
Maximum Remaining Earn-out Potential | 0 | ' |
Estimated Fair Value | 25,400 | 26,900 |
Payments made during 2014 | 150 | ' |
MedApps [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Acquisition Date | 2-Jul-12 | ' |
Acquisition Date Fair Value | 13,100 | ' |
Maximum Remaining Earn-out Potential | 8,600 | ' |
Remaining Earn-out Period | '2014 | ' |
Estimated Fair Value | 7,600 | 8,200 |
Payments made during 2014 | 5,000 | ' |
Amedica Biotech, Inc. [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Acquisition Date | 3-Jul-12 | ' |
Acquisition Date Fair Value | 8,900 | ' |
Maximum Remaining Earn-out Potential | 8,100 | ' |
Remaining Earn-out Period | '2013 | ' |
Estimated Fair Value | 7,935 | 7,500 |
Payments made during 2014 | 0 | ' |
DiagnosisOne, Inc. [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Acquisition Date | 31-Jul-12 | ' |
Acquisition Date Fair Value | 22,300 | ' |
Maximum Remaining Earn-out Potential | 33,000 | ' |
Estimated Fair Value | 26,900 | 26,600 |
Payments made during 2014 | 0 | ' |
Epocal. [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Acquisition Date | 1-Feb-13 | ' |
Acquisition Date Fair Value | 75,000 | ' |
Maximum Remaining Earn-out Potential | 65,500 | ' |
Estimated Fair Value | 45,600 | 47,200 |
Payments made during 2014 | 0 | ' |
Other [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Acquisition Date | 'Various | ' |
Acquisition Date Fair Value | 58,877 | ' |
Maximum Remaining Earn-out Potential | 20,229 | ' |
Estimated Fair Value | 10,756 | 13,183 |
Payments made during 2014 | $2,421 | ' |
Minimum [Member] | TwistDx, Inc [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Remaining Earn-out Period | '2014 | ' |
Minimum [Member] | Ionian Technologies, Inc [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Remaining Earn-out Period | '2014 | ' |
Minimum [Member] | Method Factory Inc. (Wellogic) [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Remaining Earn-out Period | '2014 | ' |
Minimum [Member] | DiagnosisOne, Inc. [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Remaining Earn-out Period | '2014 | ' |
Minimum [Member] | Epocal. [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Remaining Earn-out Period | '2014 | ' |
Minimum [Member] | Other [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Remaining Earn-out Period | '2014 | ' |
Maximum [Member] | TwistDx, Inc [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Remaining Earn-out Period | '2025 | ' |
Maximum [Member] | Ionian Technologies, Inc [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Remaining Earn-out Period | '2015 | ' |
Maximum [Member] | Method Factory Inc. (Wellogic) [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Remaining Earn-out Period | '2019 | ' |
Maximum [Member] | DiagnosisOne, Inc. [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Remaining Earn-out Period | '2017 | ' |
Maximum [Member] | Epocal. [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Remaining Earn-out Period | '2018 | ' |
Maximum [Member] | Other [Member] | ' | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' | ' |
Remaining Earn-out Period | '2016 | ' |
Material_Contingencies_Contrac1
Material Contingencies - Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions (Parenthetical) (Detail) (USD $) | 3 Months Ended |
In Thousands, unless otherwise specified | Mar. 31, 2014 |
Business Acquisition, Contingent Consideration [Line Items] | ' |
Earn-out period | '15 years |
Method Factory Inc. (Wellogic) [Member] | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' |
Maximum Remaining Earn-out Potential | 0 |
Method Factory Inc. (Wellogic) [Member] | Earn-out Potential [Member] | ' |
Business Acquisition, Contingent Consideration [Line Items] | ' |
Maximum Remaining Earn-out Potential | 49,900 |
Equity_Investments_Additional_
Equity Investments - Additional Information (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Schedule of Equity Method Investments [Line Items] | ' | ' |
Equity earnings of unconsolidated entities, net of tax | $5,352 | $2,934 |
SPD [Member] | ' | ' |
Schedule of Equity Method Investments [Line Items] | ' | ' |
Equity earnings of unconsolidated entities, net of tax | 5,100 | 2,500 |
Ownership percentage | 50.00% | ' |
TechLab [Member] | ' | ' |
Schedule of Equity Method Investments [Line Items] | ' | ' |
Equity earnings of unconsolidated entities, net of tax | $300 | $200 |
Ownership percentage | 49.00% | ' |
Equity_Investments_Financial_I
Equity Investments - Financial Information for SPD and TechLab on Combined Condensed Results of Operations (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Equity Method Investments And Joint Ventures [Abstract] | ' | ' |
Net revenue | $48,933 | $49,155 |
Gross profit | 42,980 | 37,113 |
Net income after taxes | $10,830 | $5,577 |
Equity_Investments_Financial_I1
Equity Investments - Financial Information for SPD and TechLab on Combined Condensed Balance Sheet (Detail) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Equity Method Investments And Joint Ventures [Abstract] | ' | ' |
Current assets | $72,582 | $63,985 |
Non-current assets | 38,376 | 38,541 |
Total assets | 110,958 | 102,526 |
Current liabilities | 38,524 | 38,053 |
Non-current liabilities | 6,430 | 6,175 |
Total liabilities | $44,954 | $44,228 |
Guarantor_Financial_Informatio2
Guarantor Financial Information - Additional Information (Detail) | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2013 |
7.25% Senior notes [Member] | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' |
Interest rate of debt instrument | 7.25% | 7.25% | 7.25% |
8.625% Senior subordinated notes [Member] | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' |
Interest rate of debt instrument | 8.63% | 8.63% | 8.63% |
6.5% Senior subordinated notes [Member] | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' |
Interest rate of debt instrument | 6.50% | 6.50% | 6.50% |
Guarantor_Financial_Informatio3
Guarantor Financial Information - Guarantor Financial Information Consolidating Statement of Operations (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Net product sales | $495,445 | $508,276 |
Services revenue | 215,965 | 226,909 |
Net product sales and services revenue | 711,410 | 735,185 |
License and royalty revenue | 5,212 | 4,064 |
Net revenue | 716,622 | 739,249 |
Cost of net product sales | 246,112 | 253,078 |
Cost of services revenue | 117,732 | 120,158 |
Cost of net product sales and services revenue | 363,844 | 373,236 |
Cost of license and royalty revenue | 1,539 | 1,756 |
Cost of net revenue | 365,383 | 374,992 |
Gross profit (loss) | 351,239 | 364,257 |
Operating expenses: | ' | ' |
Research and development | 38,699 | 41,454 |
Sales and marketing | 147,064 | 156,456 |
General and administrative | 139,536 | 135,858 |
Operating expenses | 325,299 | 333,768 |
Operating income (loss) | 25,940 | 30,489 |
Interest expense, including amortization of original issue discounts and deferred financing costs | -52,044 | -57,399 |
Other income (expense), net | 4,722 | -470 |
Income (loss) before provision (benefit) for income taxes | -21,382 | -27,380 |
Provision (benefit) for income taxes | -9,917 | -36,871 |
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax | -11,465 | 9,491 |
Equity in earnings of subsidiaries, net of tax | 0 | 0 |
Equity earnings of unconsolidated entities, net of tax | 5,352 | 2,934 |
Net income (loss) | -6,113 | 12,425 |
Less: Net income attributable to non-controlling interests | 108 | -25 |
Net income (loss) attributable to Alere Inc. and Subsidiaries | -6,221 | 12,450 |
Preferred stock dividends | -5,250 | -5,250 |
Net income (loss) available to common stockholders | -11,471 | 7,200 |
Issuer [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Net product sales | 0 | 0 |
Services revenue | 0 | 0 |
Net product sales and services revenue | 0 | 0 |
License and royalty revenue | 0 | 0 |
Net revenue | 0 | 0 |
Cost of net product sales | 688 | 948 |
Cost of services revenue | 73 | 0 |
Cost of net product sales and services revenue | 761 | 948 |
Cost of license and royalty revenue | 0 | 0 |
Cost of net revenue | 761 | 948 |
Gross profit (loss) | -761 | -948 |
Operating expenses: | ' | ' |
Research and development | 5,615 | 4,423 |
Sales and marketing | 1,868 | 1,392 |
General and administrative | 18,488 | 14,027 |
Operating expenses | 25,971 | 19,842 |
Operating income (loss) | -26,732 | -20,790 |
Interest expense, including amortization of original issue discounts and deferred financing costs | -51,258 | -56,858 |
Other income (expense), net | 4,694 | 4,770 |
Income (loss) before provision (benefit) for income taxes | -73,296 | -72,878 |
Provision (benefit) for income taxes | -38,423 | -62,811 |
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax | -34,873 | -10,067 |
Equity in earnings of subsidiaries, net of tax | 28,355 | 22,244 |
Equity earnings of unconsolidated entities, net of tax | 405 | 248 |
Net income (loss) | -6,113 | 12,425 |
Less: Net income attributable to non-controlling interests | 0 | 0 |
Net income (loss) attributable to Alere Inc. and Subsidiaries | -6,113 | 12,425 |
Preferred stock dividends | -5,250 | -5,250 |
Net income (loss) available to common stockholders | -11,363 | 7,175 |
Guarantor Subsidiaries [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Net product sales | 213,409 | 233,551 |
Services revenue | 197,908 | 207,749 |
Net product sales and services revenue | 411,317 | 441,300 |
License and royalty revenue | 3,485 | 3,035 |
Net revenue | 414,802 | 444,335 |
Cost of net product sales | 114,135 | 121,236 |
Cost of services revenue | 115,325 | 115,971 |
Cost of net product sales and services revenue | 229,460 | 237,207 |
Cost of license and royalty revenue | 92 | 17 |
Cost of net revenue | 229,552 | 237,224 |
Gross profit (loss) | 185,250 | 207,111 |
Operating expenses: | ' | ' |
Research and development | 14,845 | 18,100 |
Sales and marketing | 74,959 | 83,431 |
General and administrative | 68,782 | 67,146 |
Operating expenses | 158,586 | 168,677 |
Operating income (loss) | 26,664 | 38,434 |
Interest expense, including amortization of original issue discounts and deferred financing costs | -5,628 | -7,021 |
Other income (expense), net | 3,648 | 6,259 |
Income (loss) before provision (benefit) for income taxes | 24,684 | 37,672 |
Provision (benefit) for income taxes | 17,367 | 17,082 |
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax | 7,317 | 20,590 |
Equity in earnings of subsidiaries, net of tax | 68 | -614 |
Equity earnings of unconsolidated entities, net of tax | 0 | 0 |
Net income (loss) | 7,385 | 19,976 |
Less: Net income attributable to non-controlling interests | 0 | 0 |
Net income (loss) attributable to Alere Inc. and Subsidiaries | 7,385 | 19,976 |
Preferred stock dividends | 0 | 0 |
Net income (loss) available to common stockholders | 7,385 | 19,976 |
Non-Guarantor Subsidiaries [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Net product sales | 336,037 | 320,839 |
Services revenue | 18,057 | 19,160 |
Net product sales and services revenue | 354,094 | 339,999 |
License and royalty revenue | 5,018 | 3,533 |
Net revenue | 359,112 | 343,532 |
Cost of net product sales | 183,774 | 172,574 |
Cost of services revenue | 8,054 | 8,142 |
Cost of net product sales and services revenue | 191,828 | 180,716 |
Cost of license and royalty revenue | 4,738 | 4,243 |
Cost of net revenue | 196,566 | 184,959 |
Gross profit (loss) | 162,546 | 158,573 |
Operating expenses: | ' | ' |
Research and development | 18,239 | 18,931 |
Sales and marketing | 70,237 | 71,633 |
General and administrative | 52,266 | 54,685 |
Operating expenses | 140,742 | 145,249 |
Operating income (loss) | 21,804 | 13,324 |
Interest expense, including amortization of original issue discounts and deferred financing costs | -4,544 | -3,417 |
Other income (expense), net | 5,825 | -1,603 |
Income (loss) before provision (benefit) for income taxes | 23,085 | 8,304 |
Provision (benefit) for income taxes | 9,681 | 8,971 |
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax | 13,404 | -667 |
Equity in earnings of subsidiaries, net of tax | 0 | 0 |
Equity earnings of unconsolidated entities, net of tax | 5,064 | 2,688 |
Net income (loss) | 18,468 | 2,021 |
Less: Net income attributable to non-controlling interests | 108 | -25 |
Net income (loss) attributable to Alere Inc. and Subsidiaries | 18,360 | 2,046 |
Preferred stock dividends | 0 | 0 |
Net income (loss) available to common stockholders | 18,360 | 2,046 |
Eliminations [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Net product sales | -54,001 | -46,114 |
Services revenue | 0 | 0 |
Net product sales and services revenue | -54,001 | -46,114 |
License and royalty revenue | -3,291 | -2,504 |
Net revenue | -57,292 | -48,618 |
Cost of net product sales | -52,485 | -41,680 |
Cost of services revenue | -5,720 | -3,955 |
Cost of net product sales and services revenue | -58,205 | -45,635 |
Cost of license and royalty revenue | -3,291 | -2,504 |
Cost of net revenue | -61,496 | -48,139 |
Gross profit (loss) | 4,204 | -479 |
Operating expenses: | ' | ' |
Research and development | 0 | 0 |
Sales and marketing | 0 | 0 |
General and administrative | 0 | 0 |
Operating expenses | 0 | 0 |
Operating income (loss) | 4,204 | -479 |
Interest expense, including amortization of original issue discounts and deferred financing costs | 9,386 | 9,897 |
Other income (expense), net | -9,445 | -9,896 |
Income (loss) before provision (benefit) for income taxes | 4,145 | -478 |
Provision (benefit) for income taxes | 1,458 | -113 |
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax | 2,687 | -365 |
Equity in earnings of subsidiaries, net of tax | -28,423 | -21,630 |
Equity earnings of unconsolidated entities, net of tax | -117 | -2 |
Net income (loss) | -25,853 | -21,997 |
Less: Net income attributable to non-controlling interests | 0 | 0 |
Net income (loss) attributable to Alere Inc. and Subsidiaries | -25,853 | -21,997 |
Preferred stock dividends | 0 | 0 |
Net income (loss) available to common stockholders | ($25,853) | ($21,997) |
Guarantor_Financial_Informatio4
Guarantor Financial Information - Guarantor Financial Information Consolidating Statement of Comprehensive Income (Loss) (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Net income (loss) | ($6,113) | $12,425 |
Other comprehensive income (loss), before tax: | ' | ' |
Changes in cumulative translation adjustment | -11,340 | -75,355 |
Unrealized losses on available for sale securities | -17 | 0 |
Unrealized gains on hedging instruments | 8 | 11 |
Minimum pension liability adjustment | 74 | 605 |
Other comprehensive income (loss), before tax | -11,275 | -74,739 |
Income tax benefit related to items of other comprehensive income (loss) | 0 | 0 |
Other comprehensive income (loss), net of tax | -11,275 | -74,739 |
Comprehensive income (loss) | -17,388 | -62,314 |
Less: Comprehensive income attributable to non-controlling interests | 108 | -25 |
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | -17,496 | -62,289 |
Issuer [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Net income (loss) | -6,113 | 12,425 |
Other comprehensive income (loss), before tax: | ' | ' |
Changes in cumulative translation adjustment | 157 | -201 |
Unrealized losses on available for sale securities | 0 | ' |
Unrealized gains on hedging instruments | 0 | 0 |
Minimum pension liability adjustment | 0 | 0 |
Other comprehensive income (loss), before tax | 157 | -201 |
Income tax benefit related to items of other comprehensive income (loss) | 0 | 0 |
Other comprehensive income (loss), net of tax | 157 | -201 |
Comprehensive income (loss) | -5,956 | 12,224 |
Less: Comprehensive income attributable to non-controlling interests | 0 | 0 |
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | -5,956 | 12,224 |
Guarantor Subsidiaries [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Net income (loss) | 7,385 | 19,976 |
Other comprehensive income (loss), before tax: | ' | ' |
Changes in cumulative translation adjustment | -129 | 0 |
Unrealized losses on available for sale securities | -17 | ' |
Unrealized gains on hedging instruments | 0 | 0 |
Minimum pension liability adjustment | 0 | 0 |
Other comprehensive income (loss), before tax | -146 | 0 |
Income tax benefit related to items of other comprehensive income (loss) | 0 | 0 |
Other comprehensive income (loss), net of tax | -146 | 0 |
Comprehensive income (loss) | 7,240 | 19,976 |
Less: Comprehensive income attributable to non-controlling interests | 0 | 0 |
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | 7,240 | 19,976 |
Non-Guarantor Subsidiaries [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Net income (loss) | 18,468 | 2,021 |
Other comprehensive income (loss), before tax: | ' | ' |
Changes in cumulative translation adjustment | -11,368 | -75,154 |
Unrealized losses on available for sale securities | 0 | ' |
Unrealized gains on hedging instruments | 8 | 11 |
Minimum pension liability adjustment | 74 | 605 |
Other comprehensive income (loss), before tax | -11,286 | -74,538 |
Income tax benefit related to items of other comprehensive income (loss) | 0 | 0 |
Other comprehensive income (loss), net of tax | -11,286 | -74,538 |
Comprehensive income (loss) | 7,180 | -72,517 |
Less: Comprehensive income attributable to non-controlling interests | 108 | -25 |
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | 7,072 | -72,492 |
Eliminations [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Net income (loss) | -25,853 | -21,997 |
Other comprehensive income (loss), before tax: | ' | ' |
Changes in cumulative translation adjustment | 0 | 0 |
Unrealized losses on available for sale securities | 0 | ' |
Unrealized gains on hedging instruments | 0 | 0 |
Minimum pension liability adjustment | 0 | 0 |
Other comprehensive income (loss), before tax | 0 | 0 |
Income tax benefit related to items of other comprehensive income (loss) | 0 | 0 |
Other comprehensive income (loss), net of tax | 0 | 0 |
Comprehensive income (loss) | -25,852 | -21,997 |
Less: Comprehensive income attributable to non-controlling interests | 0 | 0 |
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries | ($25,852) | ($21,997) |
Guarantor_Financial_Informatio5
Guarantor Financial Information - Guarantor Financial Information Consolidating Balance Sheet (Detail) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||||
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | $433,026 | $361,908 | $327,233 | $328,346 |
Restricted cash | 4,222 | 6,373 | ' | ' |
Marketable securities | 781 | 858 | ' | ' |
Accounts receivable, net of allowances | 528,793 | 548,729 | ' | ' |
Inventories, net | 371,136 | 364,185 | ' | ' |
Deferred tax assets | 62,616 | 60,689 | ' | ' |
Prepaid expenses and other current assets | 120,529 | 129,672 | ' | ' |
Intercompany receivables | 0 | 0 | ' | ' |
Total current assets | 1,521,103 | 1,472,414 | ' | ' |
Property, plant and equipment, net | 545,051 | 545,164 | ' | ' |
Goodwill | 3,090,056 | 3,093,691 | ' | ' |
Other intangible assets with indefinite lives | 55,916 | 56,702 | ' | ' |
Finite-lived intangible assets, net | 1,617,254 | 1,684,611 | ' | ' |
Restricted cash | 28,856 | 29,370 | ' | ' |
Deferred financing costs, net and other non-current assets | 80,056 | 84,073 | ' | ' |
Investments in subsidiaries | 0 | 0 | ' | ' |
Investments in unconsolidated entities | 90,445 | 86,830 | ' | ' |
Deferred tax assets | 7,449 | 7,959 | ' | ' |
Intercompany notes receivables (payables) | 0 | 0 | ' | ' |
Total assets | 7,036,186 | 7,060,814 | ' | ' |
Current liabilities: | ' | ' | ' | ' |
Current portion of long-term debt | 65,252 | 49,112 | ' | ' |
Current portion of capital lease obligations | 6,220 | 6,855 | ' | ' |
Accounts payable | 190,448 | 187,371 | ' | ' |
Accrued expenses and other current liabilities | 430,261 | 429,848 | ' | ' |
Intercompany payables | 0 | 0 | ' | ' |
Total current liabilities | 692,181 | 673,186 | ' | ' |
Long-term liabilities: | ' | ' | ' | ' |
Long-term debt, net of current portion | 3,745,796 | 3,772,788 | ' | ' |
Capital lease obligations, net of current portion | 15,090 | 14,407 | ' | ' |
Deferred tax liabilities | 307,574 | 329,249 | ' | ' |
Other long-term liabilities | 194,989 | 188,336 | ' | ' |
Intercompany notes payables (receivables) | 0 | 0 | ' | ' |
Total long-term liabilities | 4,263,449 | 4,304,780 | ' | ' |
Stockholders' equity | 2,075,566 | 2,077,966 | ' | ' |
Non-controlling interests | 4,990 | 4,882 | ' | ' |
Total equity | 2,080,556 | 2,082,848 | 2,124,903 | 2,182,704 |
Total liabilities and equity | 7,036,186 | 7,060,814 | ' | ' |
Issuer [Member] | ' | ' | ' | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 13,020 | 14,801 | 8,626 | 3,623 |
Restricted cash | 84 | 2,221 | ' | ' |
Marketable securities | 0 | 0 | ' | ' |
Accounts receivable, net of allowances | 0 | 0 | ' | ' |
Inventories, net | 0 | 0 | ' | ' |
Deferred tax assets | 4,984 | 5,191 | ' | ' |
Prepaid expenses and other current assets | 538,410 | 512,123 | ' | ' |
Intercompany receivables | 304,817 | 317,357 | ' | ' |
Total current assets | 861,315 | 851,693 | ' | ' |
Property, plant and equipment, net | 19,312 | 15,086 | ' | ' |
Goodwill | 0 | 0 | ' | ' |
Other intangible assets with indefinite lives | 0 | 0 | ' | ' |
Finite-lived intangible assets, net | 10,245 | 11,006 | ' | ' |
Restricted cash | 0 | 0 | ' | ' |
Deferred financing costs, net and other non-current assets | 51,746 | 55,207 | ' | ' |
Investments in subsidiaries | 3,821,577 | 3,802,475 | ' | ' |
Investments in unconsolidated entities | 30,174 | 29,005 | ' | ' |
Deferred tax assets | 0 | 0 | ' | ' |
Intercompany notes receivables (payables) | 1,099,817 | 1,100,746 | ' | ' |
Total assets | 5,894,186 | 5,865,218 | ' | ' |
Current liabilities: | ' | ' | ' | ' |
Current portion of long-term debt | 60,000 | 45,000 | ' | ' |
Current portion of capital lease obligations | 0 | 0 | ' | ' |
Accounts payable | 8,280 | 12,584 | ' | ' |
Accrued expenses and other current liabilities | 85,170 | 63,990 | ' | ' |
Intercompany payables | 660,712 | 728,541 | ' | ' |
Total current liabilities | 814,162 | 850,115 | ' | ' |
Long-term liabilities: | ' | ' | ' | ' |
Long-term debt, net of current portion | 3,705,215 | 3,735,137 | ' | ' |
Capital lease obligations, net of current portion | 0 | 0 | ' | ' |
Deferred tax liabilities | -65,370 | -43,246 | ' | ' |
Other long-term liabilities | 25,384 | 19,753 | ' | ' |
Intercompany notes payables (receivables) | -660,771 | -774,507 | ' | ' |
Total long-term liabilities | 3,004,458 | 2,937,137 | ' | ' |
Stockholders' equity | 2,075,566 | 2,077,966 | ' | ' |
Non-controlling interests | 0 | 0 | ' | ' |
Total equity | 2,075,566 | 2,077,966 | ' | ' |
Total liabilities and equity | 5,894,186 | 5,865,218 | ' | ' |
Guarantor Subsidiaries [Member] | ' | ' | ' | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 82,048 | 85,453 | 52,986 | 67,941 |
Restricted cash | 2,915 | 2,915 | ' | ' |
Marketable securities | 776 | 853 | ' | ' |
Accounts receivable, net of allowances | 250,603 | 238,782 | ' | ' |
Inventories, net | 170,165 | 168,058 | ' | ' |
Deferred tax assets | 27,375 | 20,541 | ' | ' |
Prepaid expenses and other current assets | -432,500 | -405,954 | ' | ' |
Intercompany receivables | 715,596 | 759,497 | ' | ' |
Total current assets | 816,978 | 870,145 | ' | ' |
Property, plant and equipment, net | 286,490 | 288,637 | ' | ' |
Goodwill | 1,842,309 | 1,841,377 | ' | ' |
Other intangible assets with indefinite lives | 14,300 | 14,300 | ' | ' |
Finite-lived intangible assets, net | 959,002 | 995,868 | ' | ' |
Restricted cash | 0 | 0 | ' | ' |
Deferred financing costs, net and other non-current assets | 7,586 | 8,353 | ' | ' |
Investments in subsidiaries | 270,857 | 267,824 | ' | ' |
Investments in unconsolidated entities | 0 | 0 | ' | ' |
Deferred tax assets | 0 | 0 | ' | ' |
Intercompany notes receivables (payables) | 720,017 | 630,628 | ' | ' |
Total assets | 4,917,539 | 4,917,132 | ' | ' |
Current liabilities: | ' | ' | ' | ' |
Current portion of long-term debt | 962 | 323 | ' | ' |
Current portion of capital lease obligations | 3,165 | 3,751 | ' | ' |
Accounts payable | 79,319 | 69,076 | ' | ' |
Accrued expenses and other current liabilities | 161,351 | 164,762 | ' | ' |
Intercompany payables | 148,533 | 149,031 | ' | ' |
Total current liabilities | 393,330 | 386,943 | ' | ' |
Long-term liabilities: | ' | ' | ' | ' |
Long-term debt, net of current portion | 100 | 100 | ' | ' |
Capital lease obligations, net of current portion | 5,563 | 5,938 | ' | ' |
Deferred tax liabilities | 290,283 | 284,448 | ' | ' |
Other long-term liabilities | 61,026 | 58,823 | ' | ' |
Intercompany notes payables (receivables) | 1,419,782 | 1,444,741 | ' | ' |
Total long-term liabilities | 1,776,754 | 1,794,050 | ' | ' |
Stockholders' equity | 2,747,455 | 2,736,139 | ' | ' |
Non-controlling interests | 0 | 0 | ' | ' |
Total equity | 2,747,455 | 2,736,139 | ' | ' |
Total liabilities and equity | 4,917,539 | 4,917,132 | ' | ' |
Non-Guarantor Subsidiaries [Member] | ' | ' | ' | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 337,958 | 261,654 | 265,621 | 256,782 |
Restricted cash | 1,223 | 1,237 | ' | ' |
Marketable securities | 5 | 5 | ' | ' |
Accounts receivable, net of allowances | 278,190 | 309,947 | ' | ' |
Inventories, net | 218,246 | 219,892 | ' | ' |
Deferred tax assets | 32,120 | 31,451 | ' | ' |
Prepaid expenses and other current assets | 10,713 | 23,547 | ' | ' |
Intercompany receivables | 69,903 | 75,424 | ' | ' |
Total current assets | 948,358 | 923,157 | ' | ' |
Property, plant and equipment, net | 239,523 | 241,737 | ' | ' |
Goodwill | 1,247,747 | 1,252,314 | ' | ' |
Other intangible assets with indefinite lives | 41,675 | 42,402 | ' | ' |
Finite-lived intangible assets, net | 648,007 | 677,737 | ' | ' |
Restricted cash | 28,856 | 29,370 | ' | ' |
Deferred financing costs, net and other non-current assets | 20,764 | 20,559 | ' | ' |
Investments in subsidiaries | 191,920 | 191,947 | ' | ' |
Investments in unconsolidated entities | 49,510 | 44,637 | ' | ' |
Deferred tax assets | 7,449 | 7,959 | ' | ' |
Intercompany notes receivables (payables) | 48,779 | -741,016 | ' | ' |
Total assets | 3,472,588 | 2,690,803 | ' | ' |
Current liabilities: | ' | ' | ' | ' |
Current portion of long-term debt | 4,290 | 3,789 | ' | ' |
Current portion of capital lease obligations | 3,055 | 3,104 | ' | ' |
Accounts payable | 102,849 | 105,711 | ' | ' |
Accrued expenses and other current liabilities | 183,775 | 201,132 | ' | ' |
Intercompany payables | 281,071 | 274,707 | ' | ' |
Total current liabilities | 575,040 | 588,443 | ' | ' |
Long-term liabilities: | ' | ' | ' | ' |
Long-term debt, net of current portion | 40,481 | 37,551 | ' | ' |
Capital lease obligations, net of current portion | 9,527 | 8,469 | ' | ' |
Deferred tax liabilities | 82,616 | 88,039 | ' | ' |
Other long-term liabilities | 108,619 | 109,806 | ' | ' |
Intercompany notes payables (receivables) | 1,109,602 | 320,125 | ' | ' |
Total long-term liabilities | 1,350,845 | 563,990 | ' | ' |
Stockholders' equity | 1,541,713 | 1,533,488 | ' | ' |
Non-controlling interests | 4,990 | 4,882 | ' | ' |
Total equity | 1,546,703 | 1,538,370 | ' | ' |
Total liabilities and equity | 3,472,588 | 2,690,803 | ' | ' |
Eliminations [Member] | ' | ' | ' | ' |
Current assets: | ' | ' | ' | ' |
Cash and cash equivalents | 0 | 0 | 0 | 0 |
Restricted cash | 0 | 0 | ' | ' |
Marketable securities | 0 | 0 | ' | ' |
Accounts receivable, net of allowances | 0 | 0 | ' | ' |
Inventories, net | -17,275 | -23,765 | ' | ' |
Deferred tax assets | -1,863 | 3,506 | ' | ' |
Prepaid expenses and other current assets | 3,906 | -44 | ' | ' |
Intercompany receivables | -1,090,316 | -1,152,278 | ' | ' |
Total current assets | -1,105,548 | -1,172,581 | ' | ' |
Property, plant and equipment, net | -274 | -296 | ' | ' |
Goodwill | 0 | 0 | ' | ' |
Other intangible assets with indefinite lives | -59 | 0 | ' | ' |
Finite-lived intangible assets, net | 0 | 0 | ' | ' |
Restricted cash | 0 | 0 | ' | ' |
Deferred financing costs, net and other non-current assets | -40 | -46 | ' | ' |
Investments in subsidiaries | -4,284,354 | -4,262,246 | ' | ' |
Investments in unconsolidated entities | 10,761 | 13,188 | ' | ' |
Deferred tax assets | 0 | 0 | ' | ' |
Intercompany notes receivables (payables) | -1,868,613 | -990,358 | ' | ' |
Total assets | -7,248,127 | -6,412,339 | ' | ' |
Current liabilities: | ' | ' | ' | ' |
Current portion of long-term debt | 0 | 0 | ' | ' |
Current portion of capital lease obligations | 0 | 0 | ' | ' |
Accounts payable | 0 | 0 | ' | ' |
Accrued expenses and other current liabilities | -35 | -36 | ' | ' |
Intercompany payables | -1,090,316 | -1,152,279 | ' | ' |
Total current liabilities | -1,090,351 | -1,152,315 | ' | ' |
Long-term liabilities: | ' | ' | ' | ' |
Long-term debt, net of current portion | 0 | 0 | ' | ' |
Capital lease obligations, net of current portion | 0 | 0 | ' | ' |
Deferred tax liabilities | 45 | 8 | ' | ' |
Other long-term liabilities | -40 | -46 | ' | ' |
Intercompany notes payables (receivables) | -1,868,613 | -990,359 | ' | ' |
Total long-term liabilities | -1,868,608 | -990,397 | ' | ' |
Stockholders' equity | -4,289,168 | -4,269,627 | ' | ' |
Non-controlling interests | 0 | 0 | ' | ' |
Total equity | -4,289,168 | -4,269,627 | ' | ' |
Total liabilities and equity | ($7,248,127) | ($6,412,339) | ' | ' |
Guarantor_Financial_Informatio6
Guarantor Financial Information - Guarantor Financial Information Consolidating Statement of Cash Flows (Detail) (USD $) | 3 Months Ended | |
In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
Cash Flows from Operating Activities: | ' | ' |
Net income (loss) | ($6,113) | $12,425 |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ' | ' |
Equity earnings (losses) of subsidiaries, net of tax | 0 | 0 |
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs | 4,141 | 5,217 |
Depreciation and amortization | 98,086 | 104,970 |
Non-cash charges for sale of inventories revalued at the date of acquisition | 0 | 461 |
Impairment of inventory | 589 | 0 |
Non-cash stock-based compensation expense | 5,704 | 4,123 |
Impairment of long-lived assets | 161 | 0 |
(Gain) loss on sale of fixed assets | 2,072 | 172 |
Equity earnings of unconsolidated entities, net of tax | -5,352 | -2,934 |
Deferred income taxes | -24,636 | -50,907 |
Other non-cash items | -3,659 | 1,941 |
Changes in assets and liabilities, net of acquisitions: | ' | ' |
Accounts receivable, net | 19,898 | -20,167 |
Inventories, net | -12,745 | -17,171 |
Prepaid expenses and other current assets | 4,330 | -5,833 |
Accounts payable | 5,231 | -1,988 |
Accrued expenses and other current liabilities | 8,363 | 42,096 |
Other non-current liabilities | 13,313 | 795 |
Cash paid for contingent consideration | -3,475 | -2,139 |
Intercompany payable (receivable) | 0 | 0 |
Net cash provided by operating activities | 105,908 | 71,061 |
Cash Flows from Investing Activities: | ' | ' |
Decrease in restricted cash | 2,151 | -8,573 |
Purchases of property, plant and equipment | -27,540 | -36,105 |
Proceeds from sale of property, plant and equipment | 129 | 1,143 |
Cash received from disposition | 4,373 | 0 |
Cash paid for acquisitions, net of cash acquired | 0 | -158,421 |
Cash paid for investments | -507 | ' |
Cash received from equity method investments | -507 | 10,771 |
Cash received from sales of marketable securities | 60 | 0 |
Increase in other assets | -2,925 | -5,569 |
Net cash used in investing activities | -24,259 | -196,754 |
Cash Flows from Financing Activities: | ' | ' |
Cash paid for financing costs | -7 | -1,427 |
Cash paid for contingent purchase price consideration | -4,195 | -19,098 |
Proceeds from issuance of common stock, net of issuance costs | 14,698 | 6,135 |
Proceeds from issuance of long-term debt | 939 | 10,053 |
Payments on long-term debt | -15,823 | -19,638 |
Net proceeds (payments) under revolving credit facilities | 233 | 162,483 |
Cash paid for dividends | -5,323 | -5,323 |
Excess tax benefits on exercised stock options | 292 | 104 |
Principal payments on capital lease obligations | -1,840 | -1,721 |
Net cash provided by (used in) financing activities | -11,026 | 131,568 |
Foreign exchange effect on cash and cash equivalents | 495 | -6,988 |
Net increase (decrease) in cash and cash equivalents | 71,118 | -1,113 |
Cash and cash equivalents, beginning of period | 361,908 | 328,346 |
Cash and cash equivalents, end of period | 433,026 | 327,233 |
Issuer [Member] | ' | ' |
Cash Flows from Operating Activities: | ' | ' |
Net income (loss) | -6,113 | 12,425 |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ' | ' |
Equity earnings (losses) of subsidiaries, net of tax | -28,355 | -22,244 |
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs | 3,857 | 5,153 |
Depreciation and amortization | 1,399 | 1,287 |
Non-cash charges for sale of inventories revalued at the date of acquisition | 2,407 | 0 |
Impairment of inventory | 0 | ' |
Non-cash stock-based compensation expense | ' | 1,660 |
Impairment of long-lived assets | 0 | ' |
(Gain) loss on sale of fixed assets | 0 | 0 |
Equity earnings of unconsolidated entities, net of tax | -405 | -248 |
Deferred income taxes | -21,658 | -30,889 |
Other non-cash items | 0 | -762 |
Changes in assets and liabilities, net of acquisitions: | ' | ' |
Accounts receivable, net | 0 | 0 |
Inventories, net | 0 | 0 |
Prepaid expenses and other current assets | -26,287 | -473,927 |
Accounts payable | -4,305 | -604 |
Accrued expenses and other current liabilities | 18,625 | 478,784 |
Other non-current liabilities | 9,106 | -126 |
Cash paid for contingent consideration | -3,417 | -2,139 |
Intercompany payable (receivable) | 67,749 | 64,910 |
Net cash provided by operating activities | 12,603 | 33,280 |
Cash Flows from Investing Activities: | ' | ' |
Decrease in restricted cash | 2,125 | -7,933 |
Purchases of property, plant and equipment | -6,323 | -37 |
Proceeds from sale of property, plant and equipment | 269 | 0 |
Cash received from disposition | 0 | ' |
Cash paid for acquisitions, net of cash acquired | ' | -151,372 |
Cash paid for investments | -504 | ' |
Cash received from equity method investments | ' | 0 |
Cash received from sales of marketable securities | 0 | ' |
Increase in other assets | -311 | -3,210 |
Net cash used in investing activities | -4,744 | -162,552 |
Cash Flows from Financing Activities: | ' | ' |
Cash paid for financing costs | -7 | -1,427 |
Cash paid for contingent purchase price consideration | -4,072 | -19,098 |
Proceeds from issuance of common stock, net of issuance costs | 14,698 | 6,135 |
Proceeds from issuance of long-term debt | 0 | 0 |
Payments on long-term debt | -15,000 | -16,845 |
Net proceeds (payments) under revolving credit facilities | 0 | 170,000 |
Cash paid for dividends | -5,323 | -5,323 |
Excess tax benefits on exercised stock options | 53 | 71 |
Principal payments on capital lease obligations | 0 | 0 |
Net cash provided by (used in) financing activities | -9,651 | 133,513 |
Foreign exchange effect on cash and cash equivalents | 11 | 762 |
Net increase (decrease) in cash and cash equivalents | -1,781 | 5,003 |
Cash and cash equivalents, beginning of period | 14,801 | 3,623 |
Cash and cash equivalents, end of period | 13,020 | 8,626 |
Guarantor Subsidiaries [Member] | ' | ' |
Cash Flows from Operating Activities: | ' | ' |
Net income (loss) | 7,385 | 19,976 |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ' | ' |
Equity earnings (losses) of subsidiaries, net of tax | -68 | 614 |
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs | 125 | 55 |
Depreciation and amortization | 58,445 | 62,711 |
Non-cash charges for sale of inventories revalued at the date of acquisition | 1,093 | 0 |
Impairment of inventory | 0 | ' |
Non-cash stock-based compensation expense | ' | 1,096 |
Impairment of long-lived assets | 0 | ' |
(Gain) loss on sale of fixed assets | 2,010 | 227 |
Equity earnings of unconsolidated entities, net of tax | 0 | 0 |
Deferred income taxes | -1,399 | -10,300 |
Other non-cash items | 1,197 | 275 |
Changes in assets and liabilities, net of acquisitions: | ' | ' |
Accounts receivable, net | -11,821 | -1,968 |
Inventories, net | -8,576 | -10,617 |
Prepaid expenses and other current assets | 23,130 | 413,274 |
Accounts payable | 11,975 | -7,823 |
Accrued expenses and other current liabilities | -3,339 | -387,671 |
Other non-current liabilities | 2,148 | -2,959 |
Cash paid for contingent consideration | 0 | 0 |
Intercompany payable (receivable) | -70,945 | -77,486 |
Net cash provided by operating activities | 11,360 | -596 |
Cash Flows from Investing Activities: | ' | ' |
Decrease in restricted cash | 0 | -630 |
Purchases of property, plant and equipment | -12,941 | -14,732 |
Proceeds from sale of property, plant and equipment | 664 | 2,106 |
Cash received from disposition | 0 | ' |
Cash paid for acquisitions, net of cash acquired | ' | 0 |
Cash paid for investments | 0 | ' |
Cash received from equity method investments | ' | 0 |
Cash received from sales of marketable securities | 60 | ' |
Increase in other assets | -2,185 | -881 |
Net cash used in investing activities | -14,402 | -14,137 |
Cash Flows from Financing Activities: | ' | ' |
Cash paid for financing costs | 0 | 0 |
Cash paid for contingent purchase price consideration | 0 | 0 |
Proceeds from issuance of common stock, net of issuance costs | 0 | 0 |
Proceeds from issuance of long-term debt | 939 | 1,007 |
Payments on long-term debt | -301 | -445 |
Net proceeds (payments) under revolving credit facilities | 0 | 0 |
Cash paid for dividends | 0 | 0 |
Excess tax benefits on exercised stock options | 207 | 17 |
Principal payments on capital lease obligations | -1,080 | -817 |
Net cash provided by (used in) financing activities | -235 | -238 |
Foreign exchange effect on cash and cash equivalents | -128 | 16 |
Net increase (decrease) in cash and cash equivalents | -3,405 | -14,955 |
Cash and cash equivalents, beginning of period | 85,453 | 67,941 |
Cash and cash equivalents, end of period | 82,048 | 52,986 |
Non-Guarantor Subsidiaries [Member] | ' | ' |
Cash Flows from Operating Activities: | ' | ' |
Net income (loss) | 18,468 | 2,021 |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ' | ' |
Equity earnings (losses) of subsidiaries, net of tax | 0 | 0 |
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs | 159 | 9 |
Depreciation and amortization | 38,166 | 41,001 |
Non-cash charges for sale of inventories revalued at the date of acquisition | 2,204 | 461 |
Impairment of inventory | 589 | ' |
Non-cash stock-based compensation expense | ' | 1,367 |
Impairment of long-lived assets | 161 | ' |
(Gain) loss on sale of fixed assets | 62 | -55 |
Equity earnings of unconsolidated entities, net of tax | -5,064 | -2,688 |
Deferred income taxes | -3,037 | -9,605 |
Other non-cash items | -4,856 | 2,428 |
Changes in assets and liabilities, net of acquisitions: | ' | ' |
Accounts receivable, net | 31,719 | -18,199 |
Inventories, net | -105 | -7,129 |
Prepaid expenses and other current assets | 11,790 | 35,633 |
Accounts payable | -2,439 | 6,439 |
Accrued expenses and other current liabilities | -7,278 | -29,830 |
Other non-current liabilities | -1,895 | 3,880 |
Cash paid for contingent consideration | -58 | 0 |
Intercompany payable (receivable) | 3,196 | 12,576 |
Net cash provided by operating activities | 81,782 | 38,309 |
Cash Flows from Investing Activities: | ' | ' |
Decrease in restricted cash | 26 | -10 |
Purchases of property, plant and equipment | -9,093 | -26,358 |
Proceeds from sale of property, plant and equipment | 112 | 4,085 |
Cash received from disposition | 4,373 | ' |
Cash paid for acquisitions, net of cash acquired | ' | -7,049 |
Cash paid for investments | -3 | ' |
Cash received from equity method investments | ' | 10,771 |
Cash received from sales of marketable securities | 0 | ' |
Increase in other assets | -482 | -1,478 |
Net cash used in investing activities | -5,067 | -20,039 |
Cash Flows from Financing Activities: | ' | ' |
Cash paid for financing costs | 0 | 0 |
Cash paid for contingent purchase price consideration | -123 | 0 |
Proceeds from issuance of common stock, net of issuance costs | 0 | 0 |
Proceeds from issuance of long-term debt | 0 | 9,046 |
Payments on long-term debt | -522 | -2,348 |
Net proceeds (payments) under revolving credit facilities | 233 | -7,517 |
Cash paid for dividends | 0 | 0 |
Excess tax benefits on exercised stock options | 32 | 16 |
Principal payments on capital lease obligations | -760 | -904 |
Net cash provided by (used in) financing activities | -1,140 | -1,707 |
Foreign exchange effect on cash and cash equivalents | 729 | -7,724 |
Net increase (decrease) in cash and cash equivalents | 76,304 | 8,839 |
Cash and cash equivalents, beginning of period | 261,654 | 256,782 |
Cash and cash equivalents, end of period | 337,958 | 265,621 |
Eliminations [Member] | ' | ' |
Cash Flows from Operating Activities: | ' | ' |
Net income (loss) | -25,853 | -21,997 |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ' | ' |
Equity earnings (losses) of subsidiaries, net of tax | 28,423 | 21,630 |
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs | 0 | 0 |
Depreciation and amortization | 76 | -29 |
Non-cash charges for sale of inventories revalued at the date of acquisition | 0 | 0 |
Impairment of inventory | 0 | ' |
Non-cash stock-based compensation expense | ' | 0 |
Impairment of long-lived assets | 0 | ' |
(Gain) loss on sale of fixed assets | 0 | 0 |
Equity earnings of unconsolidated entities, net of tax | 117 | 2 |
Deferred income taxes | 1,458 | -113 |
Other non-cash items | 0 | 0 |
Changes in assets and liabilities, net of acquisitions: | ' | ' |
Accounts receivable, net | 0 | 0 |
Inventories, net | -4,064 | 575 |
Prepaid expenses and other current assets | -4,303 | 19,187 |
Accounts payable | 0 | 0 |
Accrued expenses and other current liabilities | 355 | -19,187 |
Other non-current liabilities | 3,954 | 0 |
Cash paid for contingent consideration | 0 | 0 |
Intercompany payable (receivable) | 0 | 0 |
Net cash provided by operating activities | 163 | 68 |
Cash Flows from Investing Activities: | ' | ' |
Decrease in restricted cash | 0 | 0 |
Purchases of property, plant and equipment | 817 | 5,022 |
Proceeds from sale of property, plant and equipment | -916 | -5,048 |
Cash received from disposition | 0 | ' |
Cash paid for acquisitions, net of cash acquired | ' | 0 |
Cash paid for investments | 0 | ' |
Cash received from equity method investments | ' | 0 |
Cash received from sales of marketable securities | 0 | ' |
Increase in other assets | 53 | 0 |
Net cash used in investing activities | -46 | -26 |
Cash Flows from Financing Activities: | ' | ' |
Cash paid for financing costs | 0 | 0 |
Cash paid for contingent purchase price consideration | 0 | 0 |
Proceeds from issuance of common stock, net of issuance costs | 0 | 0 |
Proceeds from issuance of long-term debt | 0 | 0 |
Payments on long-term debt | 0 | 0 |
Net proceeds (payments) under revolving credit facilities | 0 | 0 |
Cash paid for dividends | 0 | 0 |
Excess tax benefits on exercised stock options | 0 | 0 |
Principal payments on capital lease obligations | 0 | 0 |
Net cash provided by (used in) financing activities | 0 | 0 |
Foreign exchange effect on cash and cash equivalents | -117 | -42 |
Net increase (decrease) in cash and cash equivalents | 0 | 0 |
Cash and cash equivalents, beginning of period | 0 | 0 |
Cash and cash equivalents, end of period | $0 | $0 |